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Summary 
Acute hospitals have seen unprecedented demographic changes, where older age, frailty and 
cognitive impairment now characterise the majority of health service users. Delirium is very 
common in this setting, and adverse outcomes are well described. However, studies investigating 
cognitive outcomes after delirium in unselected samples have been lacking. This thesis had four 
objectives: (1) To estimate the prevalence of delirium in the general population (2) To assess the 
association of delirium with cognitive outcomes (3) To investigate how these associations relate 
to underlying dementia pathology (4) To develop novel methods for retrospectively ascertaining 
delirium. 
 
Methods: 
Data from three population-based neuropathology cohort studies were used: Vantaa 85+; 
Cambridge City over-75s Cohort (CC75C); MRC Cognitive Function and Ageing Study (CFAS).  
(1) To ascertain the prevalence of delirium in the general population, a measure of delirium was 
developed using data recorded in standardised interview schedules, with criterion validity 
evaluated through the association with mortality and dementia risk.  
(2) The association with cognitive outcomes was tested in a series of logistic regression models, 
where delirium was the exposure and dementia (or worsening dementia severity) was the 
outcome. In addition, the association with change in Mini-Mental Status Examination 
(MMSE) score was assessed using random-effects linear regression.  
(3) In brain donors from all three cohorts, the independent effects of delirium, dementia 
pathology, and their interaction, were investigated using the same approach.  
(4) A chart-based method for deriving a retrospective diagnosis for delirium was developed, 
validated against bedside psychiatrist diagnosis. Vignettes from the medical record were 
abstracted and delirium status decided by expert consensus panel. 
 
Results: 
(1) Age-specific prevalence in CFAS increased with age from 1.8% in the 65-69 year age group 
to 13.5% in the ≥90 age group (p<0.01 for trend). 
(2) Delirium was consistently associated with adverse cognitive outcomes: new dementia (OR 
8.7, 95% CI 2.1 to 35); worsening dementia severity (OR 3.1, 95% CI 1.5 to 6.3); faster 
change in Mini-Mental Status Examination (MMSE) score (1.0 additional points/year, 
p<0.01) 
(3) In the neuropathology analyses, decline attributable to delirium was -0.37 MMSE points/year 
(p<0.01). Decline attributable to dementia pathology was -0.39 MMSE points/year (p<0.01). 
However, the combination of delirium and dementia pathology resulted in the greatest 
decline, where the interaction contributed a further -0.16 MMSE points/year (p=0.01), 
suggesting that delirium worsened cognitive trajectories in dementia, but through distinct 
pathophysiological pathways not accounted for by Alzheimer’s, vascular or Lewy body 
pathology. 
(4) The chart abstraction method yielded a sensitivity of 0.88 and specificity 0.75 for ‘possible 
delirium’, with lower sensitivity (0.58) and higher specificity (0.93) for ‘probable delirium’ 
(AUC 0.86, 95% CI 0.82 to 0.89). 
 
This thesis adds to the small body of work on delirium in prospective studies, with the first ever 
analyses conducted in whole populations. The findings suggest new possibilities regarding the 
pathology of cognitive impairment, positioning delirium and/or its precipitants as a critically 
inter-related mechanism. 
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1 Introduction: what is delirium? 
Delirium is a serious acute neuropsychiatric syndrome which affects around 20% of hospitalised 
older adults (Inouye 2006; Siddiqi et al. 2006; Young et al. 2007; MacLullich et al. 2011; Ryan et 
al. 2013). It is characterised by inattention and fluctuating cognitive and/or perceptual deficits in 
the context of acute illness. The syndrome arises due to a wide range of aetiological precipitants, 
commonly: infections, hypoxia, or medications. The size of the insult necessary to precipitate 
delirium is inversely proportional to the vulnerability of the individual (Inouye et al. 1996). In 
this way, delirium is a sensitive – but not specific – sign of illness in older persons. Delirium can 
also be conceptualised as a consequence of cognitive decompensation under conditions of 
physiological stress. 
This introductory chapter will outline some of the theoretical issues concerning delirium as a 
clinical entity, illustrating them with a case study. Following this is a more detailed description of 
delirium phenomenology, in the context of the standard psychiatric classification systems 
(particularly the American Psychiatric Association’s Diagnostic and Statistical Manual, DSM). 
Lastly, research into delirium pathophysiology will be reviewed, examining the literature from 
experimental animal models and clinical studies. 
Chapter outline 
 Overview of concepts 
 Case study 
 Delirium phenomenology 
 Delirium pathophysiology 
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1.1 Overview of concepts 
A central feature of delirium is its development as a result of interacting predisposing and 
precipitating factors (Figure 1-1). In persons with high vulnerability e.g. older adults or children; 
prior cognitive impairment, a relatively minor illness can precipitate delirium, e.g. urinary tract 
infection. Conversely, in younger adults, delirium usually only results from severe illness, e.g. 
traumatic brain injury, meningitis. Commonly recognised risk factors for delirium are given in 
Table 1-1. 
  
Figure 1-1 Multifactorial model of delirium (Inouye et al. 1996)) 
 
Table 1-1 Common risk factors for delirium.  
Predisposing factors Precipitating factors 
Age Infections 
Cognitive impairment Medications 
Depression Hypoxia 
Frailty and functional dependency Metabolic disturbance 
Co-morbidity score Physical restraints 
Nutritional state Urinary catheterisation 
Sensory impairment 
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This interacting, multifactorial model of delirium is supported by empirical data, first 
demonstrated almost two decades ago (Inouye et al. 1996). In two tandem hospitalised cohorts, 
baseline risk factors for incident delirium were determined and validated (Inouye et al. 1993). 
The multiplicative effect of precipitants on baseline risk of delirium was then established in a 
different cohort of patients (Inouye et al. 1996). These data are reproduced in Figure 1-2.  
 
Figure 1-2. Data from Inouye et al. 1996 showing that precipitating and baseline factors are 
usually insufficient to produce delirium on their own. Proportion of individuals who developed 
delirium over the course of admission is shown on the y-axis. 
 
1.1.1 Scope of thesis 
This thesis is concerned with understanding the relationship between delirium and cognitive 
decline. To investigate this, an epidemiological approach has been adopted, that is, an 
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exploration of delirium in the context of population-based cohort studies of ageing and 
dementia. In this respect, there are a number of aspects of delirium that are outside the scope of 
this discussion, as outlined below. 
Delirium is common in children as well as older adults. Vulnerabilities in brains undergoing 
maturation and development may be similar to those undergoing decline and degeneration. 
Compared to older adults, paediatric delirium has attracted much less research attention. 
Phenomenologically, the syndrome is thought to be broadly similar to that seen in adults, though 
it may develop more acutely and perceptual and psychotic disturbance may be more common 
(Leentjens et al. 2008). 
Delirium tremens refers to a specific syndrome that arises through acute alcohol withdrawal. It 
has different phenomenological characteristics, treatments and prognoses and so will not be 
considered further in this thesis. 
There is an important body of research into post-operative delirium and post-operative cognitive 
impairment. The phenomenon is observed after a range of different procedures and the risk 
profile is unlikely to be uniform across surgical and anaesthetic interventions (cardiac versus 
non-cardiac, elective versus emergency, general versus regional anaesthesia). This thesis will only 
refer to post-operative delirium if directly relevant to epidemiological studies. 
There is growing interest in prodromal and subsyndromal delirium. Increasingly, it is apparent 
that these borderline cases also carry prognostic significance (Cole et al. 2011). This will only be 
addressed where relevant to discussing case-ascertainment and delirium nosology. 
Finally, there are a number of pharmacological and non-pharmacological interventions that have 
been trialled for both delirium treatment and prevention. However, interventions for delirium 
are not a central focus for this thesis so will not be discussed in detail. 
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1.1.2 Clinical importance 
This section provides some justifications as to why delirium is worthy of study. There follows a 
case study (Section 1.2) and then a detailed description of delirium phenomenology (Section 1.3). 
1.1.2.1 Delirium is common 
Delirium is extremely common among hospitalised older adults. A systematic review describing 
the epidemiology of delirium in medical inpatients reported delirium at admission (prevalent 
delirium)2 ranging from 10% to 31% (Siddiqi et al. 2006). Delirium developing over the course of 
an admission (incident delirium) was between 3% and 29%. To put these figures in context, UK 
2011/2012 Hospital Episode Statistics (HES) reported 5.7% emergency admissions were coded 
as being due to “ischaemic heart disease” and “other forms of heart disease” (www.hscic.gov.uk). 
In settings where illness severity is greater, e.g. intensive care unit (ICU), prevalence is 
correspondingly higher. However, the wide range of reported prevalence estimates (20-80%) 
probably reflect differences in use of detection tools, illness severity and case-mix varying across 
hospitals and local practices with regard to use of sedation (Vasilevskis et al. 2012). The 
prevalence is similarly high in institutional care (range 7% to 58%), and the variation is also likely 
to be influenced by the same methodological issues (Siddiqi et al. 2009). In palliative care, 
expected prevalence of delirium on admission to specialist care is between 13% and 42% but 
rises to 59% to 89% in the last weeks before death (Hosie et al. 2013). 
                                                 
2 The literature on delirium in acute hospital settings uses the terms ‘prevalence’ and ‘incidence’ 
in a specific way that contrasts with the standard definitions in descriptive epidemiology. Using 
the point of admission as a reference, ‘prevalent delirium’ indicates delirium present at 
admission. ‘Incident delirium’ indicates delirium that develops over the course of a hospital 
admission. The distinction may reflect different aetiological precipitants, management options, 
and in some cases, outcomes (see McCusker et al. 2003). 
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1.1.2.2 Delirium is serious 
Delirium is associated with a number of adverse outcomes, over the short and long term (Siddiqi 
et al. 2006; Witlox et al. 2010). A wide range is reported for in-hospital mortality after delirium 
(6% to 62%) (Siddiqi et al. 2006). In 5 studies comparing delirium cases with controls, and 
adjusting for illness severity and co-morbidities, the results were less clear: 2 showing increased 
mortality, 3 showing no significant difference (Siddiqi et al. 2006). Length of stay may be longer 
in persons with delirium (3 studies showing increases, 7 reporting no difference). For 
institutionalisation at discharge, studies showed either increased rates (3 studies) or no difference 
(1 study). Overall, comparison is markedly hampered by differences in study design, adjusted 
covariates, outcome measures and degree of reporting. 
There is substantial evidence that delirium results in poor outcomes in older persons admitted to 
hospital over the longer-term (follow-up at least three months after delirium) (Witlox et al. 2010). 
This systematic review only included studies that investigated an independent effect of delirium 
(i.e., after adjusting for other associations with poor outcomes, for example co-morbidity or 
illness severity). In older persons admitted to hospital, pooled estimates found positive 
associations with mortality (HR 2.0 (95% CI 1.5 to 2.5), I2 = 44%; 7 studies) and 
institutionalisation (OR 2.4 (1.8 to 3.3), I2 = 0%; 7 studies).  
1.1.2.3 Delirium is a marker for dementia 
The association between delirium and dementia is complex, and is the main focus for this thesis. 
The literature will be reviewed more fully in Chapter 2. Here, it is worth highlighting the findings 
from the systematic review of long-term outcomes after delirium (Witlox et al. 2010, above). 
Two studies were included that reported an association with dementia (OR 13 (95% CI 1.9 to 
84)). The first followed 200 elective hip surgery patients, and the dementia outcome was defined 
as MMSE <23 at 38 months (Bickel et al. 2008). The second study was performed in the acute 
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hip fracture setting where 78 patients were followed after perioperative assessment for delirium 
by a psychiatrist (Lundstrom et al. 2003). Dementia outcomes were decided at consensus 
meetings. There are two major difficulties with these studies. Firstly, the dementia assessments 
were probably not blinded to prior delirium status. Secondly, it is difficult to be certain how valid 
this estimate is because the population admitted to hospital includes persons with undiagnosed 
dementia (i.e. the dementia was present before the delirium, rather than caused by it). Indeed, 
because of the high proportion of persons with undiagnosed dementia in the hospital setting 
(Sampson et al. 2009), it could be argued that persons presenting with delirium is precisely the 
population that should be screened for dementia (MacLullich et al. 2011). This inferential 
limitation to follow-up of hospitalised persons is a major justification for the epidemiological 
work in population-based studies. 
In addition to regarding dementia as a dichotomous state, there are advantages to modelling 
trajectories of cognitive decline as this regards both intra-individual and inter-individual 
differences in cognitive function as being on a continuum. The terminal cognitive decline 
hypothesis was proposed several decades ago, positing that cognitive decline might accelerate 
before death (Riegel et al. 1972), typically appreciable over the last three to eight years (Muniz-
Terrera et al. 2011). The central implication of this observation is that some of the variation in 
cognitive aging could be better approached by considering distance to death, rather than 
chronological age (Piccinin et al. 2011). How delirium may relate to this process has not 
previously been considered, and is a major element of this thesis (Chapter 6). 
1.1.2.4 Delirium is distressing 
Delirium is undoubtedly a frightening experience. Patients can be troubled by agitation and 
hyperarousal, but psychotic symptoms may be equally distressing. Moreover, hallucinations and 
delusions are more likely to go unnoticed in patients with hypoactive delirium, though delirium 
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subtype does not appear to be directly associated with distress (Partridge et al. 2013). Even 
though a degree of amnesia due to reduction in new-memory formation may be a feature of 
delirium, increasing evidence indicates significant distress in those with recollection for the 
episode (Partridge et al. 2013).  
After critical illness, the estimated prevalence of delusions or dream-like recollections ranges 
from 20% to 75% (Kiekkas et al. 2010). This wide variation is partly attributable to differences in 
illness severity, levels of sedation and other clinical variables, though some may also be due to 
under-reporting of symptoms. Symptoms of post-traumatic stress disorder (PTSD) in this 
population have been reported in 19% to 26% of patients after critical illness (Davydow et al. 
2008; Jackson et al. 2011). An illustrative example: 
"On Sunday, I was on the ICU, where a horror ceremony like in a concentration camp 
was going on. Four patients were executed. Laying in their beds, they received a death 
pill. I was one of them. … The hangman gave us the pill, with a blank face… waiting to 
carry away our dead bodies. … The torturers watched us all the time, they asked us: “Do 
you feel anything yet? How does your foot feel? How does your arm feel?” The scene 
went on like a horror film. The children of Satan were in command. They were dressed 
in green coats and had scary faces. They were waiting for our death. … Worst was, that I 
did not try to resist. How can a man throw away his life like that? Why me? Did they do a 
mistake during the surgery and try to cover it up by killing all of us? … The pills did not 
work. I did not die. So they tried it again with gas, pressing a mask on my face. …" 
ICU Delirium website3 (used with permission) 
                                                 
3 www.mc.vanderbilt.edu/icudelirium/outcomes.html#post 
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Family are also likely to be affected by the experience of delirium in a patient, particularly in 
hospice settings (Breitbart et al. 2008). Distress in professional staff is also well-documented, 
though still probably receives less attention than is warranted (Breitbart et al. 2002). 
1.1.2.5 Delirium is costly 
It is clear that associations with longer hospital admissions, short and long-term clinical 
complications and higher rates of institutionalisation result in higher costs. In the USA, 
extrapolating from the annual health care expenditure of participants in a large delirium 
prevention study, inflation-adjusted costs were calculated from insurance reimbursements and 
hospital charges. This estimates the cost of a patient admission with delirium at between $16,000 
and $64,000, suggesting the national burden of delirium may range from $38 billion to $150 
billion per year (2008 estimate) (Leslie et al. 2008). Even this is likely to be an underestimate, as it 
may not adequately account for delirium that is unrecognised, but nonetheless incurs greater 
resource utilisation. 
In the UK, a detailed analysis of the cost-effectiveness of a delirium prevention intervention was 
undertaken as part of the NICE guidelines on delirium (Akunne et al. 2012). The probabilistic 
analysis – accounting for baseline risk of delirium, adverse outcomes including new 
institutionalisation and dementia, falls, pressure ulcers and mortality – estimated the mean 
additional cost per admission as £13,200. Remarkably, the incremental cost of the intervention 
was actually less than usual for usual care: -£520, showing the substantial cost-effectiveness of 
delirium prevention. 
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1.2 Case study 
AB4 is a 78 year old man who fell and fractured his neck of femur while receiving inpatient 
psychiatric care for an episode of major depression. Prior to admission, he was functioning well 
in his own home. He was able to manage his personal care, though his daughter did his weekly 
shopping and assisted with more physically demanding tasks such as laundry and changing bed 
linen. He had some mild forgetfulness which had not changed in the previous two years and he 
was able to manage his own financial affairs. AB had a past medical history of stable angina, 
hypertension, mild chronic renal failure, benign prostatic hypertrophy, osteoarthritis of both 
knees and recurrent depression. There was no family history of note, and he was a lifelong 
teetotaller and non-smoker with a university education. 
The current episode of major depression was precipitated by the unexpected death of his son. 
His affective state worsened despite a six-week period of community treatment with 
antidepressants and grief counselling. He was admitted to psychiatric care with psychotic 
depression and weight loss, for consideration of electro-convulsive therapy. At the time of his 
fall, he was on the following medications: venlafaxine 225mg od; trazadone 50mg od; quetiapine 
25mg bd; amlodipine 5mg od; ramipril 10mg od; bisoprolol 2.5mg od; simvastatin 40mg od; 
finasteride 5mg od. 
On admission to the orthopaedic ward, AB was drowsy and though responsive to voice, he was 
not able to give an account of recent events. Temperature was 36⁰C, heart rate 100 regularly 
regular, blood pressure 105/55 and oxygen saturation was 97% on room air. Cardiovascular, 
respiratory and abdominal examinations were unremarkable. AB was only briefly able to engage 
with assessment and did not report any perceptual abnormalities. He was not aware how long 
                                                 
4 This is a fictionalised, but typical case. 
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he’d been in hospital and disorientated to time and place. On being asked to count backwards 
from 20, he gave the following answer: “20… 19… 18… 17… 16… 17… 16… 15… 13… 12… 
11.” There was psychomotor retardation and generalised depression of deep tendon reflexes. 
1.2.1 Interpretation 
AB has delirium. Despite the diagnosis of depression, symptoms of which may complicate the 
assessment of delirium, his fluctuating difficulty in engaging with assessment and inattention on a 
relatively simple cognitive task is fairly specific to delirium. This case illustrates the multifactorial 
nature of the causes of delirium. Prior to his fall (at which point he may have already been 
delirious), the major predisposing risk factors were his age, mild forgetfulness, depression, and 
being on three psychotropic medications. 
His precipitating factors will now include further medications (specifically opioid analgesia), pain, 
surgical fixation of his hip under anaesthesia, and possible post-operative ICU admission. 
Hypotension and/or dehydration may also contribute to delirium if his fluid balance is not 
addressed. Constipation from opioids and reduced mobility may be a perpetuating factor if not 
pre-empted. He is also at risk of urinary retention and may require a catheter. Laboratory indices 
may already be abnormal, with possible hyponatraemia and acute on chronic renal impairment. 
Continued delirium is very likely to complicate this patient’s post-operative course. The duration 
of the delirium will be determined by how promptly the underlying medical problems can be 
optimised, and whether any new problems arise. In the meantime, efforts to improve and 
maintain his mobility will be hampered by continued drowsiness and inattention. He will be at 
risk of deconditioning, pressure ulcers and further falls. While each of his medical and psychiatric 
conditions is potentially reversible, return home is a reasonable goal for care. However, this is 
contingent on intensive multicomponent, multiprofessional intervention. 
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1.3 Delirium phenomenology 
The term ‘delirium’ has many formal and informal synonyms (box),  but ‘delirium’ has the most 
precise and historical meaning. In addition, the term is used in the two chief nosological systems 
for classification of psychiatric disorders, viz.: DSM and the International Classification of 
Diseases (ICD). Table 1-1 details the diagnostic criteria for the most recent iterations of these 
definitions, namely DSM-IV5 and ICD-10. The DSM description has fewer required features 
than the ICD construct, and this more inclusive definition results in higher estimates of point-
prevalence when the criteria are compared directly (at least in a geriatric medicine ward setting) 
(Laurila et al. 2003). These differences in ascertainment may not, however, actually affect 
prognosis for mortality at one year (Laurila et al. 2004a). 
Terms suggestive of delirium 
 
Formal terms 
 acute confusional state 
 acute confusion 
 confusion 
 agitation 
 toxic psychosis 
 ICU psychosis 
 post-operative psychosis 
 metabolic encephalopathy 
 acute brain failure 
 organic brain syndrome 
 cerebral insufficiency 
 subacute befuddlement 
 
Informal terms 
 non-compliant with examination 
 a bit muddled 
 not themselves today 
 a bit knocked off 
 vague 
 poor historian 
 
Courtesy of Alasdair MacLullich, University of Edinburgh 
 
  
                                                 
5 DSM-5 has recently been published. Though it differs from DSM-IV, the new edition does not 
have any direct relevance to the analyses presented in this thesis. 
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Table 1-2 Definitions of delirium 
DSM-IV ICD-10 
A. Disturbance of consciousness (i.e., reduced 
clarity of awareness of the environment) with 
reduced ability to focus, sustain or shift attention.  
 
B. A change in cognition or the development of a 
perceptual disturbance that is not better accounted 
for by a pre-existing, established or evolving 
dementia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. The disturbance develops over a short period of 
time (usually hours to days) and tends to fluctuate 
during the course of the day  
 
D. There is evidence from the history, physical 
examination or laboratory findings that the 
disturbance is caused by the direct physiological 
consequences of a general medical condition.  
 
A. Clouding of consciousness, i.e. reduced clarity 
of awareness of the environment, with reduced 
ability to focus, sustain, or shift attention.   
 
B. Disturbance of cognition, manifest by both:  
1. impairment of immediate recall and recent 
memory, with relatively  intact remote 
memory;   
2. disorientation in time, place or person.   
 
C. At least one of the following psychomotor 
disturbances:    
1. rapid, unpredictable shifts from hypo-activity 
to hyper-activity;   
2. increased reaction time;   
3. increased or decreased flow of speech;   
4. enhanced startle reaction. 
   
D. Disturbance of sleep or the sleep-wake cycle, 
manifest by at least one of the following:   
1. insomnia, which in severe cases may involve 
total sleep loss, with or     without daytime 
drowsiness, or reversal of the sleep-wake cycle;   
2. nocturnal worsening of symptoms;   
3. disturbing dreams and nightmares which may 
continue as hallucinations or illusions after 
awakening.  
  
E. Rapid onset and fluctuations of the symptoms 
over the course of the day.  
  
 
F. Objective evidence from history, physical and 
neurological examination or   laboratory tests of an 
underlying cerebral or systemic disease (other than 
psychoactive substance-related) that can be 
presumed to be responsible for the clinical 
manifestations in A-D.   
   
Comments:  Emotional disturbances such as 
depression, anxiety or fear, irritability, euphoria, 
apathy or wondering perplexity, disturbances of 
perception (illusions or hallucinations, often visual) 
and transient delusions are typical but are not 
specific indications for the diagnosis.   
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It is worth examining the foundations of the DSM-IV description, exploring the difficulty with 
using the definition for standardising case-ascertainment in research. Though successive 
revisions were based on epidemiological field testing, only two studies were ever conducted for 
DSM-IV, both in tertiary hospital samples (total n=560) (Johnson et al. 1990; Liptzin et al. 1991). 
1.3.1.1 Criterion A 
Deficits in attention have been recognised as a core diagnostic feature since DSM-III-R 
(Criterion A) (Table 1-2).  
It supplanted the previous description ‘clouding of consciousness’ as the latter term was 
regarded as being too imprecise (Lipowski 1983). However, it is not clear what should constitute 
a minimum threshold for attentional deficits in the diagnosis of delirium (Lowery et al. 2010). 
Moreover, patients who present with reduced level of consciousness in an acute setting are often 
not included in delirium studies if the severity of their impairments means that they cannot 
undergo cognitive testing. These two unresolved but crucial issues reflect the general paucity of 
research on the neuropsychology of delirium (MacLullich et al. 2011). 
1.3.1.2 Criterion B 
DSM-IV also requires a change in cognition or perceptual disturbance (Criterion B). The extent 
to which delirium may have a differential effect on domains of cognition or perception is 
complex and not specified. Neuropsychiatric symptoms such as motor (Meagher et al. 2011) or 
sleep-wake (Jabbar et al. 2011) disturbance are frequently present but not specific for delirium. 
Affective symptoms, thought disorder and perceptual disturbances are also recognised as part of 
Criterion B, and assessment including these features would serve to maximise sensitivity of 
detection.  
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1.3.1.3 Criterion C 
Criterion C states that symptoms should be acute (hours to days) and fluctuate over the course 
of the day. These features are highly specific to delirium, but may vary by subtype. However, by 
their nature, they make ascertainment more difficult, because a test score may vary over periods 
of hours or even minutes. Multiple assessments per day could increase detection of deficits as 
well as eliciting fluctuation, but are likely to be impractical. Currently best practice is to use tools 
which attempt to capture relevant information (e.g. informant history, clinical case notes) in the 
period preceding the assessment. 
1.3.1.4 Criterion D 
Specifying that delirium is due to an underlying medical disorder fulfils Criterion D. However, it 
is unclear what should actually constitute ‘evidence’ for cause and effect. For the vast majority of 
cases, acute medical and surgical events (e.g. urinary tract infection) and delirium are temporarily 
linked.  However, as the pathophysiology of delirium remains elusive (MacLullich et al. 2008), 
the level of evidence required for aetiological links remains very unclear.  Also, often multiple 
aetiologies are demonstrable over the course (Laurila et al. 2008), but may be unidentifiable in 
around 10% (Meagher et al. 2008). It is not known if the precipitant influences the 
phenomenological presentation (Meagher et al. 2008).  
 
1.3.2 Delirium as a disturbance of consciousness  
From the time that delirium was framed as an organic brain syndrome, its hallmark has always 
been considered a disturbance of consciousness. This was initially described as ‘clouding of 
consciousness’, but as mentioned above, this was regarded too difficult to operationalise. Two 
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approaches to understanding this construct have emerged, which could be described as 
‘constructivist’ and ‘reductionist’.  
Broadly, the constructivist approach regards delirium as a failure of a high-order function 
(Rockwood 2004). For organisms with complex physiology, high-order functions include: 
maintenance of consciousness and upright bipedal ambulation. When complex systems fail, these 
functions are most vulnerable to disruption (Rockwood et al. 2004b). This view places delirium 
in the context of frailty – that is, not a specific neuropsychiatric problem as much a failure of the 
whole organism. Frailty arises from loss of redundancy in physiological systems, and this lack of 
robustness is key. From this perspective, delirium is a manifestation of frailty and should be 
understood principally through this characterisation of predisposing factors (Rockwood et al. 
2004a). 
 
1.3.3 Phenomenology as an empirical construct 
A reductionist view seeks to separate the phenomenon of ‘clouded consciousness’ into 
component parts. This includes the full range of neuropsychiatric domains: cognition, thought, 
language, sleep-wake cycle, perception, affect, and motor behaviour, and recent work has 
examined the stability of these constructs in different countries and clinical settings (Franco et al. 
2009; Meagher et al. 2012; Trzepacz et al. 2012; Franco et al. 2013). A principal idea in 
phenomenological studies is that syndromes have high-frequency ‘core’ symptoms, and less-
frequent ‘associated’ symptoms. Evidence from exploratory and confirmatory factor analyses 
proposes that delirium phenomenology can be understood in three core domains, each of which 
contribute to consciousness as a distributed brain function: ‘cognitive’, which includes attention 
deficits; ‘higher level thought’, including executive symptoms, impairments in language; and 
‘circadian disturbance’, including altered motor behaviour (Franco et al. 2009; Meagher et al. 
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2012; Franco et al. 2013) (Figure 1-3). Accordingly, attention (which has fronto-parietal ‘top-
down’ and reticular activating system ‘bottom-up’ substrates); complex organisation of thinking 
(executive, semantic, abstraction); and fragmentation of circadian patterns of arousal, can all be 
considered characteristic components of disrupted consciousness in delirium. 
 
Figure 1-3. Domains of delirium phenomenology, as described through factor analysis (Franco et 
al. 2013). 
 
1.3.3.1  Inattention and cognition 
Inattention is the cardinal symptom and is required for the diagnosis of delirium. It may be 
apparent on observation that the patient is distractible, with an inability to shift, focus or sustain 
attention. As above, the assessment of attention is complicated by states of low arousal, and it is 
debatable if these can be phenomenologically separated in these circumstances (Meagher et al. 
2008). Formal testing can involve ‘days of the week backwards’, ‘serial sevens’ or digit span tests. 
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However, it is not clear how well these tests truly discriminate between delirium and dementia 
(MacLullich et al. 2011; Morandi et al. 2012a). More broadly, there is a need to acknowledge that 
patients with a reduced level of alertness or agitation of a severity such that the presence or 
absence of inattention cannot be demonstrated should be classified presumptively as having 
delirium (Hall et al. 2012). However, studies that use criterion validity to establish the clinical 
significance of major disturbances of arousal – that is, to what extent it is associated with 
mortality, institutionalisation and other outcomes – are still urgently required, and some data on 
this topic are presented in Chapter 4. 
Disorientation and short-term memory impairment are usually accompanying features of the 
inattention, so persons are often amnesic (though, as described in Section 1.1.2.4, patients may 
find fragments of residual memory to be highly distressing). Equally, long-term memories are 
relatively preserved. Visuospatial and constructional impairments can be observed or assessed by 
copying actions or figures (e.g. clock drawing test).  
1.3.3.2 Higher-order cognitive deficits 
A wide range of executive dysfunctions may be apparent, including difficulty with: abstract 
thinking, initiation/perseveration, switching mental sets, working memory, temporal sequencing 
and organisation, insight and judgment. Disorganised thinking includes tangentiality and loose 
associations (Hart et al. 1996; Trzepacz et al. 2001; Laurila et al. 2004b). Language disturbances 
in delirium include dysnomia, paraphasias, impaired comprehension, dysgraphia, and word-
finding difficulties (Trzepacz et al. 2002). 
1.3.3.3 Circadian disturbance and motor activity 
Disruption of sleep-wake cycle is very frequently present in delirium, over 90% in some case-
series (Rockwood 1993; Meagher et al. 2007). It may take the form of sleep fragmentation or 
even complete reversal of sleep-wake cycle, reflecting disordered circadian rhythms. Circadian 
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disturbance may be the basis of the fluctuating clinical course in delirium, but this is not fully 
understood (Rooij et al. 2013). 
Changes in patterns of motor activity are very common in delirium, and are the basis for 
classifying clinical subtypes: hyperactive, hypoactive and mixed. Although hypoactive delirium is 
more common than hyperactive presentations, it tends to be under-detected by its very nature 
(Yang et al. 2009). Accordingly, it is difficult to be certain if motor activity is differentially 
associated with phenomenological profiles, pathophysiology, treatment or prognoses (Meagher 
2009). The cognitive deficits are probably comparable (Leonard et al. 2011). 
Though psychotic symptoms may be the most recognisable element of delirium, these features 
only occur in up to 50% of patients with delirium. Hallucinations are usually visual, though may 
be auditory. Disorders of thought content may range from overvalued ideas to frank delusions. 
Delusions are typically poorly-formed and may relate to persecutory ideas (Meagher et al. 2013).  
 
1.4 Pathophysiology 
Though there is increasing interest in the biological underpinnings of delirium, understanding of 
the fundamental pathophysiology is incomplete. Compared to the number of clinical studies in 
the last three decades, relatively less work has been done using animal models. As outlined 
above, any attempt to explain the pathophysiological substrates of delirium must account for the 
reciprocal interaction between predisposing and precipitating factors. Finding meaningful 
cognitive and behavioural animal models to explore possible hypotheses has not been 
straightforward. 
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It is convenient to consider two mechanisms for brain injury in the context of acute illness: 
direct and indirect (MacLullich et al. 2008). Direct brain insults may include hypoxaemia, stroke, 
trauma or medications. In such conditions, brain dysfunction evidently arises as a direct 
consequence of the pathological process.  
Indirect insults can be used to explain how acute pathology (precipitating factors) may interact 
with chronic disease (predisposing factors). Usually, acute pathology arises in the periphery (e.g. 
infection/inflammation, pain). A unifying idea is that aberrant stress responses have an impact 
on brain and brain function (MacLullich et al. 2008; Cunningham et al. 2013). There are a 
number of routes through which systemic processes in the periphery can have an effect on the 
brain. Inflammatory mediators can interact directly with neurons in areas where the blood-brain 
barrier is deficient; there are neurohumoral connections that communicate directly through the 
vagus nerve; endothelial glial cells can transmit cytokine signals into the brain parenchyma 
(Figure 1-4).  
 
Figure 1-4. Routes of communication from periphery to central nervous system (MacLullich et 
al. 2008). 
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Neuroendocrine axes that are responsible for managing the normal stress response may become 
pathologically disrupted such that delirium is precipitated and/or sustained. For example, 
glucocorticoid regulation through the hypothalamus-pituitary-adrenal (HPA) axis is vital, because 
sustained high levels may lead to chronic activation of low affinity receptors and this in itself, is 
cytotoxic (e.g. Cushing’s disease). Reciprocally, it is known that chronic neurodegeneration in the 
limbic system leads to dysregulation of the HPA axis so the higher order control of the cortisol 
response can become exaggerated. Together, these situate neuroinflammatory and 
neuroendocrine mechanisms as ‘aberrant stress mediators’. 
1.4.1 Experimental models 
Relevant animal models in this field have been carefully grounded in the reciprocal predisposing 
/ precipitating conceptualisation of delirium. The most developed construct has recreated 
predisposing cognitive impairment (e.g.  prion disease, selective lesioning of the cholinergic 
system) and superimposed an acute event (e.g. bacterial or viral inflammation) (Cunningham et 
al. 2013).  
At a cellular level, it is understood that neurodegenerative conditions such as Alzheimer’s disease 
can initiate responses from microglia (Wyss-Coray 2006). Microglia are the resident 
monocyte/macrophage system in central nervous system (CNS). Morphologically activated 
microglia can adopt a wide number of functional phenotypes, determined by a range conditions. 
Crucially, microglial responses to neurodegeneration are on a spectrum from M1 (classical 
macrophage activity) to M2 (growth-repair functions). Thus, these immunological phenotypes 
may be deleterious (enhancing neurodegeneration) or beneficial (clearing amyloid deposits). In 
animal models, microglia have been shown to migrate to new amyloid plaques (Meyer-
Luehmann et al. 2008). In vitro, microglial receptors (e.g. Toll-like receptor 4) can contribute to 
innate immunity through clearing amyloid plaques (Liu et al. 2005). Although the regulatory 
 23 
 
mechanisms are not well understood, it appears that the predominant response to amyloid is not 
overly aggressive, and indeed may be anti-inflammatory in part. Taken together, this results in 
microglial priming. Microglial priming is a key concept, and represents a state whereby glia are 
morphologically activated, but not pro-inflammatory. However, this primed state can result in 
phenotypic switching in response to an inflammatory challenge. 
A murine model of delirium exists which demonstrates these features, based on an ME7 (prion) 
model of neurodegeneration. Here, ME7 mice are challenged with a peripheral inflammatory 
stimulus (e.g. lipopolysaccharide (LPS), mimicking bacterial infection; poly I:C, mimicking viral 
infection) (Cunningham et al. 2007; Murray et al. 2012a). For both cognitive and motor tasks, 
ME7 + peripheral challenge mice perform worse than age-matched controls injected with 
normal saline. Similarly, for non-ME7 mice injected with a peripheral challenge, cognitive and 
motor tasks were not affected by generalised sickness-behaviour induced by LPS. 
The neuropathological findings of this model demonstrate that in ME7 + peripheral challenge 
mice, microglia exhibit an exaggerated pro-inflammatory response. CNS transcription of TNF-α, 
IL-1β and IFN-β were markedly elevated in ME7 mice compared to controls injected with LPS, 
even after adjusting for cytokine levels in periphery. Thus, the neuroinflammatory pathway 
elaborated by this model is as follows (Figure 1-5): 
 ME7 induces neurodegeneration and synaptic loss. 
 This results in microglial priming, which in itself is insufficient to produce cognitive deficits 
in early disease. 
 A peripheral inflammatory challenge initiates a phenotypic switch to aggressive up-regulation 
of inflammatory cytokines. 
 This is responsible for acute working memory and motor deficits, analogous to delirium. 
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 A key feature of this model is the predisposed brain (primed by a neurodegenerative process) 
is pushed over a functional threshold by a precipitating peripheral challenge. 
Figure 1-5. Pathological and inflammatory changes after LPS. a-c, Tomato lectin staining for 
microglial cells in brains from NBH+LPS (a), ME7+saline (b), and ME7+LPS (c) animals. d-f, 
IL-1β immunostaining in NBH+LPS (d), ME7+saline (e), and ME7+LPS (f) brains. (g and h) 
Weekly time point assessments to depict the course of neurological impairments when 
underlying disease and systemic challenge combine. Treatment with poly I:C is indicated by grey 
arrows. 
 
Though microglial priming  may be one important mediator in delirium pathophysiology,  
priming was not essential for the same cognitive deficits reproduced in cholinergically deficient 
mice, blocked by donepezil (Field et al. 2012). Therefore, the interplay between acetylcholine 
deficiency and microglial priming requires better definition. Nonetheless, these models have 
begun to explore pathophysiological pathways that may identify future targets for intervention. 
In the progressive neurodegeneration model, microglia express cyclo-oxygenase (COX) 1 and 
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synthesise prostaglandins. Inhibition of this using COX-1 selective inhibition or indeed 
ibuprofen is protective against systemic LPS or IL-1 induced cognitive deficits (Griffin 2013).  
There is not yet direct evidence that the delirium per se and the concurrent neuronal death 
actually occur by the same mechanisms. However, it has been shown in other murine models 
that lipopolysaccharide in itself can result in generation of nitric oxide, inducing neuronal 
apoptosis and persistent cognitive deficits (Semmler et al. 2005; Weberpals et al. 2009). 
  
1.4.2 Clinical studies of delirium pathophysiology 
The following sections are based on systematic reviews of the literature, updated to February 
2013, using the original search strings described in by the original systematic review (Medline 
only). 
1.4.2.1 Cerebrospinal fluid biomarkers 
Studies of cerebrospinal fluid (CSF) in delirium are difficult to perform. Apart from the general 
difficulty of recruiting participants who are often unable to give consent, the inherently invasive 
nature of CSF sampling makes such research particularly challenging. However, a few studies 
have exploited the opportunity to sample CSF from persons undergoing spinal anaesthesia for 
elective or emergency surgery. Indeed, spinal anaesthesia may in fact be the anaesthetic modality 
of choice for frail older patients, so these studies are often undertaken in highly relevant 
populations. 
A recent systematic review identified 8 studies involving 235 patients (142 with delirium) (Hall et 
al. 2011). Overall, 17 different biomarkers were considered and each article identified in the 
review focused on a narrow range of biomarkers with no overlap between studies. Studies were 
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generally small, studying heterogeneous populations with different times of CSF sampling in 
relation to delirium, and no clear conclusions could be drawn. Age and concomitant dementia 
were likely to be major confounders, and this was not always adequately addressed. Broadly, 
delirium may be associated with: increased serotoninergic and dopamine signalling; reversible fall 
in somatostatin; increased cortisol; and increase in some inflammatory cytokines (IL-8), but not 
others (TNF-α, IL-1β).  
In updating this systematic review, one additional study was identified (Witlox et al. 2011). 
Reporting a cohort of 76 individuals admitted for emergency hip fractures, this is comparable in 
size to the largest study described in the systematic review. Here, postoperative delirium was 
identified in 30 participants (40%) and this was strongly associated with premorbid cognitive 
decline (as assessed by IQCODE). However, CSF Aβ1-42, tau, and phosphorylated-tau levels 
were not associated with delirium status, nor did they correlate significantly with IQCODE 
score. The two main explanations for these findings are either: (1) the study was underpowered 
to detect mediating pathways between premorbid cognitive impairment, Alzheimer’s pathology 
biomarkers and subsequent delirium; or (2) postoperative delirium arises through 
pathophysiological pathways that are distinct from Alzheimer disease. 
Overall, CSF studies may be a valuable method for investigating pathophysiological correlates of 
delirium However, larger studies in relevant populations will be necessary. 
1.4.2.2 Neuroimaging 
The neuroimaging correlates of delirium are very difficult to establish. Many attempts to image 
people with concurrent delirium will be unsuccessful. In addition, there is a more general bias 
selecting younger and fitter participants amenable to scanning, especially if using intensive 
protocols such as MRI.  
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The literature has been summarised by a systematic review (Soiza et al. 2008). This found 12 
articles for inclusion, most with small sample sizes (total number of cases 127). There was 
substantial heterogeneity in populations, study design, and imaging modalities such that no firm 
conclusions were made. Generally, structural imaging suggested that diffuse brain abnormalities 
such as atrophy and leukoaraiosis might be associated with delirium, though few studies could 
account for differences in key variables such as age, sex, education or underlying cognitive 
function. Two functional studies reported perfusion abnormalities in delirium.  
In updating the systematic review, five further studies were identified. In addition, a single study 
reporting proton magnetic resonance spectroscopy findings in 14 persons undergoing bone 
marrow transplant for haematological malignancies (5 developing delirium, 9 not) and 10 age- 
and sex-matched controls (drawn from family and friends) was not considered further due to the 
very specific clinical circumstances under investigation (Yager et al. 2011). 
The largest-scale report was VISIONS (Gunther et al. 2012; Morandi et al. 2012b). This was a 
prospective cohort study that examined neuroimaging correlates of delirium in 47 participants 
after critical illness. Following ICU admission, in which individuals were evaluated with CAM-
ICU (33 with ≥1 day of delirium), diffusion tensor imaging (DTI) was performed at discharge 
and at 3 month follow-up (Morandi et al. 2012b). The principal DTI measure was fractional 
anisotropy, a marker of white matter integrity. Delirium duration was related to fractional 
anisotropy and this in turn was related to poorer cognitive outcomes at 3 and 12 months. In 
addition, brain volumes were also assessed and related to cognitive outcomes in the same 
manner (Gunther et al. 2012). Overall, the study found that longer duration of delirium was 
associated with smaller brain volume and more white matter disruption, and both these 
correlated with worse cognitive scores 12 months later. 
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Two studies examined delirium risk as a post-operative complication after elective cardiac 
surgery. The first showed that Fazekas score, a semi-quantitative measure of white-matter 
hyperintensities, was associated with post-operative delirium in the 18 cases developing in 130 
Japanese patients (Hatano et al. 2013). Some caution should be applied to these findings as 
delirium was ascertained through (blinded) chart review. Though the study appeared to have 
ready access to liaison psychiatry input, the under-detection of delirium is likely. In a similar 
population, fractional anisotropy (in left frontal lobe and regions of interest in the deep white 
matter) was also predictive of post-operative delirium, even after adjusting for age (Shioiri et al. 
2010). It should be noted when considering these findings that cardiac surgery, which requires a 
period of extracorporeal bypass, represents a specific route for peri-operative brain dysfunction 
that may not be generalisable to the rest of the population undergoing surgery. 
In a population of inpatients referred to a tertiary liaison psychiatry service, functional networks 
were assessed in 22 patients during delirium using fMRI (mean DRS-R-98 score 18 (SD 4.1)) 
(Choi et al. 2012). Follow-up was possible after resolution in 13 patients (median interval 5.8 
days), and age- and sex-matched controls were drawn from a database of inpatients receiving the 
same imaging protocol for other indications. This study reported reversible reduction in 
subcortical connectivity between dorsolateral prefrontal cortex and posterior cingulate during 
delirium, as well as enhanced integration in posteromedial cortices after recovery. These findings 
identify brain areas localising with cognition and attention function, and the study is unique in 
reporting fMRI results during and after delirium. Though the study design is likely to be biased 
through selection of controls (and the spectrum of medical illness in these controls), it serves as 
a possible model for future research. 
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1.4.2.3 Neurophysiology 
Electroencephalography (EEG) is an attractive mode of study in delirium as it is able to capture 
measures of global brain function. There are also opportunities to summarise temporal 
fluctuations as continuous recordings, compressed into power spectra (quantitative EEG, 
qEEG). Since the work of Engel and Romano in the 1950s, delirium has been known to be 
associated with a generalised slowing of background  activity (Engel et al. 2004). 
A systematic review identified 14 studies for inclusion, representing a range of different 
populations: 6 in older populations, 3 in ICU, sample sizes between 10 and 50) (Kooi et al. 
2012). Four studies compared dementia with delirium and dementia to normal controls. In the 
main, a psychiatrist was used to ascertain delirium. For most studies, the outcome of interest was 
the relative power measures, in order: alpha, theta, delta frequencies. These power measures 
relate to the EEG wave bands, which in themselves reflect specific characteristics of brain 
function. The relative power of the theta frequency was consistently different between delirium 
and non-delirium patients, suggesting metabolic effects on arousal might be important. Similar 
findings were reported for alpha frequencies. In two studies, the relative power of all these bands 
was different within patients before and after delirium. 
No other relevant studies were identified since publication of the systematic review.  
1.4.2.4 Neuropathology 
Only a handful of studies exist where there has been an attempt to correlate delirium with 
pathological findings at autopsy; no systematic review on the topic was identified. A case series 
has been reported on 7 patients who died during ICU admission (Janz et al. 2010). These 
patients had a mean age of 55 years (SD 8.4), with a median number of days with delirium of 7 
(IQR 2 to 12). Each case was admitted with a range of primary pathologies, but all had acute 
respiratory distress syndrome and/or septic shock contributing to the delirium. 6/7 had evidence 
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of hypoperfusion and diffuse vascular injury, with consistent involvement of the hippocampus in 
5/7.  
A case-control study examined 9 delirium cases with 6 age-matched controls (Munster et al. 
2011), investigating inflammatory cytokines and their role in delirium. Cases were drawn from 
patients who had their delirium diagnosed by a geriatrician and then died during the index 
admission. Controls were selected from other brain autopsies that had been performed for 
clinical reasons, and whose medical records documented no neuropsychiatric symptoms 
suggestive of delirium. Cases had higher scores for HLA-DR and CD68 (markers of microglial 
activation), IL-6 (cytokines pro-inflammatory and anti-inflammatory activities) and GFAP 
(marker of astrocyte activity). These results might suggest a neuroinflammatory substrate to 
delirium (or at least terminal delirium), but the conclusions are limited by biases from selection 
of controls. 
Finally, a case series reporting dementia and delirium in 4 patients with an inherited 
spinocerebellar ataxia was not considered further given the highly specific nature of the 
pathological condition (Ishikawa et al. 2002). 
 
1.5 Chapter summary 
Delirium in the older population is common, serious and important. It arises through the 
interaction of predisposing and precipitating factors. As such, it should be taken as a sign of 
acute illness having an impact on arousal mental status. The syndrome is characterised by acute 
and fluctuating inattention accompanying new cognitive and/or perceptual change. Disruption 
of circadian rhythm is also common. 
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Table 1-3. Summary of clinical methods used to investigate delirium pathophysiology 
 Biomarkers Imaging Neurophysiology Neuropathology 
Design Cohort, case-
control 
Cohort, case-
control 
Case-control Case-control, Case series 
Measures Plasma, CSF CT, MRI, MRS, 
fMRI 
Differences in 
power bands, 
quantitative EEG 
Histopathology, 
immunohistochemistry 
Outcomes Delirium, 
delirium 
severity 
Delirium, 
subsyndromal 
delirium 
Delirium, delirium 
superimposed on 
dementia 
Delirium 
Conclusions Possible role 
for cortisol, 
cytokines 
Possible role for 
white matter 
integrity, cortical 
and subcortical 
pathology 
Possible role as 
diagnostic tool 
Possible role for 
microvascular and 
inflammatory pathology 
 
The pathophysiological substrates of delirium are likely to involve a range of direct and indirect 
mechanisms of brain injury, though firm conclusions are still not established (Table 1-3). 
Neuroinflammatory and neuroendocrine pathways are implicated and these may or may not 
interact with the pathological processes that underlie dementia. 
The next chapter will discuss the epidemiological possibilities in delirium research. By reviewing 
previous literature on delirium in community samples (including a systematic review of the 
descriptive epidemiology of delirium in population-based studies), gaps in the understanding of 
delirium can be identified. This then leads to the specification of questions to be addressed by 
this thesis. 
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2 Epidemiological research in delirium 
The previous chapter detailed the clinical constructs that underlie delirium. The purpose of this 
next chapter is to place the study of delirium and its sequelae in an epidemiological context. This 
will start by examining the principles of epidemiology relevant to this thesis. Following this, two 
systematic reviews will be presented: (i) the descriptive epidemiology of delirium in population-
based studies, assessing the quantity and quality of work done to date; and (ii) the association 
between delirium and/or systemic illness with trajectories of cognitive decline. This thesis 
addresses some of the gaps identified by these systematic reviews. Accordingly, the final section 
of this chapter specifies the aims of this thesis: the investigation of delirium and trajectories of 
cognitive decline in population-based studies. 
Chapter outline 
1. Principles of epidemiology 
- Population 
- Case-ascertainment 
- Attitrition 
- Residual confounding 
2. Systematic review: population studies in delirium 
3. Systematic review: delirium and trajectories of cognitive decline 
4. Core questions and statement of aims 
 
2.1 Principles of epidemiology 
2.1.1 Population 
In considering the importance of defining a population, the question being asked is: to what 
extent is the chosen population representative of the full spectrum of persons with delirium in 
that population? For example, if the incidence of post-operative delirium in patients aged ≥70 
years with urinary tract infections is being studied, are the individuals in the study representative 
of everyone with delirium, or are there biases that arise because this is a relatively easy group to 
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identify and recruit? How does the approach to sampling enable a valid capture of the chosen 
population? These are critical questions as the provenance of the sample population has the 
potential to systematically bias findings both in magnitude and direction. 
The majority of studies in delirium have been undertaken in specific hospital settings and often 
among patients with particular medical or surgical conditions (Siddiqi et al. 2006; Witlox et al. 
2010). Together, these studies indicate that delirium is a common problem in inpatients and is 
associated with serious adverse outcomes, such as increased mortality, institutionalisation and 
dementia (Section 1.1.2). However, there are three limitations to the inferences that can be 
drawn about delirium as a whole in the existing literature. Firstly, it cannot be assumed that all 
persons with delirium from a given population will actually present to the particular hospital 
from which the respondents come. Secondly, once in hospital, there is only retrospective 
information on a person’s cognitive and functional status. This lack of reliable data on pre-
admission status makes it difficult to ascertain delirium (and pre-existing dementia) because the 
diagnosis requires determination of acute change in mental status (Section 1.3). Third, referral and 
selection bias inherent in hospital-based studies with particular subgroups of people with 
delirium leads to questionable generalisability and conflicting findings across studies. 
2.1.1.1 Example: populations in stroke epidemiology 
The importance of an unselected population has been shown through the findings of the 
Oxfordshire Community Stroke Project (OCSP) (Bamford et al. 1988; Bamford et al. 1990) and 
its successor, the Oxford Vascular Study (OXVASC) (Rothwell et al. 2004). A working definition 
for population-based study might be: ‘a study where all subgroups of the population are sampled, 
regardless of disease or residential status’ (Zaccai et al. 2006). These studies of stroke incidence 
made comprehensive efforts to ascertain all cases of transient ischemic attack (TIA) or stroke 
from a defined population registered on general practitioners’ (GP) lists, where virtually all 
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primary care is delivered. Each participating surgery maintained close personal contact with the 
study, and collaborating GPs reported suspected cases to the study as soon as patients presented. 
If participants were not admitted to hospital directly, they were assessed on the day of referral in 
a dedicated research clinic or at the participant’s own home. All computerised diagnostic codes 
were reviewed, strengthened by record linkage systems between primary and secondary care. 
Hospital and emergency department presentations were reviewed daily and all deaths out of 
hospital were identified via the Coroner’s Office. 
This strategy to include all cases from the general population resulted in major advances in 
understanding of the prognosis and outcomes from TIA and stroke, precisely because it included 
the full range of persons with acute neurovascular events. In a systematic review of studies 
reporting the risk of early stroke following TIA, it is clear that population-based studies had 
much higher estimates of early recurrence (within seven days) compared to those samples 
presenting solely to specialist stroke services (proportion recurring within seven-days in 
population-based studies 10.4% (95% CI 8.1 to 12.6%); proportion in specialist stroke services 
0.9% (95% CI 0.0 to 1.9%)) (Giles et al. 2007). It is now clear that the relationship between TIA 
and early stroke can be predicted using a clinical risk score (Rothwell et al. 2005; Giles et al. 
2010). These findings have had a major impact in the planning of stroke services and in 
improving patient outcomes (Rothwell et al. 2007). 
2.1.1.2 Example: Populations in dementia epidemiology 
There have been similar issues in respect of the descriptive epidemiology of dementia, where 
estimates vary according to setting. A systematic review of prospective studies of mild cognitive 
impairment (MCI), the current conceptualisation of a dementia prodrome, sought to determine 
the criterion validity of the construct, that is, the extent to which MCI correlated with outcomes 
already considered to be valid, e.g. conversion to dementia (Mitchell et al. 2009). The consistent 
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finding was that conversion rates in the general population are much lower than in clinic 
samples. It would be reasonable to expect this, as selection into a clinic setting represents more a 
more advanced disease (or at least referral) stage. However, this also demonstrates that studying 
selected populations may lead to falsely inflated effect sizes. So for conditions which evolve 
slowly, selected clinic populations tend to overestimate outcomes of interest. Conversely, where 
outcomes may occur over a short interval, selected samples may underestimate the association. It 
is clear that population-based studies are essential if we are to contextualise the limitations of 
clinic samples. 
For delirium research, there is a need to consider how explicitly the population is defined. 
Ideally, one would start with a broad, unselected denominator (i.e. a true population-based study) 
followed-up with serial cognitive and functional assessments. This would represent a 
comprehensive range of symptoms and severities, but also identify what happens, to whom, and 
when. This would help to establish the determinants and effects of delirium most completely. Of 
course, ensuring that a study population is comprehensive in this way requires substantial effort, 
but there are gains of equal degree in terms of achieving results with external generalisability. 
 
2.1.2 Case-ascertainment 
In order to reliably track states of health in populations, looking for emerging patterns and 
trends, one must be able to define exposures and outcomes of interest in a standardised way. For 
psychiatric syndromes, the reference-standard definition is necessarily a set of clinically agreed 
descriptions of psychopathology, preferably collected in a standardised manner, rather than any 
objective measures. The possibility that biomarkers might eventually contribute to case-
ascertainment is briefly reviewed below. 
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2.1.2.1 From definition to operationalisation 
There are some differences between the ICD (World Health Organization) and the DSM 
(American Psychiatric Association) definitions of delirium, and these have an impact on case-
ascertainment (Liptzin et al. 1991; Cole et al. 2003b; Laurila et al. 2004a) (Section 1.3). The 
definitions evolve with each revision and therefore are not stable over time. More problematic is 
that these clinical criteria have the potential to be interpreted differently by individual clinicians. 
For example, the threshold for impairment on cognitive testing in delirium may decrease with 
age, in line with a belief that some deficit is to a degree expected, and thus not abnormal, in older 
age (Brayne 1993). One way of mitigating this variability is to use an algorithmic approach to 
case-ascertainment (described in more detail in Section 2.1.2.3 and Chapter 5). 
2.1.2.2 Diagnosing delirium in the context of dementia 
Expanding on the issues around case-ascertainment introduced in Section 1.3, the boundaries for 
the delirium syndrome become more complex when considering co-morbid dementia. DSM 
separates the delirium and dementia definitions, but the problem of identifying one 
superimposed on the other remains. This is crucial because delirium can be missed, under an 
assumption that observed cognitive deficits are due to dementia. When delirium and dementia 
co-exist, the delirium symptoms (for example, prominent inattention with fluctuating deficits) are 
thought to dominate the presentation over the impairments seen in dementia, and this has been 
reviewed in detail (Meagher et al. 2008; Meagher et al. 2010; Blazer et al. 2012). However, if 
much of the delirium fieldwork explicitly excluded persons with dementia, the resultant 
conceptualisation may have over-emphasised features that are more likely to be reported in 
cognitively intact persons (e.g. psychotic symptoms). Conversely, delirium scales which include 
assessments of memory or other cognitive deficits known to be present in dementia (such as the 
Delirium Rating Scale – Revised – 98) (Trzepacz et al. 2001) may be confounded by the presence 
of dementia. Moreover, some delirium assessment instruments have been validated in separate 
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delirium and dementia groups, so that no assessment of the phenomenological overlap can be 
made.  One consequence of this is that scores in memory subscales are worse due to dementia, 
regardless of if there is also delirium. Currently it is not known if delirium and dementia can be 
distinguished in a cross-sectional assessment on cognitive and phenomenological grounds alone, 
but some studies suggest that this might be possible (Brown et al. 2009; Brown et al. 2011; 
Chester et al. 2012). 
A history (likely from an informant, even if dementia is not yet diagnosed) is required to 
establish the acuity of change from baseline. In hypoactive delirium, the fluctuating course may 
be less obvious and so may be more difficult to distinguish from co-existing dementia. There is 
considerable phenomenological overlap between hyperactive delirium and behavioural and 
psychological symptoms of dementia (BPSD) and the boundaries are not well-established. 
Pragmatically, symptoms should only be attributed to BPSD if an acute medical precipitant has 
been ruled out (Meagher et al. 2008). 
The chief difficulty with operationalising delirium, then, is that the main constructs and their 
boundaries are not clearly defined. DSM does not specify duration, severity, minimum 
thresholds, or which symptoms should fluctuate over which time frames. However, empirical 
data suggest that each of these parameters may influence outcomes and so perhaps define 
prognostic groups (Table 2-1) (Meagher et al. 2008; Blazer et al. 2012). Further detailed 
population-based fieldwork involving increased use of standardised definitions and 
measurements with high reliability, preferably objective, is essential if case-definitions are to 
describe useful phenotypes. Despite these limitations, the aim is to operationalise these criteria 
so that case-ascertainment can be achieved in a consistent manner in the research setting. The 
next section considers in more detail approaches to operationalisation in epidemiological studies, 
using dementia as an exemplar. 
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Table 2-1 Clinical features in delirium not currently defined by DSM criteria with a theoretical 
influence on determining prognostic categories. 
Clinical feature Effect on prognosis Comment References 
Motoric subtypes Hypoactive delirium 
associated with higher 
mortality, especially where 
co-morbid dementia 
Motoric assessment, including 
accelerometer-based measures 
have scope to inform prognostic 
categories 
(O'Keeffe 
1999; 
Meagher 
2009; Yang 
et al. 2009) 
Duration Minimum and maximum 
duration unclear. 
Delirium may evolve into 
dementia. Short term v 
persistent delirium proposed 
(though not adopted) in DSM-5 
(threshold not specified) 
 
Temporal 
fluctuations 
Specifying short 
fluctuations (hours) 
favours identification of 
hyperactive over 
hypoactive subtype 
Hypoactive delirium has poorer 
prognosis, so any specification 
of temporal fluctuations should 
take this into account 
 
Severity Clinical rating scales in 
existence (e.g. DRS-98, 
MDAS, Delirium Index). 
Higher scores associated 
with worse outcomes 
Categories of severity might be 
incorporated into diagnostic 
criteria, but the issue of 
measurement is still difficult 
(Adamis et 
al. 2006) 
Subsyndromal 
delirium 
Higher mortality and 
worse cognitive outcomes 
Variably defined, represents a 
state between normality and full 
delirium syndrome. Current 
definition of delirium might 
perhaps be broadened to 
include milder deficits. 
(Cole et al. 
2003c; 
Meagher et 
al. 2012) 
 
2.1.2.3 Operationalisation in dementia epidemiology 
Dementia is clinically defined by identifying progressive deficits in two or more cognitive 
domains sufficient to impair function in activities of daily living. The three population-based 
studies that form the basis of this thesis can be used as examples to illustrate the different ways 
in which this definition has been operationalised in the context of research (each study is 
described more fully in Chapter 3. Vantaa 85+ defined dementia cases through the agreement of 
two neurologists at clinical examination (Polvikoski et al. 2006). While this was more reliable 
than assessment by a single clinician, more than one assessment introduces greater variability in 
the measures and how this is addressed can hamper cross-study comparisons. In the Cambridge 
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City over-75 Cohort (CC75C) brain donors (Fleming et al. 2007), as well as other studies in both 
Europe (Ott et al. 1995) and North America (Launer et al. 1995), the approach to case-
ascertainment was addressed through the agreement of dementia diagnoses at multidisciplinary 
consensus meetings, held after all study information became available. This method of case-
ascertainment is labour-intensive and so limits its practical use to some extent. 
In parallel to the development of the multidisciplinary conference to standardise case-
ascertainment, use of the Present State Examination (PSE) (Wing et al. 1977) led to the 
possibility of creating diagnostic categories through algorithms. The PSE – and the version 
validated in older persons, the Geriatric Mental State (GMS) (Copeland et al. 1976) – is a 
systematic operationalisation of the psychiatric mental state examination. It uses answers 
generated from the interview to group symptom clusters which can then be used to derive 
diagnostic groups. Once these categories have been validated against clinician-applied diagnoses, 
this algorithm approach can be automated and applied by trained lay interviewers. The MRC 
Cognitive Function and Ageing Study (MRC-CFAS) (Brayne 2006) used such an approach with 
the Automated Geriatric Examination for Computer Assisted Taxonomy (AGECAT) (Copeland 
et al. 1986). This allowed for much greater numbers of persons to be examined and MRC-CFAS 
remains one of the largest population-based studies of dementia incidence of its kind. The 
algorithm diagnosis has been considered again more recently by studies such as the Health and 
Retirement Study (Plassman et al. 2007), which includes attempts to reduce the cost of case-
ascertainment (Weir et al. 2011). In addition, an algorithm approach has been applied to the 
consensus diagnosis itself, with the aim of making the process more time-efficient (Duara et al. 
2010). 
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2.1.2.4 Biomarkers and psychiatric syndromes 
Biomarkers have been widely considered in dementia in the hope that a greater understanding of 
dementia pathophysiology might be able to contribute to case-ascertainment, or even supplant 
the current clinical reference standard (Sunderland et al. 2006; Dubois et al. 2007; McKhann et 
al. 2011). There has been substantial progress in the field, identifying amongst other things, 
amyloid burden in vivo (Klunk et al. 2004) and putative markers of neurodegeneration (Blennow 
et al. 2003; Mosconi 2005). However, such work has only ever been generalisable to the selected 
populations able to tolerate procedures such as PET-MRI or lumbar puncture.  
There is a real need for biomarker research to be validated within the context of a general 
population before they can be proposed as part of a new reference standard (Brayne et al. 2012). 
Most individuals with dementia in Western societies are aged over 80 years, but such persons 
have been under-represented in research. The consequences of selection bias in relation to 
putative biomarkers can be illustrated by autopsy work in MRC-CFAS, where two important 
findings have been reported (Matthews et al. 2009; Savva et al. 2009). Firstly, the relationship 
between recognised neuropathological markers of dementia (amyloid load and neurofibrillary 
tangles in both hippocampus and neocortex) had weaker relationships with clinical dementia in 
individuals in their late 80s and 90s (Savva et al. 2009). Secondly, it is clear that mixed 
(particularly vascular) pathologies all contributed to dementia in this unselected population and 
that many other people tolerate moderate to high levels of pathology without expressing clinical 
symptoms and signs (Matthews et al. 2009). These are serious challenges yet to be sufficiently 
addressed in biomarker validation studies. 
There are lessons to be learned for clinical delirium research. Current plasma biomarker 
candidates, such as apolipoprotein E, insulin-like growth factor-1 and S-100β for predicting 
delirium risk, prognosis or severity have recently been reviewed (Khan et al. 2011). The CSF, 
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neuroimaging and neurophysiological correlates were reviewed in Section 1.4.2. It is clear that 
biomarkers in delirium are still in their infancy, but advances in our understanding of delirium 
pathophysiology may eventually help to refine case-ascertainment, provided that these are done 
in relevant populations. 
In conclusion, the optimal operationalisation of DSM-IV for delirium would require (i) a reliable 
and valid test of inattention that operates well with or without co-existing dementia; (ii) reliable 
and valid assessments of cognition and neuropsychiatric symptoms (iii) temporal nature of acute 
change captured by regular observation, with or without a contribution from informants. 
Ultimately, validation studies of biomarkers could be undertaken in unselected populations, 
serving to improve delirium knowledge at the clinical and population levels.  
 
2.1.3 Attrition  
Loss to follow-up is common to all longitudinal studies of older persons.  Reasons for loss of 
follow-up include drop-out and death between interviews (Chatfield et al. 2005). This is also 
known as censoring – where individuals contribute to the observed period of follow-up, but 
where loss to follow-up means that case-status cannot be ascertained. There is a clear effect on 
how accurately associations with outcomes can then be made. Elaborating how these biases can 
be addressed is relevant for all follow-up studies of delirium. 
It is important to explore possible reasons why outcome data may be missing. This involves 
considering whether the fact that data are missing might be associated with any other variables 
known (and unknown) to the study. Three characterisations of missing data mechanisms have 
been proposed: missing completely at random (MCAR), missing at random (MAR) and missing 
not at random (MNAR) (Table 2-2) (Little 2002).  
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Table 2-2 Theoretical mechanisms for missing data. 
Mechanism 
(Little 2002) 
 
Definition Example 
 
Implications for delirium 
research 
MCAR Does not depend 
on observed or 
unobserved data 
Lost data due to technical error 
such as mis-calibration of MRI 
machine 
Missing data is usually 
ignorable, but this is a rare 
situation 
MAR Depends on 
observed data 
Unable to tolerate MRI 
sequences, predictable from 
knowledge of participant’s 
cognition or ADL 
Other parameters may explain 
the mechanism of missingess, 
but not fully enough to provide 
unbiased estimates in analyses. 
MNAR Depends on the 
value  the outcome 
would have taken 
had it been 
observed 
Attrition through death, driven 
by incident delirium or 
dementia that was not captured 
by the follow-up schedule 
The most common mechanism 
of missing data in aging 
research. Requires specific and 
robust mechanisms for case-
ascertainment, with statistical 
analyses to account for attrition. 
MCAR missing completely at random; MAR missing at random; MNAR missing not at random; MRI 
magnetic resonance imaging; ADL activities of daily living 
 
Several approaches are available to analyse incomplete data. The simplest method consists of   
excluding cases with missing observations. This method, known as complete case analysis, is a 
very inefficient way of analysing data, and does not make use of all available information. 
Because data in longitudinal studies of older persons are unlikely to be MCAR, such an approach 
will bias the analysis in favour of better performing participants. This illustrates why missing data 
cannot simply be ignored; the very fact that some data are missing is informative and an 
appropriate analysis must be adopted. 
 Other ad hoc methods are based on the idea of ‘filling in’ or imputing missing values to complete 
the data. Imputation has been proposed as a method of accounting for missing data on 
exposures (independent covariates) and outcomes (dependent variables). However, it should be 
noted that imputing outcomes is intrinsically problematic. This is because studies aim to determine 
a given outcome, and it would be unsatisfactory for this to be simulated in any way. Examples of 
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imputation methods include: ‘last observation carried forward’ (LOCF) imputation; regression 
mean imputation; and multiple imputation.   
LOCF is an imputation method that consists of replacing every unobserved value by the last 
observed value. This is a reasonable approach, as mentioned above, because to some extent the 
last observation (of for example, low cognitive test score) is associated with a higher likelihood 
of drop-out. However, it makes a strong assumption of no change over the unobserved time, 
and this is very unlikely in delirium. Regression mean imputation imputes the missing value by 
the predicted value given the variables that are available. This predicted value is obtained from a 
regression analysis where the outcome is the variable being imputed and the observed variables 
as covariates. One disadvantage with this approach is that regression mean imputation will 
underestimate variances in the outcome and so in general, estimates of associations produced 
using this method will be biased. Multiple imputation is a much improved technique of imputing 
missing observations.  It consists of creating several copies of completed datasets according to 
certain rules, and conducts the planned analysis on each of these completed datasets, combining 
the results obtained. Multiple imputation is a valid method of analysis when we are willing to 
assume that missing observations are MAR and produces appropriate measures of precision. 
Further, it is particularly useful when missing data occur in covariates. 
If imputation for missing outcome data is to be avoided, other analytical techniques are 
recommended. If it is assumed that missing data are MAR, random-effects modelling is a 
statistical technique that produce robust estimates and use all available data. However, if a 
MNAR mechanism is a more reasonable assumption to make, then more sophisticated statistical 
techniques such as shared parameter models might be the most adequate method of analysis 
(Henderson et al. 2000). Shared parameter models consist of two sub-models: a longitudinal 
random-effects sub-model for the description of change over time, and one time-to-event sub-
model to describe features of the survival process. To link both, some of the parameters of the 
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longitudinal model are included as covariates in the survival sub-model. Shared parameter 
models have been applied to longitudinal studies of aging (McArdle et al. 2005; Ghisletta et al. 
2006; Muniz Terrera et al. 2011). In the presence of missing data due to death and dropout, the 
shared parameter model can be extended to account for the two reasons for dropout (i.e. death 
and dementia), modelling them using a competing risk approach. The use of these techniques is 
not widespread in the ageing literature, but if it is believed that a MAR assumption is not valid, 
these more refined analytical methods should be considered. While these techniques have been 
important in the dementia epidemiology, they have yet to be applied systematically to follow-up 
studies of delirium which almost certainly under-estimate the effect of drop-out (Adamis 2009; 
Deiner et al. 2009; Neufeld et al. 2011).   
 
2.1.4 Residual confounding 
Observational epidemiology seeks to identify associations between exposures (independent 
variables) and outcomes (dependent variables). Delirium can be considered in both contexts. For 
example, delirium might be modelled as an exposure with dementia as an outcome. Alternatively, 
sometimes delirium is considered the outcome, where for example, statin therapy is the 
exposure. These analyses should be undertaken with attention to the possibility of confounding.  
Confounding occurs when an apparent relationship between an exposure and an outcome is 
actually being driven by a third variable. For example, in examining the association of dementia 
with mortality, if two groups are not balanced in respect of the distribution of ages, the group of 
older persons (who are more likely to have dementia) may show a higher mortality by virtue of 
their being older, rather than because of the dementia. In these analyses, regression models can 
be used to adjust for age (or any other variable simultaneously). This serves to isolate the effect 
of dementia on mortality after accounting for all other variables that might otherwise be 
 45 
 
associated with risk of death. This is one of the reasons that observational studies cannot directly 
prove causative relationships, as one cannot be certain that all possible confounders have been 
identified (or measured). This is known as residual confounding.  
As outlined in section 1.1, the psychiatric formulation identifies two dimensions that need to be 
accounted for when considering prospective associations in delirium studies: precipitating and 
predisposing factors. Precipitating factors include measures of illness severity (which may include 
measures of intensity of surgery) and predisposing factors include cognitive impairment and 
frailty.  
Can the effects of predisposing and precipitating factors be accounted for, such that the 
independent associations with delirium can be assessed? In other words, is delirium directly 
responsible for the association in question, or is it a marker for some more fundamental, less-
measurable mechanism? This problem was recognised in the systematic review of outcomes after 
delirium in hospitalised patients, where one of the inclusion criteria was that studies had to adjust 
for co-morbid illness or illness severity (Witlox et al. 2010) (Section 1.1.2.2). The review 
considered predisposing and precipitating factors together, and the individual studies 
operationalised these dimensions as follows: 
Predisposing factors, for example: presence of dementia or cognitive and functional 
impairment on e.g. MMSE, IQCODE; Charlson co-morbidities index; functional measures such 
as activities of daily living. 
Precipitating factors, for example: acute physiology and chronic health evaluation II 
(APACHE II) score (Acute Physiology scale); physiological or metabolic parameters: systolic 
blood pressure, C-reactive protein, urea, creatinine. 
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Scales combining assessments of both factors, for example: Burvill scale (a physician 
judgment-based scoring of several organ systems where severity of acute and chronic conditions 
and their contribution to disability are assessed).  
All studies made an attempt to adjust for predisposing factors, suggesting that it is easier to 
operationalise this dimension. To account for illness severity, many studies used APACHE, 
which has not, as yet, been validated outside ICU or in older persons (Minne et al. 2011). The 
other approach to adjusting for illness severity was to use a marker of overall metabolic or 
physiological disturbance. 
Another systematic review assessed prognostic models for mortality in those aged 50 years and 
over (Minne et al. 2011). In particular, the review evaluated the number of models that had been 
validated in other cohorts. Of 193 models identified, only 4 were found to have more than two 
external validation studies: Charlson co-morbidities Index (CCI) (Charlson et al. 1987); Deyo 
score (Deyo et al. 1992) (adapted from the CCI); Simplified Acute Physiology Score (SAPS) (Le 
Gall et al. 1993); Multidimensional Prognostic Index (MPI) (Pilotto et al. 2008). 
The CCI is very well established, and provides a weighted score representing co-morbidities (and 
therefore chronic predisposing factors). One problem is that the weightings and the conditions 
were validated over 20 years ago and so secular trends limit its validity. For example, a diagnosis 
of acquired immunodeficiency syndrome scores the same as metastatic disease and peptic ulcer 
disease is weighted the same as congestive heart failure. The Deyo score is subject to the same 
limitations. SAPS-II is only relevant to the ICU population. The MPI operationalises the 
comprehensive geriatric assessment and also only reflects the predisposing factors, rather than 
any acute precipitant. 
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Overall, the question remains as to how to reliably detect and, where possible, quantify acute 
precipitating factors in delirium. Moreover, the possibilities of measuring particular factors (e.g. 
degree of invasiveness) will vary according to setting. Another approach from the acute internal 
medicine literature examines ‘early warning scores’ (EWS). The best performing tool to date is 
the VitalPAC early warning score (ViEWS) (Prytherch et al. 2010). This was devised to predict 
in-hospital mortality within 24-hours of acute admission and uses a weighted aggregate of seven 
parameters: pulse rate; respiratory rate; temperature; systolic blood pressure; oxygen saturation; 
inspired oxygen; level of consciousness. The model was validated on 35,585 patient episodes, 
and the median age was 68 years. This approach has not been considered before in delirium, but 
could be valuable. However, many of these indicators may not perform in the same way in older 
people (Metlay et al. 1997), and measures of level of consciousness overlap with many symptoms 
of delirium. 
 
2.1.5 Section conclusions 
The epidemiological study of delirium requires attention to population, case-ascertainment, 
attrition and residual confounding. With these principles in mind, the quantity and quality of 
epidemiological research in delirium can be assessed in the following two systematic reviews: (i) 
descriptive epidemiology of delirium in community settings, and (ii) delirium and/or acute illness 
in relation to trajectories of cognitive decline.  
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2.2 Systematic review: population-based studies of delirium 
Question:  
What is the descriptive epidemiology (prevalence and incidence) of delirium in the general 
population? 
 
Review of the population-based studies ascertaining delirium gives an indication of the burden in 
community settings, as well as the strategies used to gather sufficient data to make cognitive 
diagnoses. Here, studies reporting the descriptive epidemiology of delirium in population-based 
studies were of primary interest. For the purposes of this review, ‘population-based’ was defined 
as studies sampling from a geographically-defined population, regardless of health or residential 
status. 
2.2.1 Methods 
The methods followed the meta-analysis of observational studies in epidemiology (MOOSE) 
guidelines (Stroup et al. 2000). 
2.2.1.1 Eligibility criteria 
Cross-sectional (prevalence) or cohort (prevalence and incidence) studies reporting delirium 
measures were considered. Studies were required to define delirium according to a standardised 
classification system, be conducted in groups sampled from the whole population unrestricted by 
residential or health status, and could be in any language. 
2.2.1.2 Search strategy and data extraction 
A systematic search of Medline (from 1950) on Pubmed, Embase (from 1980) on embase.com 
and the Science Citation Index (from 1950) on Web of Science (all until 31st December 2012) 
was conducted. Conference abstracts indexed in the Science Citation Index were considered. 
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Bibliographies of included articles and other reviews were screened. In accordance with MOOSE 
recommendations, abstracts were screened and data extracted in duplicate. The second reader 
was Andrew Hall, University of Edinburgh and the findings were published as Davis 2013. 
Comprehensive text word, Medical Subject Headings and Emtree terms were used to find 
relevant studies (search strategies given in Appendix, Section 10.1). Any estimates of prevalence 
or incidence (and their standard errors) were extracted, along with any relevant clinical variables, 
specifically: age, sex and education (where reported). 
2.2.1.3 Studies describing epidemiology in enriched sub-samples 
One important strategy in population epidemiology is the over-sampling of sub-groups of 
interest. For example, over-sampling groups more likely to have delirium (older, more pre-
existing cognitive impairment) would identify more cases. Findings from such studies only 
remain externally generalisable if this enrichment process (of higher risk groups) is balanced by a 
random sub-sample of the rest of the denominator (lower risk groups). This approach was taken 
in CFAS (described in more detail in Section 3.3, expanded further in Chapter 4). 
Analytically, this could be dealt with by two methods. Firstly, back-weighted estimates can be 
calculated to account for the sampling strategy, and it might be appropriate to use these 
estimates in quantitative synthesis. The second strategy, if only a narrative synthesis is warranted, 
is simply to report enriched estimates, but be clear about the provenance of the denominator. 
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2.2.1.4 Data analysis 
Statistical analyses were performed in Stata version 12.1 (Statacorp, USA). Given the range of 
different populations identified in the studies, estimates were pooled using a DerSimonian and 
Laird random-effects model (DerSimonian et al. 1986). 95% confidence intervals were calculated 
and statistical heterogeneity was assessed using the τ2 statistic. 
2.2.2 Results 
96 studies were identified (Figure 2-1), 10 of which retrieved for full text review. Three studies 
reported point-prevalence of delirium, and two reported period-prevalence. Vantaa 85+ (a 
constituent cohort of this thesis) was also identified as this applied a retrospective diagnosis of 
delirium in the context of a cohort study of dementia incidence (described more fully in Section 
3.1). Characteristics of these studies are summarised in Table 2-3. 
.  
 
Figure 2-1. Flow diagram indicating identification of eligible studies. 
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Table 2-3 Population-based studies of delirium prevalence and incidence 
Study Population 
and setting 
Design Delirium 
ascertainment 
Enriched 
sample? 
Risk of bias 
Point Prevalence 
East 
Baltimore 
(Folstein et 
al. 1991) 
Census 
blocks, 
random 
sample 18-64 
and all 
residents 
age≥65 
DIS, with clinical 
assessment of random 
subsample (n=398) and 
any others with positive 
DIS (n=412). 
SPE and 
psychiatric 
assessment (DSM-
III and ICD-9) 
Yes High non-
response. 
Girona 
(Vilalta-
Franch et 
al. 2009) 
Door-to-door 
sampling of 
adults age ≥70 
(n=1581 
eligible) 
All screened participants 
(n=1460) with 
MMSE<24 (n=335) and 
random sample MMSE 
≥ 24 (n=314) 
Neurologist and 
psychologist 
administered 
CAMDEX. 
Yes Low 
CSHA 
(Andrew et 
al. 2006) 
Random 
sample all 
adults age≥65 
clustered in 5 
regions, over-
sampling 
adults age≥75 
Clinical examination of 
random subsample 
(n=2914) including all 
institutionalised adults 
and screen positive for 
cognitive impairment 
(3MS<78/100) 
DSM-III-R applied 
at consensus 
conference based 
on 
neuropsychiatric 
evaluation. 
Yes Delirium only 
assigned if no 
underlying 
dementia 
Period prevalence 
GERDA 
(Eriksson 
et al. 2011) 
All women 
aged ≥90 
years, 50% of 
those aged 85-
89 years 
All participants (n=503) 
examined with MMSE 
and OBS scale 
DSM-IV applied 
based on study 
information, 
informant / carer 
interviews, medical 
records. 
(one month 
period) 
No Retrospective. 
Vantaa 
85+ 
(Rahkonen 
et al. 2001) 
Recruitment 
of all adults 
resident in 
Vantaa 
age≥85 years 
(n=601 
eligible) 
All participants assessed 
with informant, with 
clinical, cognitive and 
functional examinations 
History of delirium 
by retrospective 
interview of 
participant and 
informant with 
reference to 
medical case notes 
(three year period) 
No Retrospective, 
high attrition 
over three 
years due to 
death; 
survivor 
effect. 
East Baltimore Mental Health Study; CSHA Canadian Study of Health and Ageing; GERDA Gerontological 
Regional Database 
DIS Diagnostic Interview Schedule; SPE Standardised Psychiatric Examination;  
CAMDEX Cambridge Mental Disorders in Elderly Examination 
OBS Organic Brain Syndrome 
MMSE Mini-Mental State Examination; 3MS Modified MMSE. 
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All studies reporting point-prevalence used a basic screening measure, with more detailed 
characterisation of screen-positive and a random subsample of screen-negative participants. The 
East Baltimore Survey (Folstein et al. 1991) used a stratified population sample of adults 
(including all households residents aged ≥65 years) screened with the NIMH Diagnostic 
Interview Schedule (DIS) and interviewed in more detail using the Standardised Psychiatric 
Examination (SPE) and a clinical assessment (blind to the previous DIS scores). As mentioned in 
Section 2.1.2.3, the SPE was an attempt to standardise the psychiatric assessment by using a 
‘probe and question’ structure with a glossary of symptom definitions generating diagnostic 
categories that could be directly related to DSM-III (Wing et al. 1977) (Romanoski et al. 1988). 
An analysis of response rates among screen positive and negative persons was reported. 
Ultimately, only 6 cases of prevalent delirium were identified giving an age-specific prevalence of 
10.9 (95% CI 0.0 to 22.5) per 1000 persons aged ≥55 years. It is not clear if any of these cases 
had co-existent dementia. 
The Girona study used another validated interview schedule (Cambridge Mental Disorders of the 
Elderly Examination, CAMDEX), after screening with MMSE. 1460 individuals aged ≥70 years 
participated in this door-to-door study (92% of the eligible population according to municipal 
census records) (Vilalta-Franch et al. 2009). The standardised information gathered allows a 
diagnosis of delirium and/or dementia to be made. 14 cases of delirium were detected 
(prevalence = 9.6 (95% CI 4.4 to 14.9) per 1000 persons) 12 of whom also had dementia. The 
prevalence of delirium in persons with dementia was much higher: 79.5 (95% CI 35 to 126) per 
1000 persons. 
The Canadian Study of Health and Ageing (CSHA) screened a population aged ≥65 years with 
the modified Mini-Mental State Examination. DSM-III-R diagnoses were applied through 
consensus meetings following two independent neuropsychological evaluations (Andrew et al. 
2006). Diagnoses of delirium and dementia were considered mutually exclusive. The 21 cases 
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identified represent a point-prevalence of 6.3 (95% CI 4.1 to 9.6) per 1000 persons. It is likely 
that this estimate is lower than the other studies because no persons were assigned a delirium 
superimposed on dementia category. 
The eligible population for the GERDA study comprised all women aged ≥90 years and half 
those aged 85-89 years, of whom 81% were recruited (Eriksson et al. 2011). Participants (n=504) 
were examined in their usual place of residence using MMSE and delirium symptomatology was 
assessed using the Organic Brain Syndrome scale (Jensen et al. 1993), which combines 
neuropsychiatric symptoms with an observational scale and has been shown to perform well 
against other diagnostic algorithms such as the Confusion Assessment Method (Bjorkelund et al. 
2006). Diagnoses pertaining to delirium in the previous month were ultimately decided by a 
geriatrician with access to all study data, informant and carer interviews and medical records, 
based on DSM-IV criteria. In this sample, the one-month period prevalence for delirium was 272 
(95% CI 235 to 312) per 1000 persons. Delirium prevalence was strongly associated with age 
(85-89 years 19%; 90-94 years 24%; ≥95 39%) and dementia (OR 5.8 (95% CI 3.5 to 9.5) for 
clinically diagnosed Alzheimer’s disease). 
The estimates from the point-prevalence studies are all from enriched subsamples. Therefore, it 
is not possible to pool the estimates, even if using random-effects meta-analysis. However, there 
is a consistent finding that population prevalence of delirium is relatively low (even when 
including participants in care homes). The period prevalence estimates (30% and 20%) are 
closely associated with age. 
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2.2.3 Discussion 
Overall, it is apparent that there are very few population-based studies that have assessed 
delirium prevalence. However, it is probable that point-prevalence of delirium in the community 
is low. In terms of the key epidemiological principles, these results are from unselected 
populations (by design) and case-ascertainment was broadly in accordance with a standardised 
approach to delirium diagnosis. In these descriptive prevalence studies, no attempt was made to 
link with outcome, so attrition (though not missing data) and residual confounding are less of an 
issue. As for depression, or examples from infectious disease epidemiology, transient syndromes 
are by nature difficult to capture in field surveys.  
Table 2-3 details the risk of bias arising from the design. The Girona study was at lowest risk of 
bias because it used a door-to-door approach and achieved a high proportion of responses. 
Moreover, the enriched ascertainment subsample also included screen-negative participants. This 
allows for a reliable estimate of prevalence back-weighted to the base population. The East 
Baltimore study had a similar design, but was hampered by low proportion responding. Beyond 
basic comparisons of the demographic characteristics of responders versus non-responders, it is 
difficult to estimate the direction of bias in ascertainment. In CSHA, the consensus panel for 
ascertainment made delirium and dementia mutually exclusive categories, likely leading to 
significant under-ascertainment of delirium. 
There were an insufficient number of studies to consider formal techniques such as meta-
regression. However, age and proportion with dementia are likely to be independent predictors 
of delirium prevalence, even in population-based samples. Because CSHA is the largest study, 
and this did not include delirium in persons with a dementia diagnosis, the pooled prevalence is 
also likely to be an underestimate. In addition, it is known from doorstep reports that 
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intercurrent illness and therefore any associated delirium reduces response rates in 
epidemiological surveys, so the detected prevalence may be very low by design.  
Importantly, these studies describe an approach to characterising a base population, enriching it 
with groups likely to eventually yield more incident delirium cases (older, persons with pre-
existing cognitive impairment). The next steps would be to establish a system whereby acute 
changes in mental status can be identified (e.g. via general practitioners). Like in the OXVASC 
study (Section 2.1.1.1), this requires excellent links between hospital and community services. 
Such linkage has yet to be successfully exploited in delirium, but is crucial if the determinants 
and effects of delirium are to be most comprehensively investigated.  
 
2.3 Systematic review: delirium and trajectories of cognitive decline 
Question:  
What cognitive outcomes are associated with delirium and/or acute illness in studies 
prospectively ascertaining pre-morbid (pre-delirium) cognitive function? 
 
The aim of this section is to review the existing literature relevant to the epidemiology of 
delirium as it relates to dementia in community populations, addressing the prospective 
relationship between delirium and dementia in community settings. Section 1.1.2.3 summarised 
the evidence that delirium is associated with new dementia diagnoses following hospital 
admission, though also acknowledged that this is likely to be confounded by undiagnosed (pre-
morbid) dementia. 
This systematic review seeks to examine the relationship between delirium and subsequent 
cognitive impairment more broadly. This association is best addressed using studies with a 
specific design, namely those with prospective information on cognitive function prior to the 
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onset of delirium. In addition to delirium, the prospective follow-up of trajectories of cognitive 
decline due to acute illness and/or hospitalisation were also of interest. 
2.3.1 Methods 
The methods also followed the meta-analysis of observational studies in epidemiology 
(MOOSE) guidelines (Stroup et al. 2000). 
2.3.1.1 Eligibility criteria 
All prospective studies reporting delirium and dementia were eligible for inclusion. More 
generally, studies reporting cognitive outcomes before and after an episode of delirium and/or 
acute illness or hospitalisation were considered. Studies were excluded if they were in children, or 
related solely to alcohol withdrawal states. 
2.3.1.2 Search strategy and data extraction 
A systematic search of Medline (from 1950) on Pubmed, Embase (from 1980) on embase.com 
and the Science Citation Index (from 1950) on Web of Science (all until 31st December 2012) 
was conducted. Conference abstracts indexed in the Science Citation Index were considered. 
Bibliographies of included articles and other reviews were screened. The second reader for this 
review was Alessandro Morandi, Ancelle della Carità Hospital, Cremona. 
Comprehensive text word, Medical Subject Headings and Emtree terms were used to find 
relevant studies (search strategies in Appendix Section 10.2). Any estimates of association 
between delirium and cognitive outcomes (OR, RR, or other more sophisticated approaches, 
such as change-point modelling) were extracted, along with their standard errors, confounders 
adjusted for, and measures of attrition. 
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2.3.1.3 Data analysis 
The diversity of designs, populations and analytic methods precluded anything other than a 
narrative synthesis of the data. 
2.3.2 Results 
The search identified 503 studies, 21 of which merited full text review.6 Ultimately, six studies 
were included and their epidemiological characteristics are summarised in Table 2-4.  
The Vantaa 85+ cohort study is a population-based investigation of dementia in persons aged 
≥85 years resident in Vantaa, Finland. This cohort contributes to the EClipSE study, and further 
details of this are given in the section below (Section 3.4). Vantaa is the only population-based 
prospective study to have reported measures of delirium exposure in relation to dementia 
(Rahkonen et al. 2001). Here, participants were assessed for incident dementia three years after 
study entry. At follow-up participants and/or their proxy informants were asked about a history 
of delirium, and investigators had access to hospital records. There was a strong association with 
dementia (OR 5.3 (95% CI 2.0 to 14)). However, this analysis should be regarded as cross-
sectional (albeit over a three year period) and so no prospective relationship can be determined. 
A more detailed examination of data from this cohort comprises a component of this PhD 
(Chapter 5).  
                                                 
6 This included an article published from this thesis (Davis, 2012), but not considered here. 
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Table 2-4 The epidemiological characteristics of studies of delirium / critical illness with 
cognitive outcomes. 
 Population Exposure Outcome Risk of bias 
(Fong et al. 
2009) 
(Gross et al. 
2012) 
Memory clinic 
patients 
Retrospective 
diagnosis of 
delirium from 
case notes 
Worsening on 
Blessed 
information-
Memory-
Concentration 
score 
Only considered persons with 
prior cognitive impairment. 
59% missing data (54% due to 
reports of hospitals outside area 
where delirium could be 
ascertained). 
(Ehlenbach et 
al. 2010) 
Members of 
Health 
Maintenance 
Organization, 
institutionalised 
adults excluded 
Hospitalisations 
reported on 
insurance 
claims forms 
Dementia 
(DSM-IV; 
consensus 
conference) 
Not population-based. Not 
delirium specifically. 
(Iwashyna et al. 
2010) 
‘Nationally 
representative 
sample’, but 
institutionalised 
adults excluded 
Hospitalisations 
reported on 
insurance 
claims forms 
Severe 
cognitive 
impairment on 
35-scale 
Possibly population-based. Not 
delirium specifically. 
(Wilson et al. 
2012a) 
Urban 
population 
based on 
census 
Hospitalisation 
based on 
Medicare 
claims 
Rate of change 
in global 
cognitive test 
score 
79% response rate for baseline 
screen. Analysis only conducted 
on 18% original baseline 
sample due to missing data 
(39% could not be linked, 21% 
died, 19% insufficient follow-
up. 
(Rahkonen et al. 
2001) 
Population-
based sampling 
all residents age 
≥85. 
Participant and 
informant 
interview with 
access to 
medical records 
Dementia 
(DSM-III-R; 
individual 
clinician) 
Truly population-based sample. 
Dementia outcomes not 
standardised, delirium 
ascertainment retrospective. 
High attrition from death. 
DSM Diagnostic and Statistical Manual of Mental Disorders 
 
The only other study to specifically consider delirium showed an adverse effect on cognitive 
trajectories in a group of memory-clinic patients (Fong et al. 2009). In this study, delirium was 
identified through review of clinical notes, using a previously validated tool. In addition to the 
study population being restricted to a memory-clinic group, these results are limited by only 
considering change in a linear model before and after the first episode of delirium, and this may 
be an over-simplification. However, more complex analyses using random-effects models 
confirmed faster cognitive decline in a subset (n=263) with longer follow-up (median 3.2 years) 
(Gross et al. 2012). 
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A report from the Adult Changes in Thought (ACT) study found critical illness (without 
specifically considering delirium) was associated with incident dementia (adjusted HR 1.4 (95% 
CI 1.1 to 1.7)) (Ehlenbach et al. 2010). Similar findings were reported using a change-point 
model comparing pre- and post-hospitalisation trajectories of cognitive decline (Wilson et al. 
2012a). 
Consistent with this, participants being followed in the Health and Retirement Study who had an 
intercurrent episode of severe sepsis (n = 516) also had a higher risk of being subsequently 
diagnosed with severe cognitive impairment (OR 3.3 (1.5 to 7.3)) (Iwashyna et al. 2010).  
2.3.3 Discussion 
In the identified studies, delirium has been defined in disparate ways, ranging from direct 
ascertainment through standardised interview through to review of medical records, much 
related to pragmatic possibilities. The ideal approach would assess cases prospectively with the 
contemporaneous application of operationalised diagnostic criteria. An alternative involves a 
retrospective review of medical records. While this can be validated in terms of its diagnostic 
accuracy, it is likely to underestimate hypoactive forms of delirium, as well as those not 
presenting to hospital. Other studies have considered critical illness as a proxy for delirium (and 
vice versa). It is also worth noting a nested case-control analysis of dementia diagnoses in the 
General Practice Research Database showing that infectious episodes were associated with 
subsequent dementia (Dunn et al. 2005). 
The sources of bias in these studies can be understood in respect of the four epidemiological 
principles outlined above. Only one assessed delirium in a population-based sample. HRS started 
off excluding persons in institutional care, though followed participants if they were 
subsequently admitted into a care home. The other cohorts had varying degrees of selection. 
Case-ascertainment was inferential in each study – retrospective or not directly recording 
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delirium at all. Attrition was partially addressed, but there was a substantial amount of missing 
data in most of the studies even from baseline. Potential confounding was accounted for to 
some extent in most of the analyses, and residual confounding discussed.  
 
2.4 Core questions and statement of aims for thesis 
This chapter has described some key principles for investigating epidemiological questions. A 
systematic review of the literature identified a small number of studies of the descriptive 
epidemiology of delirium in population-based cohorts. A second systematic review has also 
shown that delirium and/or acute hospitalisation has rarely been considered in cohort studies, 
but there is a suggestion that it may adversely affect trajectories of cognitive decline. These 
findings build on the issues raised in Chapter 1, namely that though delirium is common and 
serious, there is insufficient evidence to understand the temporal relationship between delirium 
and cognitive decline. Prospectively linking delirium with permanent decrements in cognitive 
function challenges the current construct of dementia because it suggests that dementia 
pathophysiology may be affected by processes outside the brain, e.g. peripheral infection.  
Whether this could occur through mechanisms already known to be pathological in dementia, 
such as tau phosphorylation or amyloid cleavage, or through entirely novel pathways is a major 
research question. Taken together, there is a need to leverage information from existing 
population-based cohort studies of dementia incidence to understand the epidemiological, 
cognitive, clinical and biological sequelae of delirium. This thesis attempts to provide such an 
understanding. 
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Aim: To assess the clinical impact of delirium on long-term cognitive outcomes in descriptive, 
analytical and biological terms. 
Objective 1: Estimate the prevalence of delirium in the general population. This can be achieved 
by examining the reporting of delirium symptom clusters in population-based cohort studies 
employing a standardised psychiatric interview schedule. 
Objective 2: Assess the association of delirium with cognitive outcomes. By using the delirium 
measure derived above, along with delirium exposures determined directly in any cohort studies, 
the prospective association with dementia and cognitive decline can be investigated. 
Objective 3: Investigate how these associations relate to underlying dementia pathology. In the 
population studies with neuropathology specimens, the independent contributions of delirium 
and dementia pathology to cognitive decline can be modelled. This would allow assessment as to 
whether any association between delirium and cognitive decline could occur through Alzheimer, 
vascular or Lewy body pathology, or otherwise through distinct and novel pathways. 
Objective 4: Develop novel methods for retrospectively ascertaining delirium. This could be 
achieved by using extracts from the clinical record of inpatients, where delirium had been 
concurrently ascertained by an experienced clinician at the bedside (reference standard). Key 
extracts could be assembled as a vignette, and a consensus expert panel could retrospectively 
determine a delirium diagnosis (index test). 
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3 Constituent cohort studies 
The data for this thesis are primarily drawn from three cohort studies. This chapter provides a 
detailed description of these cohorts to give the full context for the findings presented in the 
following chapters (Chapters 4 to 7). This chapter also contains a specific section on how 
delirium was defined for this thesis in each study, that is, how delirium was operationalised as an 
exposure. Detailed neuropathology methods are reported in Appendix Section 10.4. 
Vantaa 85+, CC75C, and MRC-CFAS are the three constituent cohorts of this thesis. There are 
two common features to the design of these cohorts: (i) population-based sampling; and (ii) a 
brain donation programme with standardised neuropathological assessment of autopsy material.  
Chapter outline 
 Vantaa 85+ 
 Cambridge City over-75s Cohort  
 MRC-Cognitive Function and Ageing Study 
 Epidemiological CLinico-Pathological Studies in 
Europe Collaboration (EClipSE) 
 
A systematic review conducted in 2005 identified six population-based studies of dementia 
incidence with neuropathological data (Zaccai et al. 2006). The studies included in this thesis 
represent half of the population studies ever conducted on the topic, and the entirety of data 
from European populations. Individual participant data from these three cohorts have been 
brought together in the Epidemiological Clinico-pathological Studies in Europe (EClipSE) 
harmonisation project (section 3.4). The provenance of the EClipSE project arose through the 
recognition that participant-level data could be combined for more powerful analyses, and in 
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addition to the systematic reviews presented in the previous Chapter, this dataset forms the basis 
of the primary analysis for this thesis. 
The key features of the studies are summarised in Table 3-1. The following sections present the 
epidemiological details of each cohort. Similarities and differences between the cohorts are 
explored in section describing the EClipSE project (section 3.4).  
Table 3-1 Summary of studies used in this thesis. 
Study Total sample Site Age sample Donors 
Vantaa 85+ 553  Vantaa, Finland ≥85 290 (52%) 
CC75C 2,166  Cambridge, UK ≥75 241 (11%) 
CFAS 18,226  UK multicentre* ≥65 456 (3%) 
Abbreviations: CFAS Cognitive Function and Ageing Study; CC75C Cambridge City over-75s 
Cohort. 
* CFAS sampled from six geographical areas: four urban (Newcastle, Nottingham, Liverpool, 
Oxford) and two rural (Cambridgeshire, Gwynedd) 
 
 
3.1 Vantaa 85+ 
The aim of the Vantaa 85+ study was to investigate the population health of the oldest-old by 
assessing burden of illness, functional abilities and service needs of all residents of the city of 
Vantaa, southern Finland. 
3.1.1 Population, setting and study design 
Vantaa is a city in southern Finland. All persons aged ≥85 years resident in the city were eligible, 
based on information from the Population Register Centre (Maistraattit). Participants and their 
informants were invited to attend baseline assessments by a study neurologist and nurse at the 
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local hospital, or examined in their own home or institution if necessary. 601 individuals were 
eligible, and 553 consented to participate in the study. Of these 48 persons not recruited, 11 were 
due to refusal to participate, 1 could not be contacted and 36 died between agreeing to 
participate and the first examination. Baseline assessment was in 1991, with follow-up 
examinations in 1994, 1996, 1999, 2001. Figure 3-1 shows the follow-up schedule and numbers 
examined at each wave. 
 
Figure 3-1 Vantaa 85+ cohort flow diagram. Wave A = 1991; Wave B = 1994; Wave C = 1996; 
Wave D = 1999; (Wave E = 2001, not shown). 
 
3.1.2 Clinical assessments 
The standard interview included socio-demographic questions, social networks and well-being. 
Questions on chronic illnesses and medication were corroborated by access to medical records 
and physical examination. 
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Cognition was assessed at every wave using the Mini-Mental State Examination (MMSE) 
(Folstein et al. 1975), the Short Portable Mental Status Questionnaire (Pfeiffer 1975), and the 
Clinical Dementia Rating Scale (Morris 1993). Depression was assessed using the Depression 
Status Inventory (Zung 1972). Functional abilities were measured with the Personal and 
Instrumental Activities of Daily Living scales (Katz et al. 1963; Lawton et al. 1969). Hospital, 
primary care and social work records were also used to help identify incident dementia in 
participants between last assessment and death.  
3.1.3 Dementia assessments 
Dementia diagnosis by DSM-III-R criteria (APA, (1987)) was agreed by two neurologists 
simultaneously examining each participant. Dementia subtypes were classified using National 
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease 
and Related Disorders Association for Alzheimer’s dementia (McKhann et al. 1984) and 
National Institute of Neurological Disorders and Stroke and Association Internationale pour la 
Recherché et l'Enseignement en Neurosciences for vascular dementia (Roman et al. 1993).  
3.1.4 Neuropathology and genetic assessments 
Biological samples included autopsy and neuropathological examination in 290 (52%) of 
participants (described in more detail below) and bloods (of which 94% have been sequenced).   
3.1.5 Impact of the study 
Because the oldest-old are generally under-represented in dementia research (Schoenmaker et al. 
2004), the descriptive findings alone from the cohort can be regarded as significant contributions 
to the literature. The key results of the study highlighted the difficulties of clinico-pathological 
correlations in dementia in unselected populations of the oldest-old (Polvikoski et al. 2001). It 
challenged the idea that medial temporal lobe atrophy on MRI could differentiate Alzheimer’s 
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from other dementia subtypes (Barkhof et al. 2007). Apolipoprotein 4 (ApoE) was associated 
with neocortical amyloid (Polvikoski et al. 1995), strongest in those with dementia (Myllykangas 
et al. 1999). In demonstrating this, Vantaa 85+ was the first to show that (ApoE) was biologically 
important in this age group.  
In addition to the generalisability of an unselected sample, the main strengths of the study come 
from the very high participation and the integration of the study with health and social care 
information. Autopsy data in 52% of the sample is among the highest ever reported. The main 
weaknesses come from the high attrition early in the study (through death), and the 2-3 year 
follow-up schedule which might have under-estimated clinically important events. 
 
3.2 CC75C 
The Cambridge City over-75s Cohort (CC75C) is one of the largest and longest-running 
population-based studies of the oldest-old.  
3.2.1 Population, setting and study design. 
The sampling was designed to recruit persons aged ≥75 years from representative general 
practices in the city of Cambridge. Dementia prevalence was estimated from a population of 
2610 (95% of those eligible) (O'Connor et al. 1989). The baseline cohort to the longitudinal 
incidence phases comprised slightly fewer participants (n= 2165) through the exclusion of one of 
the original GP practices because of differential recruitment. These have been followed-up over 
2-4 year intervals. The flowchart in Figure 3-2 summarises the main stages to date.  
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Figure 3-2 CC75C flow pathway (survey 10, 2012 not shown). 
 
3.2.2 Clinical assessments 
The structured schedule was administered by trained interviewers. Questions included those on 
socio-demographic, health-related questions (self-reported illness, healthcare use and medication) 
and functional capacity. Cognitive assessments were based on the Cambridge Cognitive 
Examination (CAMCOG) (Huppert et al. 1995) and included the MMSE.  
Informant data were collected in subsequent surveys, especially valuable given the high attrition 
due to mortality. Proxy interviews on a subsample of participants (including brain donors) were 
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undertaken, known as the Retrospective Informant Interview (RInI). These structured interviews 
covered physical and cognitive functioning (based on the CAMDEX schedule), as well as 
information on health and social care needs during the final illness of the participant. These 
interviews are a major source of information on delirium exposure (see section 3.5). 
3.2.3 Dementia ascertainment 
After the baseline cognitive screening assessment, those who scored 23 or below in the MMSE, 
and a sample of those with MMSE scores 24 or 25, were assessed using the Cambridge Mental 
Disorders of the Elderly Examination (CAMDEX) (Roth et al. 1986), a structured schedule 
specifically designed to detect mild dementia. The CAMDEX includes a mental state 
examination, a psychiatric history, detailed cognitive testing, and an interview with a proxy 
informant. 
In the brain donors, dementia status at death was established by consensus conferences based on 
DSM-IV, using all available information (but blinded to neuropathology data). Subtype and 
severity information was also decided by reference to DSM-IV criteria and were consistent with 
other diagnostic systems, e.g. CAMDEX and NINCDS-ADRDA (Brayne et al. 2009). 
3.2.4 Neuropathology and genetic assessments 
Bloods were collected from year 10 (survey 4). The brain donation programme was established 
after survey 2, and was the first population-based study to approach both those with and without 
dementia in this way. Brain tissue samples were available in 246 (11% of the follow-up cohort), 
with donors showing no significant differences from the rest of the cohorts in terms of dementia 
prevalence and age (Brayne et al. 2009). 
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3.2.5 Impact of the study 
CC75C was one of the earliest studies of dementia epidemiology in UK. As well as estimates of 
prevalence and incidence in a representative sample of oldest-old, it has reported data on the 
impact of cognitive impairment on health services, long-term care, terminal decline and palliative 
care. CC75C also added to the understanding of continuous distributions of cognition and 
cognitive change in the general population. Consistent with the Vantaa 85+ findings, the 
neuropathology work showed that classical Alzheimer’s pathology was demonstrable in persons 
without dementia. As with Vantaa 85+, the main limitations relate to attrition due to death or 
incomplete follow-up. 
 
3.3 CFAS 
The Medical Research Council-Cognitive Function and Ageing Study (MRC-CFAS, or simply 
CFAS) is one of the largest population-based studies of dementia epidemiology to date. The aims 
of the study have evolved since its inception, and cover a wide range of themes, including 
descriptive epidemiology, neuropathology, molecular epidemiology, and public health policy. 
3.3.1 Population, setting and study design 
CFAS is a multi-centre study. Four centres sampled from urban areas: Newcastle, Nottingham, 
Oxford and Liverpool), and two sampled from rural areas: Cambridgeshire and Gwynedd 
(Figure 3-3). Five sites are identical, and one (Liverpool) started before the others and until its 
third wave, had a different sampling and assessment schedule. The core design for case 
ascertainment in the five identical sites followed a two-stage framework. A screening 
examination was followed by a more detailed assessment of the 20% with the lowest cognitive 
scores and a random subsample from the remaining 80%. Individuals were followed as 
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frequently as possible (every 1-2 years in the brain donor sample) and at year 10, the entire 
cohort was re-examined (Figure 3-4). Liverpool started recruitment in 1989, the other sites from 
1991. 
 
Figure 3-3. Geographic sampling areas in CFAS (used with permission). 
 
Family Health Service Authority (FHSA) lists were used as the sampling frame within a defined 
geographical area, and this specifically included persons resident in institutions. The eventual 
sample was stratified to have equal numbers aged 65 to 74 and aged 75 and over, resulting in 
around 2500 participants in each area (in Liverpool, around 5000 participants stratified by 5 year 
age band and sex).  
The follow-up waves for the identical sites are shown in Figure 3-4. The first phase consisted of 
the baseline prevalence screen and detailed assessment, with higher risk participants followed-up 
more intensively for incident dementia. 
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Figure 3-4. CFAS cohort flow pathway (Liverpool not shown). C12-C16 only for those agreeing 
to brain donation. 
 
Detailed analyses of attrition and loss to follow-up have been undertaken. Individuals who 
refused were shown to have higher mortality than participants and the effect of this over varying 
timeframes has been investigated (Matthews et al. 2004; Matthews et al. 2006). 
3.3.2 Clinical assessments 
Interviews were carried out in participants’ own home by trained lay interviewers using laptops 
and automated software. Interviewers had undergone a continuous process of training with 
regular meetings and rating sessions. The assessment interview was based on the Geriatric 
Mental State Examination (GMS) (Copeland et al. 1986), and as such is a structured schedule 
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amenable to administration by non-clinicians. The standardised GMS comprises measures that 
explore psychiatric symptoms of organicity, depression, anxiety and psychosis. In persons 
perceived as being too frail, ill or tired, a ‘priority mode’ could be activated to focus on a 
minimum dataset. All information was based on self-report, but informant proxies were also 
interviewed (in the History and Aetiology Schedule). Each interviewer undertook assessments 
blinded to the data acquired in previous phases. As for CC75C, proxy informants of brain 
donors were interviewed after a participant had died, using a similar RInI questionnaire. It has 
been shown that retrospective informant data correlates well with cognitive scores measured in 
late life (Marioni et al. 2011). 
Throughout CFAS, the main cognitive measures were the mini-mental state examination, 
supplemented with additional questions from the CAMDEX schedule. 
3.3.3 Dementia ascertainment 
The structured interview schedule collected information on psychiatric symptoms necessary for 
categories to be assigned based on a computerised algorithm, thereby directly operationalising 
the diagnostic criteria. This approach has been validated against clinical diagnoses based on 
DSM-III-R (Kay et al. 1998). 
3.3.4 Neuropathology and genetic assessments 
All persons attending the year 6 assessment were approached for blood specimens. 
Apolipoprotein E effects on dementia risk (Keage et al. 2010) and neuropathology (Nicoll et al. 
2011). The brain donation programme was a component of the study from the outset, 
oversampling dementia cases by design. Some participants intending to donate brain tissue are 
still being followed, but 456 brains (3%) comprise the most recently analysed dataset (Matthews 
et al. 2009; Savva et al. 2009). 
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3.3.5 Impact of the study 
CFAS is the largest epidemiological study of its kind, covering the descriptive epidemiology of 
dementia (MRC CFAS 1998; Matthews et al. 2005), as well as intermediate cognitive states 
(Stephan et al. 2008). CFAS has also been instrumental in exploring the relationship between 
cognitive impairment and mortality, disability, carer burden and health care costs (Melzer et al. 
1999; MRC CFAS 2000; Neale et al. 2001; Spiers et al. 2005; Comas-Herrera et al. 2007). The 
descriptive epidemiology of other AGECAT-derived psychiatric syndromes, e.g. depression, has 
been reported (McDougall et al. 2007; Kvaal et al. 2008). CFAS has also added to our 
understanding of neurocompensation and cognitive reserve, particularly with respect to 
education (Brayne et al. 2010). As detailed elsewhere in this thesis CFAS has made a sizeable 
contribution to the understanding of the neuropathological correlates of dementia in unselected 
populations.  
 
3.4 EClipSE 
The Epidemiological Clinico-pathological Studies in Europe (EClipSE) collaboration represents 
the data harmonisation of these three population-based cohort studies (Table 3-1) (EClipSE 
Collaboration 2009). The principal aim of the project is to increase the statistical power of the 
studies using individual patient data. This allows for more sophisticated investigations of clinico-
pathological relationships, including interactions between variables. It is the largest collection of 
brains from unselected populations with 987 participants in the current dataset. 
3.4.1 Similarities across the cohorts 
All three cohorts are population-based studies, and each study started roughly the same time 
(within six years of each other). Though CFAS recruited persons aged 65 and older, persons over 
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75 were over-sampled, so, together, these cohorts are representative of the oldest-old from the 
era. Two studies are from the UK, and relied on similar population-registration systems and 
sampling techniques. CC75C and Vantaa 85+ targeted whole populations aged ≥75 and ≥85 
respectively, with no sampling necessary. Each study was linked to national statistics services that 
allowed tracking of participant mortality. 
3.4.2 Differences across the cohorts 
There are some important differences between cohorts. Firstly, there may be differences that 
arise from cultural, linguistic or geographical reasons. The distribution of years of education 
differs markedly across cohorts. In Vantaa, the median years of education was 4, and 52% of 
participants had exactly this number of years, making it more difficult to account for the effects 
of education on clinical and pathological outcomes (Brayne et al. 2010).  
The operationalisation of dementia was different in each study. Vantaa relied on two assessments 
by neurologists at each study visit, reaching agreement with respect to DSM-III-R. For brain 
donors, CC75C used a multidisciplinary consensus after participants had died, based on all 
available information including informant interview data, based on DSM-IV. CFAS used the 
AGECAT algorithm derived from DSM-III-R and for those without full interview data all 
available clinically relevant data blinded to neuropathology was used to determine dementia 
status at death (e.g. death certification, informant interviews). One other difference is that Vantaa 
participants were examined by a neurologist, so there is a greater level of clinical detail compared 
to self-reported conditions in the UK cohorts. 
3.4.3 Representativeness of brains 
The proportion of participants undergoing brain donation ranged from 3% for CFAS, 10% for 
CC75C, and 52% for Vantaa 85+. Whereas the opportunity for brain donation was routinely 
offered to Vantaa participants, the UK cohorts over-sampled for cognitive impairment as the 
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donation process was offered to the more intensively assessed groups (except Nottingham, 
where all participants were approached). Therefore, despite the proportion of brain donors 
CFAS being low, the sampling is such that the overall representativeness of the cohort was 
maintained. In Vantaa 85+, brain donors are similar to persons not donating for clinical 
parameters: age at death, sex, education, dementia status at death, duration of dementia. Other 
than a greater proportion of persons with cognitive impairment and dementia, CC75C and CFAS 
brain donors were otherwise representative of the rest of the cohort in terms of age at death.  
3.4.4 Clinical data 
Demographic data include date of birth, sex, marital status, years of education, social class, place 
of residence. Measures of social contact and religious participation were also available in each 
study. In addition, physical health, personal and instrumental activities of daily living, and 
psychiatric symptomatology are available. 
The MMSE is the primary measure of cognition across all studies and interviews. Other 
neuropsychological data are available, more so in CC75C and CFAS, though these are not 
directly comparable to the other measures in Vantaa 85+. Substantial data from informant 
interviews are also available in the UK cohorts, and these constitute much of the information on 
delirium exposures (Section 3.5 and Chapter 0). 
3.4.5 Neuropathological and genetic data 
Each study assessed neuropathology in parafﬁn-embedded brain tissue, blind to clinical status. 
The median post-mortem interval was less than 24 hours, but with some variation across studies. 
CC75C and CFAS used the full Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD) protocol (Mirra et al. 1991) along with Braak staging as a semi-quantitative measure of 
neurofibrillary tau. Vascular pathology was assessed in a variety of ways, including microvascular 
and large artery disease. Lewy bodies in the substantia nigra were assessed with haematoxylin and 
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eosin, but also included immunohistochemical staining against α-synuclein (or ubiquitin in some 
of the earlier CC75C specimens). Vantaa 85+ also reported neuronal loss in the substantia nigra 
as a marker of Lewy-body disease. CFAS and CC75C participants have a CERAD 
neuropathological classiﬁcation of dementia subtype. ApoE genotype was available on 70% 
(n=680) of the sample. The neuropathological methods are detailed further in section 10.4 and in 
Chapter 5. 
3.4.6 Comment 
The EClipSE collaboration represents a unique dataset, with an opportunity to undertake 
analyses on clinic-pathological correlations in the largest collection of brains from unselected 
populations created to date. Other work in the field has tended to focus on selected populations 
(e.g. tertiary referral centres), though there may be several filters before arriving at a study 
sample. Though the characteristics of donors are comparable to non-donors, oversampling of 
cognitively impaired participants in CFAS led to an enriched sample in this respect. Nonetheless, 
the broad representativeness of the participants remains high. Previous work in each study 
contributing to EClipSE has offered significant advances to our understanding in the field – 
precisely because the findings are drawn from unselected samples.  
The central aim of this thesis is to understand how delirium inter-relates with longitudinal 
trajectories of cognitive change, dementia and neuropathological status at death. 
 
3.5 Delirium operationalisation 
A core task for this thesis was gathering all possible sources of information on delirium, or 
possible delirium, from each of the cohort studies. No study prospectively identified incident 
delirium. Therefore detailed characterisation of delirium phenomenology, severity, duration and 
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aetiology was not possible in these population studies. Nonetheless, informant data and 
information from medical case notes provided indirect information about delirium and other 
changes in mental status in the context of acute illness such that a variable corresponding to 
likely delirium exposure could be derived by integrating information from all these sources. 
Table 3-2 summarises the available sources. 
Table 3-2. Summary of data sources for derivation of delirium exposure. 
Study Sources In whom When 
Vantaa 85+ At every interview, history of 
delirium asked on direct 
questioning to participant and 
informant, with reference to 
medical records and DSM-III-R 
checklist. 
Every participant At baseline and in every 
subsequent interview 
(Years 0, 3, 5, 8, 10) 
CC75C Delirium part of CAMDEX 
CAMDEX-informant at RInI 
MCI subset 
Brain donors 
Years 0, 2, 3, 5 
Shortly after death 
CFAS GMS questions 
HAS 
RInI 
 
Every participant 
20% subset 
Brain donors 
Throughout 
Throughout 
Shortly after death 
CAMDEX Cambridge Mental Disorders of the Elderly Examination 
RInI Retrospective Informant Interview 
GMS Geriatric Mental State, HAS History and Aetiology Schedule 
 
In Vantaa 85+, ascertaining history delirium was an explicit component of the study from the 
outset (Rahkonen et al. 2001). History of delirium was specifically asked about at baseline and at 
each follow-up. Participants and their informants were asked about symptoms of delirium 
according to the DSM-III-R checklist. Participant recall was corroborated with records from 
primary and secondary care, which were available at the time of interview. A study diagnosis of 
delirium history prior to recruitment, or at subsequent waves, was determined if the examining 
clinicians deemed that the evidence overall supported a diagnosis of delirium history. 
The relevant questions from the interview schedules in CC75C and CFAS are given in Appendix 
Section 10.3. Delirium symptoms were a component of the CAMDEX schedule used in CC75C. 
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This was applied to a random subset of participants with MMSE scores 24 or 25 during the first 
five waves. An adaptation of the CAMDEX schedule formed part of the retrospective informant 
interview (RInI) and these questions were concerned with symptoms observed in the time since 
last study assessment and death, including the final illness. 
In CFAS, the History and Aetiology Schedule (HAS) was an informant questionnaire applied to a 
subset of participants at each prevalence and incidence screen and assessment. In addition, 
questions from the GMS on attention and clouding of consciousness were used to infer delirium 
status. As with CC75C, information from the RInIs was used to assess delirium status in the last 
phase of life. These interviews have been vital sources in the work on terminal cognitive decline.  
 
3.6 Summary and orientation to subsequent chapters 
This chapter has described the cohorts from which the analyses in this thesis have been based. 
Chapter 4 details how these component questions were operationalised to construct a delirium 
diagnosis in CFAS that could be validated against mortality and dementia risk. Chapter 5 shows 
how these findings were replicated in Vantaa 85+, with further analysis of the impact of delirium 
on trajectories of cognitive decline. The neuropathological basis of this relationship is explored 
using 987 brains from the EClipSE (Chapter 6). Chapter 7 describes the validation of a chart-
based method for deriving a retrospective diagnosis for delirium. This gives new possibilities for 
this technique to furnish existing and on-going cohort studies with a measure of delirium. 
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4 Descriptive epidemiology of delirium in CFAS 
4.1 Summary 
In the general population, the epidemiological relationships between delirium and adverse 
outcomes are not well defined. The aims of this chapter cover: (1) construction of an algorithm for 
the diagnosis of delirium using the Geriatric Mental State (GMS) examination; (2) testing the 
criterion validity of this algorithm against mortality and dementia risk; (3) reporting the age-specific 
prevalence of delirium as determined by this algorithm. 
Participant and informant data in a randomly weighted subsample of the MRC Cognitive Function 
and Ageing Study were taken from a standardised assessment battery. The algorithmic definition 
of delirium was based on the DSM-IV classification. Outcomes were: proportional hazard ratios 
for death; odds ratios of dementia at 2-year follow-up. 
Data from 2197 individuals, representative of a population of 13004, were used (median age 77 
years, 64% women). Delirium was associated with a new dementia diagnosis at 2 years (OR 8.82, 
95% CI 2.76 to 28.2) and death (HR 1.28, 95% CI 1.03 to 1.60), even after adjustment for acute 
illness severity. Similar associations were seen for subsyndromal delirium. Age-specific prevalence 
increased with age from 1.8% in the 65-69 year age group to 13.5% in the ≥90 age group (p<0.01 
for trend). For subsyndromal delirium, age-specific period prevalence ranged from 8.2% (65-69 
years) to 40.3% (≥90 years). 
These results demonstrate the possibility of constructing an algorithmic diagnosis for delirium 
using data from the GMS schedule, with criterion validity for mortality and dementia risk. These 
are the first population-based analyses able to account prospectively for both illness severity and a 
previous study-diagnosis of dementia.  
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4.2 Introduction 
Delirium is a serious neuropsychiatric syndrome presenting with inattention and global changes in 
cognition (MacLullich et al. 2011). Delirium arises as a consequence of a neurological or systemic 
illness. It is well-recognised that there is an inverse relationship between predisposing (ageing, 
cognitive impairment) and precipitating (illness severity) factors (O'Hanlon et al. 2013). Delirium is 
therefore a sensitive marker of acute illness in older people. This association with acute illness has 
resulted in the vast majority of delirium studies being undertaken in hospital cohorts (Khan et al. 
2012). However, this introduces selection biases as not all persons with delirium may reach 
medical attention and comparisons to pre-morbid cognitive functions are difficult.  
In hospital samples, a major concern is that delirium contributes to persistent cognitive deficits, 
independently of predisposing and precipitating factors (Witlox et al. 2010). This has also been 
considered for subsyndromal delirium, where individuals have one or more of the diagnostic 
features of delirium (Cole et al. 2003a). Indeed, any examination of the utility of a delirium 
definition should incorporate criterion validity tests for mortality and future dementia. In 
prospective community cohort studies, adverse cognitive outcomes have been associated with 
hospitalisation per se (Ehlenbach et al. 2010; Iwashyna et al. 2010; Wilson et al. 2012a), though 
none has been able to specify if delirium is a key determinant (Section 2.3). 
Even in the older population, the point-prevalence of delirium in the community is likely to be 
low, though this understanding is based on a systematic review identifying only three prevalence 
estimates in population samples (Section 2.2) (Davis 2013). Furthermore, epidemiological studies 
may under-estimate acute illness and/or prevalent delirium as people who are unwell are less likely 
to be interviewed. However, the period-prevalence is higher and the same systematic review 
identified the Gerontological Regional Database (GERDA) study reporting 27% of persons aged 
85 and older in the general population with delirium in the previous month (Eriksson et al. 2011). 
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This suggests that whole population samples could efficiently investigate delirium if stratified 
subsamples at higher risk for cognitive impairment are more intensively studied. 
Delirium is clinically defined by application of a psychiatric reference standard such as the DSM, 
where the core features are altered consciousness, cognitive and/or perceptual disturbance, acute 
and fluctuating change, in relation to a general medical condition (Section 1.3). Based on this, there 
is an opportunity to construct an algorithmic diagnosis for delirium in population-based cohort 
studies collecting psychiatric symptoms. Such an approach is well-established in dementia, but yet 
to be systematically applied in delirium, and particularly not in population studies. Accordingly, 
using data from the population-based Medical Research Council Cognitive Function and Ageing 
Study (CFAS) the aims here are to: (1) construct an algorithm for the diagnosis of delirium in 
population-based studies using the Geriatric Mental State (GMS) examination based on clinical 
principles; (2) test the criterion validity of this algorithm against mortality and dementia risk; (3) 
report the age-specific prevalence of delirium as determined by this algorithm. 
 
4.3 Methods 
4.3.1 Population 
Data from the MRC Cognitive Function and Ageing Study (CFAS) were used. The principal 
methods for CFAS have previously been presented in detail in Section 3.3. In brief, CFAS was a 
multi-centre study, with sampling from four urban (Newcastle, Nottingham, Oxford and 
Liverpool), and two rural areas (Cambridgeshire and Gwynedd) in the UK. The present report 
only concerns the five identical sites (excluding Liverpool). Family Health Service Authority 
(FHSA) lists were used as the sampling frame within a defined geographical area, and this 
specifically included people resident in institutions. Figure 4-1 shows the two stage sampling 
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process for case ascertainment. A screening examination was started in 1991 (S0, n=13004). Then, 
a stratified sample consisted of approximately 20% selected depending on centre, age (equal 
numbers aged 65–74 and ≥75), and cognitive ability (weighted toward the more cognitively frail, 
based on the screening assessment), and a random subsample from the remaining 80% (A0, 
n=2640). Interviews of participant informants were also undertaken (H0, n=2197). Participants 
were followed at two years, with further subsets thereafter, including a full sweep at 6 and 10 years. 
The number of participants at baseline and at the first two-year follow-up is shown in Figure 4-1. 
Mortality outcomes were notified through reports linked to the Office of National Statistics. 
 
Figure 4-1. Assessment and follow-up schedule for the first two years of CFAS. 
 
4.3.2 Interviews 
Interviews were carried out in participants’ own home (including care homes) by trained 
interviewers. At screening, information on socio-demographic, physical and behavioural status was 
collected in addition to health (including self-reported chronic conditions) and cognitive function, 
assessed using the MMSE.  The assessment interview was based on the GMS (Copeland et al. 
1986), and as such is a structured schedule amenable to administration by trained non-clinicians. 
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The GMS comprises measures exploring psychiatric symptoms of organicity, depression, anxiety 
and psychosis, with ratings for each derived using the AGECAT algorithm. The study diagnosis of 
dementia was based on the GMS B3 AGECAT algorithmic differential diagnosis, where the 
dementia component is organicity at case level O3 and above. This approach has been validated 
against clinical diagnoses based on DSM-III-R (Kay et al. 1998). All information was based on self-
report and cognitive testing using the CAMDEX. Informant proxies were also interviewed in a 
standardised manner using a set of questions complementary to the GMS known as the History 
and Aetiology Schedule (HAS). Informants were asked questions exploring psychiatric symptom 
clusters occurring in ‘recent weeks and months’. Each interviewer for C2 undertook assessments 
blinded to data acquired in the baseline phase (S0/A0/H0).  
Questions from A0 and H0 (Figure 4-1) pertaining to delirium symptoms are shown in Table 4-1. 
These were used to define an algorithm for a study definition of delirium based on DSM-IV, 
where participants were required to demonstrate all three of: (i) acute change; (ii) fluctuation); (iii) 
inattention and/or drowsiness (Box 4-1). Subsyndromal delirium was defined as having at least 
one of these features. In addition, interviewers were asked to judge if responses were affected by 
their subjective rating of any acute illness in the participants (categorised as: none, mild, moderate, 
or severe). 
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Table 4-1. The prevalence of delirium symptom clusters at baseline. 
Symptom Interview question (yes / no) N (2197) % 
Acute 
change 
Has there been sudden worsening in mental confusion in recent 
weeks or months, which has continued to the present time? 
(informant) 
199 9.1% 
    
Fluctuation Are there episodes lasting days or weeks when his/her thinking 
seems quite clear and then becomes muddled? 
264 12.0
% 
 Are there long periods during the day when s/he is lucid and not 
confused (that is, knows where s/he is and knows what s/he is 
doing and saying)? 
  
 Does s/he get confused at night, wander about or talk nonsense?   
 Or at any other time? What about during the day time?   
    
Inattention Impaired ability to focus sustain and shift attention 230 8.7%
* 
    
Drowsiness Disturbance of consciousness, that is either being sleepy, or 
awake but unaware of their surroundings Judged delirium 
142 6.5% 
 Is the subject drowsy now?   
    
Delirium 
judgment 
Could a physical illness (not drugs or alcohol intoxication) be 
sufficient explanation for the subject's mental or psychiatric 
symptoms (e.g. delirious due to acute infection)? 
34 1.6% 
*Question comes from prevalence assessment A0, denominator 2640, all other questions from 
History and Aetiology Schedule 
 
Box 4-1. Delirium algorithm 
Delirium
  
 
= (Acute change) + (Fluctuation) + (Inattention and/or drowsiness) 
OR 
= Judgment: a physical illness … be sufficient explanation for the subject's 
mental or psychiatric symptoms (e.g. delirious due to acute infection) 
 
4.3.3 Statistical analyses 
Stata 12.1 (StataCorp) was used for all analyses. The criterion validity of the delirium algorithm was 
tested in two ways: (i) hazard for mortality and (ii) odds of a new diagnosis of dementia at two year 
follow-up. The association between delirium and mortality was evaluated using Cox proportional 
hazards models, adjusted by age, sex and prevalent dementia. The association between delirium 
and dementia was assessed using logistic regression where the outcome was new dementia at two-
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year follow-up (C2, Figure 4-1) in the population known to be dementia-free at baseline, adjusted 
by age and sex (A0, Figure 4-1). Each delirium symptom was tested for both outcomes, as well as 
the overall algorithmic diagnosis. Testing the criterion validity of the algorithmic diagnosis also 
adjusted for interviewers’ rating of acute illness severity. Post-estimation tests included Hosmer-
Lemershow goodness-of-fit and Schoenfeld residuals for logistic and Cox models respectively. The 
exact procedures for conducting regression analyses are described in the box below. 
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Box 4-2. Statistical procedures for multiple regression. 
1. Decide outcome of interest (dependent variable) 
- The nature of the outcome and the structure of the data determine the type of 
regression analysis, e.g. 
 Binary = logistic regression 
 Rate ratios = Poisson regression 
 Time-to-event = e.g. proportional hazards regression 
 Continuous = linear regression 
2. Selection of independent variables 
- Should be clinically justified, usually include age and sex 
- Over-adjustment is clinically and statistically possible. A maximum number of 
covariates is based on the sample size, usually considered in a ratio of 1:10. 
3. Inspection of distributions 
- Continuous variables: Gaussian? Or is transformation necessary? Unusual distributions 
might merit categorisation, but this results in loss of power and cut points should be 
clinically meaningful 
- Categorical variables: ordinal variables modelled as individual parameters, rather than 
as one quantity unless the grades are statistically and clinically meaningful. 
4. Estimate model 
- Each independent variable on outcome 
- correlations between each pair of covariates, considering clinical aspects each time 
- No automated variable selection (e.g. forward or backward stepwise approaches) 
- Final model based on parsimony and likelihood ratio testing 
5. Post-estimation testing (exact methods vary with regression technique) 
- Inspection of residuals 
- Formal tests, e.g. goodness-of-fit or Schoenfeld residuals 
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4.4 Results 
The subsample selected for this analysis included 2197 individuals assessed by both the GMS 
(participant) and HAS (informant) schedules at the assessment interview (A0). Median age was 77 
(interquartile range 71-84), and 1403 (64%) were women. In this weighted subsample of the whole 
baseline cohort, 511 (23%) had prevalent dementia. Table 4-1 lists the delirium symptom clusters 
and questions used to explore these, along with the prevalence of individual symptoms. Table 4-2 
gives the raw numbers for delirium in relation to prevalent and incident dementia and death over 
the two year period. 
Table 4-3 shows the results of the Cox proportional hazards survival analyses, adjusted by age, sex 
and prevalent dementia. In this weighted subsample, each delirium symptom was independently 
associated with higher mortality. This was also the case for the algorithmic diagnosis, even after 
adjustment for acute illness severity (HR 1.28, 95% CI 1.03 to 1.60). A similar risk for 
subsyndromal delirium was apparent (HR 1.41, 95% CI 1.23 to 1.62). 
Table 4-2. Cases of delirium and dementia, along with outcomes at 2 years. 
 No delirium 
(n=2075) 
 Delirium 
(n=122) 
 cases denominator   %  cases denominator   % 
Dementia at baseline 425 2065 21  86 119 72 
Death before 2 years 334 2065 16  53 119 45 
Incident dementia at 2 year 
follow-up 
102 1129 9  9   20 45 
Groups described here are from the assessed population, i.e. 20% most cognitively impaired at 
screen, plus random sample of remainder. 
Delirium defined through algorithm 
Dementia diagnoses from AGECAT. 
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Table 4-3. Survival models for delirium 
 N HR LCI UCI P value 
       
Delirium symptom clusters       
Inattention 2637 1.36 1.16 1.58 <0.01  
Acute change 2184 1.57 1.33 1.85 <0.01  
Fluctuation 2184 1.40 1.21 1.62 <0.01  
Drowsiness 2184 1.31 1.08 1.57 <0.01  
Judged delirium* 2184 1.92 1.35 2.74 <0.01  
       
Algorithm Delirium: final model 2159      
Delirium  1.28 1.03 1.60 0.03  
Dementia  1.83 1.63 2.06 <0.01  
Age (per year)  1.08 1.08 1.09 <0.01  
Sex (female vs male)  0.68 0.61 0.75 <0.01  
Illness severity       
 None  (Ref)     
 Mild  1.47 1.15 1.88 <0.01  
 Moderate  1.52 1.10 2.12 <0.01  
 Severe  3.14 2.23 4.42 <0.01  
        
Subsyndromal delirium: final 
model 
2159      
Subsyndromal delirium  1.41 1.23 1.62 <0.01  
Dementia  1.62 1.42 1.85 <0.01  
Age (per year)  1.08 1.07 1.09 <0.01  
Sex (female vs male)  0.67 0.61 0.75 <0.01  
Illness severity       
 None  (Ref)     
 Mild  1.32 1.03 1.70 0.03  
 Moderate  1.50 1.10 2.06 0.01  
 Severe  2.94 2.10 4.12 <0.01  
HR hazard ratio, LCI UCI 95% lower and upper confidence intervals respectively 
This table shows Cox proportional hazard models for death. 
The upper part of the table shows individual symptom clusters, and their association 
with mortality (adjusted for age, sex, baseline dementia and illness severity). 
* ‘Judged delirium’ refers to the overall impression of the interviewer that a participant 
had delirium. 
The middle part describes the full model for full syndromal delirium and the same 
adjusted covariates 
The middle part describes the full model for subsyndromal delirium and the same 
adjusted covariates 
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Table 4-4 gives the results of the logistic regression analyses assessing the odds of a dementia 
diagnosis at two year follow-up, adjusted by age and sex. In this weighted subsample, all delirium 
symptoms were associated with odds ratios greater than 1.0, but this was only statistically 
significant for acute change, fluctuation and drowsiness. The algorithmic diagnosis was 
significantly associated with a two year dementia diagnosis (OR 8.82, 95% CI 2.76 to 28.2). The 
estimate for subsyndromal delirium was half that of full syndromal delirium (OR 4.31, 95% CI 
2.41 to 7.73). 
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Table 4-4. Logistic models for 2 year dementia 
 N OR LCI UCI P value 
       
Delirium symptom clusters       
Inattention 1347 1.90 0.77 4.69 0.16  
Acute change 1149 7.63 3.47 16.75 <0.01  
Fluctuation 1347 6.84 3.67 12.77 <0.01  
Drowsiness 1347 4.83 2.50 9.35 <0.01  
Judged delirium 1149 4.44 0.78 25.26 0.09  
       
Algorithmic Delirium: final model 1140      
Delirium  8.82 2.76 28.2 <0.01  
Age (per year)  1.11 1.08 1.14 <0.01  
Sex (female vs male)  0.96 0.61 1.50 0.85  
Illness severity       
 None  (Ref)     
 Mild  1.66 0.57 4.79 0.35  
 Moderate  1.41 0.31 6.37 0.66  
 Severe  (omitted)     
       
Subsyndromal delirium: final 
model 
1140      
Subsyndromal delirium  4.31 2.41 7.73 <0.01  
Age (per year)  1.10 1.07 1.14 <0.01  
Sex (female vs male)  0.94 0.60 1.47 0.78  
Illness severity       
 None  (Ref)     
 Mild  1.02 0.35 2.95 0.98  
 Moderate  1.54 0.41 5.77 0.52  
 Severe  (omitted)     
OR odds ratio, LCI UCI 95% lower and upper confidence intervals respectively 
This table shows logistic regression models for dementia at two year follow-up. 
The upper part of the table shows individual symptom clusters, and their association 
with dementia (adjusted for age, sex, baseline dementia and illness severity). 
* ‘Judged delirium’ refers to the overall impression of the interviewer that a 
participant had delirium. 
The middle part describes the full model for full syndromal delirium and the same 
adjusted covariates 
The middle part describes the full model for subsyndromal delirium and the same 
adjusted covariates 
 
 
The age-specific period prevalence of delirium is given in Table 4-5 and Figure 4-2. The overall 
period prevalence in this enriched cognitive impairment subsample is estimated at 5.6% (95% CI 
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4.6 to 6.5). Age-specific prevalence increased with age from 1.8% in the 65-69 year age group to 
13.5% in the ≥90 age group (p<0.01 for trend). For subsyndromal delirium, age-specific period 
prevalence ranged from 8.2% (65-69 years) to 40.3% (≥90 years). In persons with prevalent 
dementia, 16.8% (95% CI 13.6 to 20.1%) had superimposed delirium.  
Table 4-5. Age-specific period prevalence of algorithmic delirium and subsyndromal delirium. 
 Delirium  Subsyndromal delirium 
Age 
(years) 
N Prevalence 
 (%) 
95% CI  N Prevalence 
 (%) 
95% CI 
65-69 8 / 453 1.8 0.6 – 3.0  45/549 8.2 5.9 – 10.5 
70-74 20 / 491 4.1 2.3 – 5.8  69/602 11.5 8.9 – 14.0 
75-89 19 / 399 4.8 2.7 – 6.9  75/472 15.9 12.6 – 19.2 
80-84 31 / 418 7.4 4.9 – 9.9  143/517 27.7 23.8 – 31.5 
85-89 23 / 280 8.2 5.0 – 11.4  113/334 33.8 28.7 – 38.9 
≥90 21 / 156 13.5 8.1 – 18.8  71/176 40.3 33.1 – 47.6 
 
 
 
Figure 4-2. Prevalence of delirium and subsyndromal delirium, by age group. 
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4.5 Discussion 
These results demonstrate the possibility of constructing an algorithmic diagnosis for delirium 
within a population-based framework using data from the GMS schedule including self and 
informant reported responses. This algorithm has criterion validity for mortality and dementia risk. 
These are the first population-based analyses able to account for both illness severity and prior 
prevalent dementia, suggesting that delirium has a deleterious effect on mortality and dementia risk 
beyond that expected from precipitating and predisposing factors alone. These findings also 
highlight the importance of age in the prevalence of delirium with the highest prevalence in the 
oldest-old group (i.e., ≥90 years). 
The strengths of this study derive from its large population-based sample size and availability of 
serial cognitive assessments in relation to incident dementia.  The major limitation is that the 
algorithm was not validated with concurrent clinical diagnosis. Furthermore, the period over which 
informants were asked to comment on delirium symptoms was not strictly defined (‘in recent 
weeks and months’) and may be overstated due to recall bias. The lack of assessments by clinicians 
also limits the precision of the data. Though the CFAS sample was population-representative in 
1991, the age-specific prevalence of dementia is lower in 2011 (Matthews et al. 2013) and so 
secular trends may constrain the accuracy of current delirium prevalence estimates.  
The estimated age-specific prevalence is lower than the only other estimate from GERDA, even 
though diagnoses included information from community medical records (Eriksson et al. 2011). 
Previously, the only population-based cohort to have assessed a delirium measure in relation to 
adverse outcomes is the Vantaa 85+ study (Rahkonen et al. 2001; Davis et al. 2012), described 
below in Chapter 5. In Vantaa 85+, delirium history was assessed at each interview by a 
neurologist with access to an informant and medical records, amounting to an estimate of period 
prevalence for the intervening 2-3 years between waves. The present analysis is much larger 
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(CFAS=2197representative of 13004 individuals, versus Vantaa=553). Though medical records 
were not available here, the advantage in CFAS is the possibility of accounting for illness severity, 
even though this assessment was subjective. The point estimates for mortality (CFAS HR 1.55 
(when unadjusted by illness severity) versus Vantaa HR 1.61) and two-year dementia risk (CFAS 
OR 8.82 versus Vantaa OR 8.65) are effectively the same. Though delirium diagnoses were derived 
through different approaches, this suggests the core features of inattention, altered arousal and 
acute fluctuations in cognitive function represent an adverse state for future outcomes regardless 
of the exact methods for operationalising the syndrome. 
In conclusion, these data add to the small literature on the population-based epidemiology of 
delirium. That delirium appears to be associated with increased dementia strengthens the argument 
that interventions for delirium may have an impact on the burden of cognitive impairment. 
Nonetheless, the core elements of the delirium-dementia relationship still require further 
exploration, particularly in the general population (Brayne et al. 2012). At the least, these findings 
indicate that it is possible to identify population samples with delirium and subsyndromal delirium 
at higher risk for dementia. 
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5 Clinical impact of delirium in Vantaa 85+ 
5.1 Summary 
Recent studies suggest that delirium is associated with risk of dementia, and also acceleration of 
decline in existing dementia. However, prior studies may have been confounded by incomplete 
ascertainment of cognitive status at baseline. Here a true population sample was used to 
determine if delirium is a risk factor for incident dementia and cognitive decline. The effect of 
delirium was also examined at the pathological level by determining associations between 
dementia and neuropathological markers of dementia in patients with and without a history of 
delirium. 
The Vantaa 85+ study examined 553 individuals (92% of those eligible) aged ≥85 years at 
baseline, 3, 5, 8 and 10 years. Brain autopsy was performed in 52%. Fixed and random-effects 
regression models were used to assess associations between (1) delirium and incident dementia 
and (2) decline in Mini-Mental State Examination scores in the whole group. The relationship 
between dementia and common neuropathological markers (Alzheimer-type, infarcts, Lewy-
bodies) was modelled, stratified by history of delirium.  
Delirium increased the risk of incident dementia (odds ratio 8.7, 95% confidence interval 2.1 to 
35). Delirium was also associated with worsening dementia severity (odds ratio 3.1, 95% 
confidence interval 1.5 to 6.3) as well as deterioration in global function score (odds ratio 2.8, 
95% CI 1.4 to 5.5). In the whole study population, delirium was associated with loss of one more 
Mini-Mental State Examination point per year (95% confidence interval 0.11 to 1.89) than those 
with no history of delirium.  
In persons with dementia and no history of delirium (N=232), all pathologies were significantly 
associated with dementia. However, in individuals with delirium and dementia (N=58), no 
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relationship between dementia and these markers was found. For example, higher Braak stage 
was associated with dementia but no delirium (odds ratio 2.0, 95% confidence interval 1.1 to 3.5, 
p = 0.02), but in those with a history of delirium, there was no significant relationship (odds ratio 
1.2 (95% confidence interval 0.2 to 6.7, p=0.85). This trend for ORs to be closer to unity in the 
delirium and dementia group was observed for neuritic amyloid, apolipoprotein ε status, 
presence of infarcts, α-synucleinopathy, and neuronal loss in substantia nigra. 
These findings are the first to demonstrate in a true population study that delirium is a strong 
risk factor for incident dementia and cognitive decline in the oldest-old. However, in this study, 
the relationship did not appear to be mediated by classical neuropathologies associated with 
dementia. 
 
5.2 Introduction 
Delirium is a severe, acute neuropsychiatric syndrome that affects at least 15% of hospitalised 
older adults (Inouye 2006; Siddiqi et al. 2006; Young et al. 2007; MacLullich et al. 2011). There 
has been much interest in whether delirium may be a marker for future dementia risk. In a 
population of memory clinic patients already diagnosed with dementia, delirium was associated 
with faster decline in cognitive test scores (Fong et al. 2009). Higher rates of dementia diagnosis 
were also observed in persons with postoperative delirium following elective hip surgery (relative 
risk 1.9, 95% CI 1.1 to 3.3) (Kat et al. 2008). These results are consistent with a systematic review 
of dementia outcomes following hospitalisation with delirium (Witlox et al. 2010). However, 
because dementia itself is a major risk factor for delirium, and around half of dementia is 
undiagnosed in hospital settings (Sampson et al. 2009), the key question of whether delirium is a 
risk factor for new onset dementia remains unanswered (MacLullich et al. 2009). Moreover, 
studies of selected hospital and memory-clinic samples may be biased toward more severe 
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disease. Capturing the full range of dementia risk following delirium within a population-based 
design would provide more generalisable risk estimates. 
The Vantaa 85+ study is a true population-based cohort study and is the only one to have 
explicitly measured delirium. This chapter address two main questions. First, does delirium 
increase the risk of incident dementia in this population? Second, in those with dementia, is a 
history of delirium associated with an increased with an increased burden of standard 
neuropathology markers of dementia? Whether delirium was associated with accelerated 
cognitive decline and increased severity of dementia was also determined.  
 
5.3 Methods 
5.3.1 Sample characteristics 
The Vantaa 85+ Cohort study methods have previously been reported in Section 3.1. Briefly, the 
study population comprised 553 persons, representing 92% of the 601 adults aged ≥85 years 
living in Vantaa in 1991. Participants were recruited from the whole population, unrestricted by 
residential or health status. Follow-up for incident dementia and other markers of health status 
occurred at 3 (n=277), 5 (n=155), 8 (n=65), and 10 (n=25) years. The study received approval 
from the Ethics Committee of the City of Vantaa. 
5.3.2 Clinical assessments 
Dementia diagnosis by DSM-III-R criteria (APA, (1987)) was agreed by two neurologists 
simultaneously examining each participant. Dementia subtypes were classified using National 
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease 
and Related Disorders Association for Alzheimer’s dementia (McKhann et al. 1984) and 
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National Institute of Neurological Disorders and Stroke and Association Internationale pour la 
Recherché et l'Enseignement en Neurosciences for vascular dementia (Roman et al. 1993). 
Further details on the clinical and cognitive assessments were described in Section 3.1.2.) 
At each interview, the examining neurologists assessed participants and informant(s) for a history 
of any episodes of delirium, specifically assessing: changes in cognitive functioning, level of 
alertness, psychotic and perceptual symptoms, with reference to a checklist of DSM-III-R criteria 
for delirium diagnosis (Rahkonen et al. 2001).  The reported history and number of episodes of 
delirium were corroborated with hospital case notes that were available at the time of 
assessment, and any additional likely episodes of delirium not recalled by participants or 
informants were ascertained through detailed inspection of hospital case and primary care case 
notes. Therefore, the study-ascertainment of delirium was retrospectively derived from multiple 
sources and the overall diagnosis accepted if the examining neurologists judged there was 
sufficient evidence from participant and informant recall and/or indication in the medical notes. 
At baseline and at each subsequent wave, the presence of the following conditions was assessed 
through interview and medical records: myocardial infarction; congestive heart failure; peripheral 
vascular disease, cerebrovascular disease; chronic lung disease; connective tissue disease; 
hemiplegia; diabetes mellitus, diabetes with complications; tumours; leukaemia; and lymphoma.  
5.3.3 Mortality 
Dates of death were collected through Statistics Finland. 
5.3.4 Neuropathology 
Brains were fixed in phosphate-buffered 4% formaldehyde solution for at least two weeks. All 
specimens were macroscopically examined by one pathologist, blind to all clinical data, using a 
standardised dissection and sampling protocol. Cerebral infarcts and lacunes were identified by 
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examination of the surface of the brain and from 1-cm-thick coronal slices of the cerebral 
hemispheres, from 5-mm-thick transverse slices of the brain stem, and sagittal slices of the 
cerebellum, histologically verified. In addition, a standardised set of samples were obtained from 
the middle frontal, superior temporal and middle temporal gyri, inferior parietal lobule, uncal 
region, hippocampal body, cingulate gyrus, occipital lobe (including the primary visual cortex) 
and midbrain. The protocols for quantifying Alzheimer-type (Braak stage (0 to 6); neuritic 
amyloid plaque (none 0 to severe 3)) (Polvikoski et al. 1995; Polvikoski et al. 2006), infarcts 
(present or absent) (Rastas et al. 2007; Ahtiluoto et al. 2010), and Lewy body (neuronal loss in 
substantia nigra (none 0 to severe 3); α-synucleinopathy (none 0 to severe 3) (Oinas et al. 2009)) 
pathologies have been described in detail (see Appendix Section 10.4.1). 
5.3.5 Genetic testing 
Apolipoprotein E (ApoE) genotyping was performed using both polymerase chain reaction and 
solid-phase mini-sequencing techniques (Syvanen et al. 1993; Polvikoski et al. 2006). 
5.3.6 Statistical analyses 
Stata 11.1 (StataCorp) was used for all analyses. Logistic regression was used to determine if 
episodes of delirium were associated with new onset of dementia. Because dementia 
neuropathology tends to be mixed in unselected populations (Matthews et al. 2009), assessment 
of the associations between delirium and clinical dementia subtypes was not attempted. Only 
episodes of delirium occurring at least one wave before participants last known as having no 
dementia were regarded as an exposure; controls were persons in whom dementia was never 
detected. Logistic regression was also used to assess worsening in Clinical Dementia Rating score 
in relation to a history of delirium before that wave. Similar analyses were conducted for 
functional sequelae, where outcomes in logistic models represented worsening in global function 
score. The association between delirium history at baseline and mortality was determined using a 
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Cox proportional hazards model. All models were adjusted for age, sex and co-morbidities (using 
equivalent weightings from the Charlson co-morbidity index) (Charlson et al. 1987). Confidence 
intervals (CI) of 95% were employed, and are reported in the results. Post-model testing included 
examination of Pearson residuals for logistic models and Schoenfeld residuals, and log-log 
survival plots for proportional hazards models. Each regression model followed the procedures 
outlined in Box 4-2. 
Longitudinal change in MMSE was modelled using random-effects linear regression for both 
MMSE at study entry (intercept) and rate of change in MMSE (slope), having first compared 
model fit for fixed intercepts and slopes using maximum likelihood estimates. ‘Time in study’ 
was used as the time metric. Covariance matrices were unstructured. The effect of delirium 
history at baseline, mean-centred age at baseline, sex, baseline functional status on intercept and 
slope was considered, and model fit assessed using likelihood ratio tests. The final model 
included adjustment for these variables for MMSE at study entry with an additional term 
adjusting for the influence of delirium history at baseline on rate of MMSE change. Finally, a 
quadratic term for the time metric was tested. After fitting models, assumptions were checked by 
constructing Q–Q plots of the standardised residuals.  
In keeping with previous methods, neuropathological variables were dichotomised into ‘high’ or 
‘low’ values (Savva et al. 2009; Brayne et al. 2010). This approach allows for simpler 
interpretation and is more likely to be robust. The relationships between these markers 
(exposure) and dementia (outcome) were evaluated using logistic regression models, adjusted for 
sex and age at death (Savva et al. 2009). These associations were then assessed, stratified by 
delirium history, to determine if the odds ratio for the dementia-pathology association differed 
between those with and without a history of delirium. The possibility of a statistical interaction 
was also tested using a multiplicative interaction term (delirium*pathology).  
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5.4 Results 
5.4.1 Participant characteristics 
Participant characteristics are summarised in Table 5-1. Figure 3-1 (page 64) shows the flow 
diagram for the study, and Figure 5-1 illustrates the subset with delirium. At baseline, there were 
71 persons (13%) with a history of delirium. There were no differences in age, sex or years of 
education between those with and without a history of delirium. However, persons with a history 
of delirium were more likely to have prevalent dementia (77% versus 33%, p<0.01) and lower 
MMSE scores (15/30 versus 21/30, p<0.01). A delirium episode was recorded at least once 
during the study in 121 persons (22%). Brain autopsy data were available in similar proportions 
of individuals with and without an episode of delirium (54% and 48% respectively, p=0.26).  
Table 5-1. Clinical characteristics of participants at baseline. 
 No history of 
delirium 
≥ 1 episode of 
delirium 
P value 
N at baseline (%) 482  (87%) 71  (13%)  
person.years 1901  164   
Mean age (SD) 88  (2.9) 90  (3.1) 1.00   
Sex (% women) 385  (80%) 55  (77%) 0.64 
Proportion with >4 years 
education (%)* 
98  (23) 10  (17) 0.31 
Mean time in study (years, 
IQR) 
3.2  (1.6—5.9) 1.9  (0.9—3.2) <0.01 
Co-morbidity score at baseline 
(IQR)† 
3  (1—4) 3  (2—5) <0.01 
Functionally independent at 
baseline (%) 
321  (67%) 24  (34%) <0.01 
Prevalent dementia 159  (33%) 55  (77%) <0.01 
MMSE      
 Baseline (IQR) 21  (17—26) 15  (10—19) <0.01 
 Last follow-up (IQR) 19  (11—24) 13  (9—17) <0.01 
A total of 121 participant s experienced delirium at any time during the study (22%). Of these, 
58 were brain donors (48%) and 232 brain donors had no history of delirium (54%) (P=0.26) 
 
† Comorbidity index uses the same weightings as the Charlson index. The maximum score is 19. 
Functionally independent refers to those who reported being fully independent or needing 
minor assistance to complete activities of daily living. 
* Years of education undetermined in 71 participants. 
The proportion of brain donor is given for persons experiencing delirium at any point during 
study. 
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Figure 5-1. Flow diagram showing history of delirium in relation to subsequent diagnosis of 
dementia. 
Participants without dementia are represented in the blue area. Those reporting a history of 
delirium are in the green boxes. Persons with or without a delirium history can receive a 
subsequent diagnosis of dementia (red box). 
 
5.4.2 Delirium and dichotomous outcomes 
A history of delirium at any wave in persons with no dementia was associated with a significantly 
higher risk of new dementia at the following wave (OR 8.7, 95% CI, 2.1 to 35) (Table 5-2). For 
all participants, delirium was also associated with a worse Clinical Dementia Rating score at 
follow-up (OR 3.1, 95% CI, 1.5 to 6.3) as well as deterioration in global function scores (OR 2.8, 
95% CI, 1.4 to 5.5) (Table 5-2). A history of delirium at study entry was associated with increased 
mortality, even after adjustment for co-morbidities (hazard ratio (HR) 1.6, 95% CI, 1.2 to 2.1). 
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Table 5-2. The association of between delirium and dichotomous clinical outcome. 
Outcome Delirium 
(n) 
No delirium 
(n) 
  LCI UCI P value 
Dementia a 10 311 OR 8.65 2.13 35.12 <0.01 
Dementia worsening b 38 226 OR 3.06 1.49 6.29 <0.01 
Functional worsening b 42 230 OR 2.76 1.38 5.52 <0.01 
Mortality c 71 469 HR 1.61 1.25 2.10 <0.01 
The results of four separate models where delirium is the exposure of interest, adjusted by age, sex 
and comorbidity, given with 95% confidence intervals (LCI, UCI) 
a The dementia outcome gives the odds ratio that a person with a history of delirium but no 
dementia was then diagnosed with incident dementia at the following wave. 
b The odds ratio of worsening in dementia (at least one point decline in clinical dementia rating 
scale) or function (at least one category decline in five-point scale from independent to fully 
dependent for all care needs) between baseline and first follow-up in persons also experiencing 
delirium. 
c Association between comorbidity and mortality is also significant in this model (HR, 1.24; 95% CI 
1.18 to 1.30) per point on comorbidity index. 
All Pearson and Schoenfeld residuals P > 0.1. 
 
5.4.3 Delirium and decline in MMSE score 
MMSE trajectory was best described by a quadratic model when contrasted with a linear model 
(Table 5-3). Figure 5-2 shows the predicted trajectories from the model fitted. MMSE scores at 
baseline were estimated at 28.6 (95% CI, 26.5 to 30.8), representing cognitive function for an 
individual with zero value on all covariates. In the whole population, cognitive function declined 
at 0.75 points per year (95% CI, 0.49 to 1.0), with a change in rate of decline of 0.07 points (95% 
CI, 0.49 to 1.0). Baseline MMSE scores of individuals with history of delirium were 3.0 points 
(95% CI, 1.4 to 4.5) lower than MMSE scores of individuals without any delirium. A history of 
delirium was associated with a significantly faster rate of decline in MMSE scores with decline of 
1.0 (95% CI, 0.11 to 1.89) MMSE point per year compared to those without delirium. 
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Table 5-3. Random-effects model of MMSE change. 
 β        LCI     UCI P value 
Intercept 28.64 26.46 30.81 <0.01  
Delirium -2.95 -4.47 -1.43 <0.01  
Age -0.15 -0.32 0.02 0.08  
Sex -1.21 -2.33 -0.08 0.04  
Functional status -2.86 -3.24 -2.48 <0.01  
      
Slope -0.75 -1.00 -0.49 <0.01  
Delirium effect on rate -1.00 -1.89 -0.11 0.03  
      
Slope acceleration -0.07 -0.10 -0.04 <0.01  
Estimates are given with 95% lower and upper confidence intervals (LCI and UCI). 
The model is mean-centred on age at baseline and ‘time-in-study’ is the time metric. 
All estimates are adjusted for MMSE at study entry. 
The upper part of the table shows estimates for the intercept, first estimating the intercept 
when all covariates = 0. The estimate changes with the addition of each covariate, subtracting 
the appropriate β coefficient where: delirium=yes; age per year; sex=female; functional status 
per increase in five-point scale. 
The lower part of the table gives coefficients estimating rate of change (per year) with the effect 
delirium has on this gradient. The slope acceleration is the quadratic term describing the overall 
trajectory of the model. 
 
Figure 5-2. Predicted trajectory of MMSE change for those with or without a history of delirium 
at baseline.  
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5.4.4 Delirium, dementia and neuropathological markers of dementia 
All neuropathological markers were significantly associated with dementia. However, when 
stratifying the group by history of delirium, the relationship between dementia there were no 
significant associations between dementia and neuropathology and genotype markers (all ORs 
closer to unity) (Figure 5-3). For example, higher Braak stage was associated with dementia but 
not delirium (OR 2.0, 95% CI 1.1 to 3.5, p = 0.02), but in those with a history of delirium, there 
was no significant relationship (OR 1.2, 95% CI 0.2 to 6.7, p = 0.85). This pattern was observed 
consistently with neuritic amyloid, ApoE status, presence of infarcts, α-synucleinopathy, and 
neuronal loss in substantia nigra. While this raises the possibility that the relationship between 
dementia and neuropathological markers is modified by a history of delirium, the investigation is 
under-powered to be sure of any relationship using an interaction term (Table 5-4). Delirium 
history was not itself associated with any of the neuropathological markers of dementia or ApoE 
status among the brain donors.  
Table 5-4. Testing interaction terms between delirium and pathology on dementia outcomes 
Parameter P value 
Delirium * Braak stage 0.79 
Delirium * Amyloid burden 0.65 
Delirium * Infarcts 0.22 
Delirium * Neuronal loss in substantia nigra 0.94 
Delirium * α-synucleopathy in substantia nigra 0.65 
Delirium * ApoE status 0.59 
All pathological variables dichotomised into highest versus lowest half (or present/absent in the 
case of infarcts and Apo ε4 status. 
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Figure 5-3. Relationship between delirium, dementia and neuropathology or genotype. 
Display of logistic regression models, with 95% confidence intervals. The y-axis is log-scaled. 
Models show association between dementia and pathology (or genotype), adjusted by age at 
death and sex. Markers were treated as dichotomous variables (high/low). For each marker, the 
relationship is given for the whole population, and then stratified by delirium history (n=58 with 
history of delirium; n=232 no history of delirium). SN = substantia nigra; Syn = 
synucleinopathy; ApoE = apolipoprotein E. 
 
 
5.5 Discussion 
5.5.1 Key findings 
This is the first study to my knowledge to examine the hypothesis that delirium is a risk factor 
for dementia using a true population-based sample of older individuals. The results strongly 
support this hypothesis. Additionally, in individuals with existing dementia, delirium was 
associated with worsening dementia severity, worsening global functional status and higher 
mortality. Moreover, in the whole population, a history of delirium was significantly associated 
with an accelerated decline in MMSE scores. This is also the first prospective cohort study to 
examine the potential effects of delirium history on the relationships between dementia and its 
 108 
 
neuropathological markers. Individuals with dementia and no history of delirium had strong 
associations with Alzheimer-type, infarcts and Lewy body pathology. In contrast, those with 
dementia and a history of delirium showed no such relationships. Though this is an intriguing 
finding, the study was not powered to determine if delirium is genuinely associated with an 
altered pattern of pathology.  
5.5.2 Strengths and limitations 
This study has several strengths. This cohort has high generalisability for the oldest-old, and has 
a high rate of brain autopsy (Zaccai et al. 2006).  The characteristics of the brain donors show no 
evidence of systematic bias (Brayne et al. 2010). While it has been shown that neuropathological 
assessments can reliably be made by a single or multiple rater(s) (Mirra et al. 1994), it is possibly 
an advantage that all scoring was interpreted by the same neuropathologist. There were multiple 
waves of measurement over a decade; this allows accurate assessment of longitudinal change.  
Some limitations of the present study should be acknowledged. Only changes from age ≥85 
years could be studied and this resulted in substantial losses to follow-up due to mortality. There 
is likely to be a survivor effect and this may result in selective differences in clinical and genetic 
characteristics. Depression also has a complex relationship with cognitive assessment and 
dementia, and no attempt was made to address this in the present analysis. The results of the 
random-effects models produced estimated parameters comparable to other population-based 
studies of general cognitive decline (Terrera et al. 2008). However, similar to many prospective 
studies of ageing, attrition was significant, and data missing-not–at-random was not accounted 
for. Despite the fact that autopsy rates were high, the absolute number of cases in each category 
of delirium exposure remained relatively low.  
Self-reported (or informant-reported) delirium may be subject to recall bias, though this is 
mitigated by corroborating the history with medical records during the interview. Though the 
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history of delirium was specifically assessed at each wave, this approach is not as accurate as 
clinician assessment during delirium and is likely to under-detect delirium given that diagnosis 
rates in routine clinical practice are generally considerably below the true prevalence (Flaherty et 
al. 2007). In the absence of robust delirium ascertainment being embedded in routine hospital 
care, only a prospective study in which researchers could assess every patient for delirium during 
every hospital admission could overcome this issue. This is impractical, however, and combining 
patient and informant interviews with inspection of case notes is a pragmatic alternative. Indeed, 
medical records have been validated for the diagnosis of delirium history (Inouye et al. 2005), 
and the diagnostic accuracy for past episodes is likely to be higher if case notes are reviewed in 
conjunction with clinical interview as is the case in the present study. 
5.5.3 Results in context 
The present results are consistent with studies reporting cognitive decline after delirium or 
intercurrent illness where there have been pre-morbid assessments of cognition (Section 2.3). As 
reviewed above, follow-up of memory-clinic patients showed delirium was subsequently 
associated with greater decline in cognitive test scores (Fong et al. 2009). In addition, a report 
from the Adult Changes in Thought study found that critical illness (without specifically 
considering delirium) was associated with incident dementia (HR 1.4 (95% CI, 1.1 to 1.7)) 
(Ehlenbach et al. 2010). Participants in the Health and Retirement Study who had an intercurrent 
episode of severe sepsis also had a higher risk of being subsequently diagnosed with severe 
cognitive impairment (OR 3.4 (95% CI, 1.5 to 7.3)) (Iwashyna et al. 2010). The larger effect size 
in the present study may reflect the older age in this cohort. 
5.5.4 Possible mechanisms 
The results are also consistent with the emerging evidence from animal models of delirium 
demonstrating that in vulnerable animals, systemic inflammatory insults can cause transient, 
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reversible deterioration in cognition and significant acceleration in disease progression after the 
transient impairments have resolved (Cunningham 2011) (Section 1.4.1). A single, moderate dose 
of LPS, consistent with the level of inflammatory insult which typically induces delirium in 
vulnerable humans, has been shown to induce de novo neuronal death in animals with existing 
neurodegenerative disease (Cunningham et al. 2005; Field et al. 2012), and to accelerate the 
progression of disease without obvious effects on extracellular amyloidosis (Cunningham et al. 
2009). In this context, it is of note that a case-control autopsy study of persons who died with 
delirium showed differential increases in IL-6 and CD68-positive microglia (Munster et al. 2011) 
(Section 1.4.2.4) Consistent with these findings, the present study suggests the possibility that 
dementia following delirium may not be as strongly linked with classical dementia 
neuropathological markers as dementia in those without a history of delirium, but further work is 
needed. 
5.5.5 Conclusions 
This study confirmed that delirium is associated with general cognitive decline, with an 8-fold 
increase in incident dementia and accelerated decline in MMSE scores. Previous investigations 
for other dementia risk factors (Daviglus et al. 2011) have often been dwarfed by the relationship 
of dementia with older age itself. The strong association with delirium, even after adjusting for 
age, in a general population underscores the clinical importance of delirium in relation to 
dementia risk. Future research should seek to include prospective delirium measures in cohort 
studies of dementia, correlating these with neuroimaging and neuropathology findings. Up to 
30% of delirium has been estimated to be preventable (Inouye et al. 1999) and definitive data 
would come from intervention trials where the outcome is secondary prevention of dementia. 
The present study suggests that this would be a plausible approach. 
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6 Delirium modifies the relationship between cognitive decline and 
dementia neuropathology 
6.1 Summary 
Delirium is associated with accelerated cognitive decline. The pathological substrates of this 
relationship are not yet known, that is, whether they are the same as those associated with the 
dementias, independent or inter-related. Here, the hypothesis that the accelerated cognitive 
decline observed following delirium is independent of classical dementia neuropathology was 
examined. 
In three population-based cohorts (the Epidemiological Clinico-pathological Studies in Europe 
Collaboration), the effects of delirium episodes on cognitive change was examined. These 
associations were then analysed in relation to the extent of neurofibrillary tangles, amyloid 
plaques, vascular lesions and Lewy bodies in neuropathological autopsies (N=987). Change in 
Mini-Mental State Examination scores (MMSE) over six years before death was modelled using 
random-effects linear regression, and interactions between delirium and pathology burden were 
assessed. 
Mean MMSE six years before death was 25 points. Individuals with delirium had worse initial 
scores (-2.75 points, p<0.01). Cognitive decline attributable to delirium was -0.37 MMSE 
points/year (p<0.01). Decline attributable to dementia pathology was -0.39 MMSE points/year 
(p<0.01). However, the combination of delirium and dementia pathology resulted in the greatest 
decline, where the interaction contributed a further -0.16 MMSE points/year (p=0.01). The 
additive nature of these variables resulted in individuals with both delirium and dementia 
pathology declining 0.72 MMSE points/year faster than age, sex and education-matched 
controls. 
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Delirium in the presence of dementia-related neuropathologies is associated with accelerated 
cognitive decline beyond that expected for delirium or the neuropathology itself. This suggests 
additional unmeasured but related neuropathological processes are initiated by delirium. Age-
related cognitive decline has many contributors, and these findings at the population level 
support a role for delirium acting independently and additively to classical dementia 
neuropathology.  
 
6.2 Introduction 
Understanding the pathological basis of cognitive impairment in whole populations is a 
prerequisite  to mitigating the increasing public health burden of dementia (Brayne et al. 2012). 
Many strands of investigation presuppose that Alzheimer, vascular and Lewy body pathologies 
are the predominant causes of dementia. This paradigm has directed the search for biomarkers, 
treatments and potential prevention strategies. Yet evidence indicates that these ‘classical’ 
pathologies do not fully account for the clinical syndrome, especially in populations of the 
oldest-old (Bennett et al. 2006; Matthews et al. 2009; Savva et al. 2009; Schneider et al. 2009; 
Cholerton et al. 2013).  
Delirium is a syndrome of acute brain dysfunction characterised by inattention and other mental 
status impairments. An emerging literature demonstrates that delirium is a strong predictor of 
new-onset dementia as well as acceleration of existing cognitive decline (Fong et al. 2009; 
MacLullich et al. 2009; Davis et al. 2012; Pandharipande 2013). This is consistent across several 
different settings: after hospitalisation (Witlox et al. 2010); in those with dementia (Fong et al. 
2009; Gross et al. 2012); in post-operative patients (Saczynski et al. 2012); and in a community 
population (Davis et al. 2012) (Section 2.3). However, whether delirium accounts for additional, 
inter-related or unexplained pathological injury contributing to dementia has not previously been 
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examined. It is possible that when dementia follows delirium it has a different pathological 
profile compared to dementia that develops without delirium. Therefore, understanding how 
delirium affects the evolution of dementia, in the context of a particular burden of pathology, 
may offer new insights into independent mechanisms explaining cognitive decline after delirium. 
In this chapter, the challenge was to examine a key hypothesis: that faster cognitive decline 
associated with delirium would act independently of the cognitive decline associated with 
classical dementia pathology. Accordingly, the extent to which delirium and classical dementia 
pathology contributed to associated cognitive decline in three unselected population-based 
cohort studies with neuropathology autopsy data was investigated: the Medical Research Council 
Cognitive Function and Ageing Study (CFAS); the Cambridge City over-75s Cohort (CC75C) 
and Vantaa 85+ study. These represent the entirety of such studies conducted in Europe, and 
provide a unique opportunity to increase the understanding of the clinical significance of 
delirium and its inter-relation with dementia pathology in the general population. 
 
6.3 Methods 
The individual studies have previously been described in detail in Chapter 3 (Brayne et al. 2006; 
Polvikoski et al. 2006; Fleming et al. 2007), and participant-level data have been harmonised as 
the Epidemiological Clinico-pathological Studies in Europe (EClipSE) Collaboration (EClipSE 
Collaboration). Briefly, participants were sampled from general practitioners’ registers (CFAS 
and CC75C, UK) and the Population Register Centre (Vantaa, Finland). CFAS, CC75C and 
Vantaa 85+ recruited persons aged ≥65, ≥75 and ≥85, respectively. Individuals were assessed 
mostly at two to four year intervals, with some subsamples having annual evaluation. The Mini-
Mental State Examination (MMSE) (Folstein et al. 1975) was performed in all three studies. 
Additional neuropsychological batteries were also performed, with some differences among the 
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studies (section 3.4.4.). Previous work has shown that participants in the brain donor programs 
showed no systematic differences in clinical characteristics compared with other participants in 
the cohorts (Brayne et al. 2010), though donors in CFAS were selected by stratified random 
sampling, weighted to those who were older and cognitively impaired (section 3.4.3.). Each study 
had ethical approval. 
6.3.1 Delirium assessments 
In CFAS and CC75C, delirium symptoms were a feature of the standardised interview schedules 
administered by trained interviewers. These schedules were able to assign diagnostic groups 
based on validated structured algorithms for psychiatric disorders, themselves based on DSM-
III-R or related classifications. Questions included: “Were there brief episodes during the 24 
hours when s/he seemed much worse and then times when quite clear?” “Were there marked 
fluctuations in his/her level of attention or alertness?” “Could a physical illness … be sufficient 
explanation for the subject's mental or psychiatric symptoms (e.g. delirious due to acute 
infection)?” A full list of relevant questions is given in appendix section 10.3.  
At each Vantaa interview, the examining neurologists assessed participants and informant(s) for 
a history of any episodes of delirium, with reference to a checklist of DSM-III-R criteria for 
delirium diagnosis (Rahkonen et al. 2001). The reported history was corroborated with medical 
case records that were available at the time of assessment (details in section 3.1.2. and Chapter 
5). 
6.3.2 Neuropathology analyses 
Parafﬁn-embedded brain tissue samples were used to assess neuropathological markers, blind to 
clinical data. Each study reported Braak stage, as a semi-quantitative measure of tau 
neurofibrillary tangles, and neocortical amyloid plaque burden from the Consortium to Establish 
a Registry for Alzheimer’s Disease protocol (Mirra et al. 1991). The presence of infarcts (> 
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10mm), lacunes and haemorrhage were histologically assessed using haematoxylin and eosin. 
Lewy bodies in the substantia nigra were assessed with haematoxylin and eosin, but also included 
immunohistochemical staining against α-synuclein (or ubiquitin in some of the earlier CC75C 
specimens) (full details given Appendix Section 10.4). 
6.3.3 Statistical analyses 
All analyses were conducted in Stata 12.1 (StataCorp, Texas). The exact steps are enumerated in 
the box below. Consistent with previous approaches, delirium exposure was operationalised as 
‘never’ or ‘ever’ (Davis et al. 2012). Change in MMSE before death was modelled using a time-
to-death random-effects model (Piccinin et al. 2011). Estimating the final trajectory towards 
death was of interest as this makes relationships with pathological data easier to define. The 
mean time from the start of the trajectory identified by the model to death was 5.2 years, and so 
the start point (intercept) for this trajectory was set (centred) at 6 years. This start point is not so 
near point of death such that rates of change (slopes) cannot be estimated, yet not so far from 
death that the pathology findings at autopsy might not plausibly be related to the estimated 
parameters. Six years before death is also comparable to start points from change-point models 
of the final trajectory of cognitive decline (Wilson et al. 2007; MacDonald et al. 2011; Wilson et 
al. 2012b), and in the range observed in other analyses (3 to 8 years) (Muniz-Terrera et al. 2011). 
Models were adjusted by age at death (centred at mean age = 90 years), sex (0=men, 1=women), 
years of education (0-3; 4-7; 8-11; 12 or more) and study. Missing data were assumed to be 
missing-at-random, given that outcome ascertainment was essentially complete in this brain 
donor cohort.  
The four classical dementia neuropathological parameters which contribute the greatest 
population attributable risk for dementia (Matthews et al. 2009) were examined: Braak stage 
(neurofibrillary tangles), neocortical amyloid plaques, vascular pathology (large artery infarcts, 
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lacunes or haemorrhage) and Lewy bodies in the substantia nigra. In keeping with previous 
methods, neuropathological variables were dichotomised (‘none-mild’ = 0; ‘moderate-severe’ = 
1) (Savva et al. 2009; Brayne et al. 2010; Davis et al. 2012). This approach allows for simpler 
interpretation and is more likely to be robust. Individuals were assigned a ‘pathology burden 
score’ based on the number of times they scored in the higher category for each of the four 
markers. Therefore, the overall pathological burden score ranged between 0 and 4, i.e. being in 
the lower category for all markers (pathology burden score = 0), in the upper category of all four 
markers (pathology burden score = 4) or some combination. Finally, interactions between 
delirium and pathology burden ([delirium history]*[pathology score]) in terms of their effect on 
both the start point (-6 years before death) and rate of change of MMSE were calculated. 
Box. Summary of statistical approach to random-effects modelling 
Formatting data 
1. Arrange all datasets in long format, where each row represents an observation at a given time 
point. Each participant will therefore be represented by multiple rows. 
2. Calculate age of participant at each observation, including age at death.  
3. Calculate the ‘time to death’ for each row. 
4. Ascertain distribution of ‘time to death’ term, and centre the data based on mean so that the 
mean is 0. 
5. Generate terms to estimate slope parameters, multiplying time-to-death by variables of 
interest: e.g., [time-to-death]*[age], or [time-to-death]*[delirium status] 
 
Models  
6. Run an intercept-only model, checking maximum likelihood and pseudo-r2. Inspect both 
fixed and random effects. 
 
6.4 Results 
There were 987 participants (290 from Vantaa 85+, 241 from CC75C, 456 from CFAS) with 
neuropathology data. Table 6-1 describes the characteristics of the sample. Mean age at death 
was 90 years (SD 6.4) and persons with delirium were slightly older, more likely to be women 
and have more years of education. Neocortical amyloid plaques, vascular pathology or Lewy 
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bodies were not significantly different in individuals with and without a history of delirium. 
Persons with delirium had higher Braak stage, though this difference did not persist after 
adjusting for dementia status. 
Table 6-1. Characteristics of study participants, according to history of delirium1 
 No delirium1 Delirium1 P value 
N 708  279    
Median follow-up; years (IQR) 4.3 (2.0-7.1) 4.7 (2.5-7.8)   
Median number of assessments in last six years2 (IQR) 2 (1-3) 3 (2-4)   
       
Study; N (%)       
 Vantaa 85+ 232 (80) 58 (20)   
 CC75C 142 (59) 99 (41)   
 CFAS 334 (73) 122 (27)   
       
Age at death; mean (SD) 89  (6.7) 90 (5.8) 0.03  
Sex; female (%) 472 (66) 210 (75) <0.01  
Years of education; median (IQR) 9 (6-13) 9 (8-14) <0.01  
       
Pathology3; N (%)       
 Braak stage 346 (50) 166 (59) <0.01  
 Neocortical amyloid plaques 344 (50) 138 (42) 0.62  
 Vascular (infarcts, lacunes or haemorrhages) 358 (56) 139 (57) 0.54  
 Lewy bodies in substantia nigra 67 (10) 27 (10) 0.99  
       
Pathology burden score4     0.10  
 0 136 (19) 41 (15)   
 1 207 (29) 72 (26)   
 2 220 (31) 107 (38)   
 3/4 149 (21) 60 (21)   
       
Any moderate-severe pathology5 576 (70) 239 (76) 0.20  
       
1 ‘Delirium’ means evidence of delirium at any time, compared to those with no history of delirium 
2 Six years is the chosen intercept for this model describing final trajectory of cognitive decline 
3 Pathology measures are dichotomised, numbers shown here are for the higher category: 
     Braak stage ranges 0 to 6; figures are those scoring 4/5/6. 
     Neocortical amyloid plaques scored none/mild/moderate/severe; figures are those scoring moderate-severe 
     Vascular indicates the presence (yes/no) of: infarcts in arteries >10mm, lacunar lesions or haemorrhage. 
     Lewy bodies scored none/mild/moderate/severe; figures are those scoring moderate-severe 
     Full details are given in supplementary appendix. 
4 Pathology burden score refers to the number of pathological measures in a higher category for an individual 
5 Any moderate-severe pathology = pathology burden score ≥ 1 
P values for differences in means/medians (continuous measures) and proportions tested using t or Wilcoxon 
and χ2 tests, respectively 
 
 
Results from the random-effects models describing delirium and cognitive decline are presented 
in 
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Table 6-2. The median number of longitudinal observations for participants in the model was 2 
(interquartile range 1-4). In the fully adjusted model (including delirium and pathology burden), 
the start point was estimated at 24.7 MMSE points. The start point should be interpreted as the 
estimated MMSE score six years before death in persons where all covariates are in the reference 
category (e.g. youngest age, no delirium). For the typical 90 year old, the mean base rate of 
decline was 0.35 points per year (base rate = all covariates in reference category, e.g., no delirium, 
lowest pathology score). There was no significant influence of study source (Vantaa 85+, CC75C 
or CFAS) on the model estimates. 
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Table 6-2. Quantifying trajectories of MMSE change in relation to delirium and dementia 
pathology 
 
*The term 'dementia pathology' refers to those classical dementia pathologies known to contribute to cognitive 
impairment, i.e. Braak stage, amyloid plaques, infarcts and Lewy bodies. 
† Observations refers to the total number of longitudinal outcomes in the model 
 
Abbreviations: MMSE: Mini-mental state examination 
 
Orientation: Each of the four columns represents a model of cognitive trajectories, adjusted by study source.  
1 Model based on only clinical variables: age, sex, education (not including delirium).  
2 Clinical model with the addition of delirium variables 
3 Clinical model with the addition of pathology variables 
4 Model fully adjusted for delirium, pathology and their interactions on intercept and slope 
 
5 The intercept and slope are given for each model. These indicate the estimated MMSE six years before death 
(intercept) and the rate of decline per year (slope). The intercept from six years before death was chosen because the 
mean time before death was 5.2 years, and the model is centred just before the mean.  The figures given in this row 
are for the baseline group, that is, where all other variables in the model are in the lowest category (see below: 
Interpretation). All models are adjusted for baseline difference in MMSE. 
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Clinical variables 
6 Age: the effect of age on the intercept, per year older than centred age at death (90 years) 
7 Age (slope): the effect of age on the rate of MMSE change, per additional year older than centred age at death (90 
years) 
8 Sex: women compared to men 
 
Delirium 
9 Delirium: the effect of a history of delirium at any point on the intercept 
10 Delirium (slope): the effect of delirium on rate of MMSE change, per additional year from six years before death 
 
Pathology 
11 Pathology burden score: effect of score on the intercept, per instance of being in a higher pathology category (0 to 
4). 
12 Pathology (slope): the effect of being in a higher pathology category on rate of MMSE change, per additional year 
from six years before death. 
 
Interaction 
13 The effect of a pathology-delirium interaction on the intercept (six years before death) 
14 The effect of a pathology-delirium interaction on the rate of MMSE change (slope), per additional year from six 
years before death.  
 
Interpretation:   
Each coefficient can be interpreted additively from the baseline intercept5 and slope5. For example, a woman in the 
clinical model1 aged 91 (1 year older than mean) with 12 years of education would have an estimated intercept of 
22.7 (base intercept) + -0.26 (due to age) + -2.11 (due to being a woman) + +2.16 (due to education) = 22.5 MMSE 
points six years before death. Expected decline per year estimated at -0.84 (base slope) + -0.02 (due to age) = -0.86 
MMSE points per year. 
 
1 Clinical model: Age, sex and education are significantly associated with trajectories of MMSE. As new terms are 
added to the model (below), the estimated coefficients generally become smaller as the additional terms explain 
more of the model variance. 
2 Clinical model + delirium: Delirium also significantly affects intercept and slope.  
3 Clinical model + pathology: Pathology is significantly associated with intercept and slope 
4 Clinical model + delirium + pathology: delirium and pathology remain significant predictors of MMSE decline. 
An interaction between delirium and pathology is not significantly associated with the intercept, but does influence 
rate of MMSE change (additional -0.16 MMSE point per year over and above the contribution of delirium and 
pathology separately. The effect of this can be visualised in Figure 6-1. 
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6.4.1 Effect of delirium on start point and rate of change 
On average, delirium was associated with a 2.8 point lower MMSE score (p<0.01) six years 
before death. For these persons, the rate of change was an additional 0.37 points per year 
(p<0.01). These coefficients are additive. Therefore, for the typical individual aged 90 years at 
death with delirium, the estimated MMSE is 24.7 points (baseline) and -2.8 points = 21.9 MMSE 
points, declining at 0.35 points (base rate) and -0.37 (due to delirium) = 0.72 points per year. 
6.4.2 Effect of pathology on start point and rate of change  
Increasing pathology burden score was associated with lower MMSE score (-0.7 for 1 instance of 
high dementia pathological marker; -2.2 point for 2 markers, -4.4 for 3 or more markers, p<0.01 
for trend). Pathology burden conferred an additional 0.39 point decline in MMSE score over and 
above the effects of age and delirium (p<0.01). 
6.4.3 Interaction between delirium and pathology 
A significant interaction between delirium and pathology estimated an additional decline of 0.16 
MMSE points per year (p=0.01). Therefore, individuals with both delirium and high dementia 
pathology had an estimated rate of decline of: -0.35 points (base rate) and -0.37 (due to delirium) 
and -0.39 points (due to pathology) and -0.16 points (due to interaction) = 1.27 points per year. 
By way of comparison, the independent effect of age alone on rate of MMSE change was 0.01 
points per year (i.e., 0.05 MMSE difference between ages 85 to 90 years).  
Figure 6-1 shows how rate of cognitive decline varies by delirium and pathology status. The 
slowest decline was seen in persons with no history of delirium and least dementia pathology. 
The fastest decline was seen in persons with both a history of delirium and most dementia 
pathology. Intermediate rates of decline were observed in individuals with delirium but least 
dementia pathology and in those with no delirium history but most dementia pathology.  
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Figure 6-1. Trajectory of cognitive decline in relation to delirium and dementia pathology at 
autopsy. 
Boxes underneath the figures show the number of persons alive at each year before death, 
according to whether they had experienced delirium. 
Left panel: trajectories of cognitive decline in individuals with most dementia pathology (higher 
dichotomised category for any of Braak stage, cortical amyloid plaques, infarcts, Lewy bodies), 
according to delirium status. P value A versus B <0.01 
Right panel: trajectories of cognitive decline in individuals with least dementia pathology (lower 
dichotomised category for all of Braak stage, cortical amyloid plaques, infarcts, Lewy bodies), 
according to delirium status. P value C versus D <0.01 
All models are adjusted by age, sex, education, baseline MMSE. 
Interpretation: Individuals with delirium and more dementia pathology have the fastest decline 
(Line A); individuals with no delirium and little dementia pathology have slowest decline (D). For 
some individuals, cognitive decline is driven by dementia pathology (no delirium, high pathology, 
B). For other individuals, cognitive decline is associated with delirium (delirium, little pathology, 
C), and this is distinct from, but contributory to, classical dementia pathology (p value A versus 
C = 0.01). 
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6.5 Discussion 
This is the first demonstration that people with both delirium and higher levels of classical 
dementia pathology show the greatest cognitive decline. Delirium, in the presence of dementia-
related neuropathology, was associated with cognitive decline beyond that expected for delirium 
or the neuropathology itself. This means that delirium may be associated with pathological 
processes driving cognitive decline which have independent components and are different from 
classical dementia pathology. These findings suggest new possibilities regarding the pathological 
correlates of cognitive impairment, positioning delirium and/or its precipitants as a critically 
inter-related mechanism. Showing this in three unselected samples further attests to the broad 
significance of these findings and their applicability to the wider population. 
These results are in keeping with other studies identified in Section 2.3., demonstrating that 
delirium is associated with faster trajectories of cognitive decline (Davis 2013). Chapter 5 raised 
the possibility that classical dementia pathologies might not mediate the observed relationship 
between delirium and dementia, though the analysis was underpowered (Davis et al. 2012). Here, 
the larger sample size, and the more precise determination of cognitive change in the six years 
before death, allows us to be more conclusive about the inter-related effect of delirium on 
clinico-pathological correlations in dementia.  
This analysis has a number of strengths. Firstly, it focuses on a major and previously 
unaddressed question arising from the prevalence of cognitive impairment and aging. In terms of 
study design, the three cohorts have high generalisability for the oldest-old, populations that are 
under-represented in dementia research despite having the highest prevalence of dementia 
(Schoenmaker et al. 2004). This is also the first analysis to examine delirium and the pathological 
correlates of cognitive decline at the end of life in the general population; the other analysis 
comes from a leading study in this area: the Religious Orders cohort study which is, however, 
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focused on specific populations (Wilson et al. 2012b). Modelling change in cognitive outcomes 
as continua, rather than simply the presence or absence of dementia, allows for an exploration of 
the impact of delirium across the whole spectrum of cognitive function, i.e. from no baseline 
impairment, through mild cognitive impairment to more severe dementia severity. The power to 
assess such effects, as interactions between delirium and neuropathology, is unique.  
A number of limitations should be taken into account. Delirium was retrospectively ascertained, 
and by slightly different methods. In Vantaa 85+, assessments for history of delirium occurred at 
each visit, using information from participants, informants and medical records. Ascertainment 
in CFAS and CC75C relied on diagnostic interviews at each study visit but is likely to 
underestimate delirium in the intervening period. The diagnostic classification criteria also varied, 
though the different diagnostic schedules for delirium have been shown to have very good 
agreement with DSM-III-R (Treloar et al. 1997). Despite these differences, the results appear to 
be consistent across the cohorts. The implication, either way, is that core symptoms in delirium 
― acute fluctuating change in attention in association with acute illness ― represents an adverse 
state for subsequent cognitive trajectories, regardless of the exact methods for operationalising 
the syndrome. As with other prospective cohort data, there remains the possibility that residual 
confounding contributes to these observed associations. Though the overall sample size is large, 
the number of brains is a small proportion of the overall study denominator (4.8%). The 
autopsies from CFAS over-sampled participants with cognitive impairment, though they remain 
representative on other clinical parameters. Another consideration is that only a limited range of 
pathological markers and comorbidities could be examined in this harmonised dataset. Finally, 
though recent research based on neuroimaging and neuropathology suggests that insults in 
earlier life can also be malignant (Janz et al. 2010; Gunther et al. 2012; Morandi et al. 2012b), this 
could not be examined within this study.  
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In conclusion, these results indicate that delirium interacts with underlying classical dementia 
pathology and so represents a potential independent, but inter-related, pathological pathway to 
chronic cognitive impairment and dementia. If delirium prevention could lead to consequent 
prevention of dementia (Inouye 2006; MacLullich et al. 2011), it will be essential to understand if 
certain dimensions of the delirium syndrome might have a greater impact on cognitive 
trajectories than others. For example, duration, severity and/or aetiology (e.g. medications versus 
acute illness, surgery versus sepsis) may be differently important. Animal studies modelling 
different aetiologies and severities have some scope to elucidate some of these questions, but 
greater clarity on these issues must also come from careful prospective studies in representative 
populations. Nonetheless, our findings indicate that clinicians need to be alert to older people’s 
cognitive changes, both during acute episodes and in follow-up across all settings, and therefore 
support wider implementation of best practice in delirium prevention. 
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7 A new technique for deriving a retrospective diagnosis of delirium 
from medical records 
7.1 Summary 
Delirium is increasingly recognised as an important potential contributor to trajectories of 
cognitive decline. Therefore, analyses of existing cohort studies measuring cognitive outcomes 
could benefit from methods to ascertain a retrospective delirium diagnosis. This study aimed to 
develop and validate such a method for delirium detection using medical records in UK and 
Ireland. 
A point prevalence study of delirium served as the reference-standard for delirium diagnosis. 
Blinded to study results, short clinical vignettes were compiled from participants’ medical records 
in a standardised manner, describing any relevant delirium symptoms recorded in the whole case 
record for the period leading up to case-ascertainment. An expert panel independently rated each 
vignette as unlikely, possible, or probable delirium and disagreements were resolved by 
consensus.   
From 95 case records, 424 independent vignettes were abstracted. Median age of subjects was 77 
years (interquartile range 55 to 83). Against the original study DSM-IV diagnosis, the chart 
abstraction method diagnosed delirium with sensitivity 0.88 and specificity 0.75; area under the 
curve 0.86 (95% CI 0.80 to 0.89).  
This chart abstraction method can retrospectively diagnose delirium in hospitalised patients with 
good accuracy. This has potential for identifying incident delirium in cohort studies where 
routine medical records are available. 
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7.2 Introduction 
Delirium is an extensive and serious problem in acute hospitals (Siddiqi et al. 2006). It is 
characterised by an acute and fluctuating failure of attention and cognitive and/or perceptual 
disturbance precipitated by medical illness. It is associated with high levels of personal and family 
distress (Partridge et al. 2013), as well as greater healthcare costs (Akunne et al. 2012). 
Delirium during hospitalisation is well recognised to be associated with poor cognitive outcomes 
(Witlox et al. 2010). Indeed, because delirium is partly preventable (Inouye et al. 1999; 
Marcantonio et al. 2001), delirium interventions might even prevent dementia (MacLullich et al. 
2011). However, around half of dementia presenting to hospital is undiagnosed (Sampson et al. 
2009), and there is often uncertainty about an individual’s premorbid cognitive function. 
Accordingly, hospital series may overestimate the association between delirium and any 
subsequent cognitive impairment. 
The prospective relationship between delirium and dementia is more reliably assessed by 
ascertaining incident delirium in the context of a cohort study measuring cognitive outcomes. 
However, such studies are extremely rare. Only one prospective study has specifically examined 
cognitive outcomes after delirium in the general population (Davis et al. 2012; Davis 2013). 
Given the wider importance of delirium’s association with dementia, attempts to identify 
delirium in other cohort studies would be highly informative, even if the delirium measures were 
retrospectively derived. 
Delirium is under-diagnosed and under-reported such that medical records are known to be 
unreliable sources for delirium (Johnson et al. 1992). Despite this, a chart-based method for 
retrospectively identifying delirium has been validated against trained interviewers using the 
Confusion Assessment Method (CAM) as a reference standard (Inouye et al. 1990; Inouye et al. 
2005). This instrument has been important in identifying incident delirium in community-based 
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persons with dementia being followed up with regular cognitive assessments, showing an 
association with more rapid trajectories of decline (Fong et al. 2009). However, this abstraction 
tool was developed in the US healthcare system and there are differences in how medical records 
are kept in UK and Ireland. Accordingly, there is a need for a complementary tool for use 
outside the USA. 
The aim of the present study is to develop and validate a retrospective measure of delirium based 
on routine medical records used in the general hospital setting in the UK and Ireland. From the 
medical records of participants in an independent study of delirium prevalence (Ryan et al. 2013), 
two separate processes were employed: (i) abstraction of symptoms relevant to the DSM-IV 
criteria for delirium to produce a short clinical vignette; (ii) an expert panel assigning diagnoses 
by consensus (index test). These diagnoses could then be validated against the DSM-IV diagnosis 
of delirium (reference standard) applied as part of the delirium prevalence study. 
 
7.3 Methods 
The protocol followed the Standards for the Reporting of Diagnostic accuracy studies guidelines  
(Bossuyt et al. 2003). Ethics approval was given by the Research Ethics Committee, University 
College Cork (ECM4(e)12/06/12). 
7.3.1 Delirium point prevalence study 
The reference standard for delirium was derived from the medical records of participants in the 
Cork Delirium Point Prevalence Study (Ryan et al. 2013). Briefly, the entire adult inpatient 
population of a general hospital (excluding ICU and moribund patients) was examined for 
delirium over a single day. Participants were assessed in two stages. Firstly, participants were 
screened for inattention using the spatial span forwards and months backwards.  Participants 
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were additionally screened for subjective and objective confusion by asking: “Have you felt 
muddled in your thinking, or confused, since you came into hospital?” Further information was 
derived from nurse informants and hospital records. Participants screening positive on any of 
these components, and a random sample of screen negative participants were assessed in more 
detail. This second stage consisted of two independent delirium assessments: the CAM (Inouye 
et al. 1990) and the Delirium Rating Scale – Revised-98 (DRS-R98) (Trzepacz et al. 2001). These 
were conducted by trained registrars or consultants in geriatric medicine and experienced 
psychiatrists, respectively. Ultimately, the diagnosis of delirium was based on DSM-IV criteria, 
applied by consensus using all available psychometric, clinical and informant data. Accordingly, 
all persons in the prevalence study could be assigned a diagnosis of delirium, subsyndromal 
delirium, or no delirium for a specific day. In addition to the assessments for delirium, pre-
morbid cognitive status was assessed using the short form of the Informant Questionnaire on 
Cognitive Decline in the Elderly (IQCODE) (Jorm 1994). This was done for all participants with 
delirium (n=55) as well as a random subsample of those aged ≥65 years without delirium (n=40). 
7.3.2 Chart abstraction technique 
A random selection of case notes was identified using the RAND() function in Excel. The 
sample was designed to maintain the underlying prevalence of delirium (that is, 20% of the 
identified hospital records were delirium cases). The case notes were then requested from the 
medical records department on a convenience basis, in batches. All clinical information was used 
for abstraction, from the date of admission, up until the date of the point-prevalence study 
(15/05/2010). If the inpatient stay had been longer than two weeks, only clinical information 
from these two weeks leading up to the index date was used. This included verbatim reports 
from the entirety of the medical, nursing and allied health professional records. Symptoms 
deemed relevant to any criterion in the DSM classification were abstracted (Table 7-1), resulting 
in a clinical vignette. The Charlson co-morbidities index (Charlson et al. 1987), metabolic and 
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physiological parameters were recorded closest to the date the reference standard was assessed. 
Abstractors were specialist trainees in geriatric medicine, and were also blind to the study 
diagnosis. Case notes were abstracted multiple times to assess the influence of abstracting author 
on the consensus process. 
Table 7-1. Abstracted symptoms in relation to DSM-IV criteria 
DSM-IV criterion Abstracted symptoms 
A. Disturbance of consciousness (i.e., reduced 
clarity of awareness of the environment) with 
reduced ability to focus, sustain or shift 
attention.  
Agitation; drowsiness; any formal rating e.g. 
AVPU or GCS 
Any verbatim comment, e.g. ‘drowsy’, ‘slept 
poorly’, ‘agitated’ 
B. A change in cognition or the development 
of a perceptual disturbance that is not better 
accounted for by a pre-existing, established or 
evolving dementia.  
Any formal cognitive assessment (AMT; 
MMSE) 
Any formal specialty assessment, e.g. 
neurology, geriatric medicine, liaison psychiatry 
Any verbatim comment, e.g. ‘more confused’, 
‘disorientated’ 
C. The disturbance develops over a short 
period of time (usually hours to days) and 
tends to fluctuate during the course of the day  
Observations at least three times daily 
(nursing) 
Any verbatim comment indicating change in 
mental state 
D. There is evidence from the history, physical 
examination or laboratory findings that the 
disturbance is caused by the direct 
physiological consequences of a general 
medical condition.  
General clinical vignette, including metabolic 
and laboratory parameters taken closest to date 
of prevalence study: AVPU score; systolic 
blood pressure; pulse; respiratory rate; oxygen 
saturation; temperature; C-reactive protein; 
urea; creatinine 
AVPU = assessment of arousal where categories are Alert, Verbally-responsive, Pain-responsive, 
Unresponsive 
GCS = Glasgow Coma Scale 
AMT = Abbreviated Mental Test 
MMSE = Mini-Mental State Examination 
 
7.3.3 Consensus diagnosis 
The consensus diagnosis process was the basis of the index test. The consensus panel comprised 
three geriatricians and an old age psychiatrist, all of whom provide specialist clinical services for 
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delirium patients.7 Assessors only had access to the abstracted vignettes, and were therefore blind 
to the underlying diagnosis. Each vignette was rated independently as: unlikely, possible, 
probable delirium. Assessors were asked to use each criterion from the DSM-IV classification to 
support their assigned diagnoses. Cases where the initial diagnoses were not unanimous were re-
examined together until consensus was reached.  
7.3.4 Statistical methods 
All analyses were conducted in Stata, version 12.1 (Stata Corps, Texas, USA). Sensitivities, 
specificities, positive and negative predictive values were calculated from 2 x 2 tables, with 
confidence intervals testing significance at 95%. ROC curves were derived from estimates of 
sensitivity and specificity. For each individual with multiple vignettes (one vignette per 
abstractor), Fisher’s exact test was used to assess if differences in the initially-assigned diagnostic 
categories varied according to abstractor.  
7.4 Results 
Case records from 95 individuals were retrieved (Figure 7-1). Two or more abstractors8 
separately extracted 424 independent vignettes. The characteristics of participants is summarised 
in Table 2. Median age was 77 years (interquartile range 55 to 83 years), 49% were women 
(n=47), and median co-morbidity score was 3 (interquartile range 1 to 5). Dementia status was 
ascertained in 31 persons (target subsample of 65 and older + all delirium cases), with a 
prevalence of 9/31 (29%). Table 2 describes physiological (level of consciousness, heart rate, 
respiratory rate, systolic blood pressure, temperature, oxygen saturation, inspired oxygen) and 
metabolic (C-reactive protein, urea : creatinine ratio) characteristics in those with and without 
                                                 
7 Dr Louise Allan and Dr Andrew Teodorczuk, Newcastle University, Dr Dan Wilson, King’s College Hospital, Prof 
Alasdair MacLullich, University of Edinburgh. 
8 Dr Elvira Kuhn, Dr Keith McGrath, Dr Sarah Coveney, Dr Niamh O’Regan, St Finbarr’s Hospital, Cork. 
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delirium. No significant differences were apparent, except that all non-delirious participants were 
‘alert’ on the AVPU scale (arousal scale where categories are ‘alert’, ‘verbally responsive’, ‘pain 
responsive’ and ‘unresponsive’), compared with 3 participants with delirium being less than alert 
(p=0.03). 
 
Figure 7-1. STARD flow diagram showing performance of index test relative to reference 
standard. ‘Convenience randomised subsample’ refers to the randomised identification of 
medical notes, which were accessed on a convenience basis. 
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Table 7-2. Characteristics of participants, by delirium diagnosis. 
 DSM delirium 
(n=29) 
No DSM delirium 
(n=66) 
P value* 
Age, median (IQR) 80.6  (74.9-88.6) 68.2 (54.5 – 80.2) 0.07 
Sex, male 14 (50%) 33 (50%) 1.00 
Dementia (y) 6/9  3/22  0.01 
Co-morbidity score, 
median (IQR) 
4 (2-6) 2 (0 – 4) 0.44 
CRP (mg/L), median 
(IQR) 
57.3 (13 – 121) 37.0 (0 – 120) 0.49 
Median Urea:creatinine 0.11 (0.09 – 0.14) 0.08 (0.06 – 0.10) 0.45 
ViEWS*    
 AVPU A = 26/29 
V/P/U = 3/29 
A = 66/66 0.03 
 HR 82.0 82.3 0.99 
 RR 19.5 18.7 0.31 
 BP 125 124 0.99 
 Temp 36.2 36.6 0.10 
 Sa02 96 96 0.99 
 Fi02 Y = 6 
N = 23 
Y = 9 
N = 57 
0.38 
DSM delirium = reference standard delirium 
IQR = interquartile range 
Dementia ascertained through IQCODE 
Co-morbidity score = Charlson co-morbidity index 
CRP C-reactive protein 
AVPU = assessment of arousal where categories are Alert, Verbally-responsive, Pain-responsive, 
Unresponsive 
HR heart rate; RR = respiratory rate; BP = systolic blood pressure in mm Hg; Temp = 
temperature in oC; Sa02 = pulse oxymetry (%); Fi02 = supplemental oxygen (y/n). 
Fi02 is scored as Y = supplemental oxygen; N = room air 
* Aggregate information derived from multiple vignettes, therefore the standard errors (not 
shown) are not robust to the clustered nature of the data. However, the p values are derived from 
estimates with robust standard errors. 
 
Table 7-3 gives the diagnostic test accuracy of the expert rater for each vignette. Using a cut-
point for ‘possible delirium’, initial independent ratings prior differences submitted to consensus 
panel, demonstrated sensitivity of 0.84 and specificity of 0.77. At a higher threshold for ‘probable 
delirium’, sensitivity was 0.63 and specificity 0.92 (AUC 0.84, 95% confidence interval (CI) 0.80 
to 0.89). Furthermore, the individual DSM-IV criteria perform less well than the raters’ overall 
impression (Table 7-3). Insofar as these could be evidenced in the clinical record, the order of 
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test accuracy for each criterion (highest to lowest) was: change in cognition (B), demonstration 
of an acute change (C), documentation of inattention (A), physiological precipitant (D). 
After a consensus diagnosis was applied, there was a small improvement in diagnostic test 
accuracy. For ‘possible delirium’, sensitivity was 0.88 and specificity 0.75; ‘probable delirium’ 
showed sensitivity 0.58 and specificity 0.93 (AUC 0.86, 95% CI 0.82 to 0.89). Vignette abstractor 
was not significantly associated with the eventual consensus diagnosis. 
Table 7-3. The diagnostic test accuracy of the consensus method for delirium diagnosis. 
 
Sensitivity 
(%) 
Specificity 
(%) 
LR+ LR- AUROC 
DSM-IV Criteria      
Inattention (y/n) 67.5 86.0 4.83 0.38 0.77 
Change in cognition (y/n) 71.1 92.2 9.14 0.31 0.82 
Acute and fluctuating (y/n) 70.2 88.6 6.16 0.34 0.79 
Physiological precipitant (y/n) 67.5 82.4 3.83 0.39 0.75 
      
Possible delirium      
Before consensus 84.3 76.7 3.62 0.21 0.84 
Final consensus 88.5 75.0 3.54 0.15 0.86 
Subgroup aged ≥70 years 88.1 67.8 2.74 0.18 0.82 
Subgroup with dementia 88.2 57.1 2.06 0.21 0.69 
 
Probable delirium 
     
Before consensus 63.0 92.1 7.97 0.40 0.84 
Final consensus 57.6 92.6 7.80 0.46 0.86 
Subgroup aged ≥70 years 54.2 89.8 5.33 0.51 0.82 
Subgroup with dementia 70.6 57.1 1.65 0.51 0.69 
LR likelihood ratio 
AUROC area under the receiver operating characteristic curve 
 
Table 7-3 also shows that sensitivity for ‘possible delirium’ remains high (0.88) in the subgroup 
of persons aged ≥70 years (n= 57) (AUC 0.82, 95% CI 0.77 to 0.87). In the ten persons with 
prior cognitive impairment identified from previously documented dementia or by IQCODE 
score (≥3.5), sensitivity for ‘possible delirium’ and ‘probable delirium’ was 0.88 and 0.71 
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respectively. Specificity in this group was 0.57 for both ‘possible delirium’ and ‘probable 
delirium’ (AUC 0.69, 95% CI 0.44 to 0.94). 
Ten cases (11%) were retrieved for which no usable vignette could be abstracted, i.e. insufficient 
clinical records in the period leading up to the day the reference standard was applied. Whether a 
vignette could yield sufficient information was decided by consensus. 
 
7.5 Discussion 
Here a new technique for retrospectively ascertaining delirium from health care record is 
presented. Diagnoses assigned by consensus panel based on abstracted clinical vignettes (index 
test) were sensitive to ‘possible delirium’ and more specific to ‘probable delirium’ when 
compared to DSM-IV diagnoses applied during assessment by a psychiatrist (reference standard). 
The diagnostic test accuracy remains similar in the subgroup of persons aged ≥70 years, though 
performed less well in the group with prior cognitive impairment. 
The strengths of this study lie in the use of routine clinical records of participants against which 
expert delirium was assessed. The consensus panel builds on a standard approach to case-
ascertainment in psychiatric epidemiology. Use of multiple vignettes showed that the two-stage 
process was robust, as variations between abstractors recorded in the vignette did not ultimately 
influence the diagnosis reached at consensus. Certain limitations must also be acknowledged. 
Diagnoses could not be assigned in 11% of cases, entirely because there were insufficient data 
from routine clinical records. The process was also relatively time consuming, though multiple 
abstractions do not seem necessary. It is also possible that hypoactive delirium is under-
recognised by this method, and depression may also complicate the diagnosis of delirium. 
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7.5.1 Findings in context 
One other approach has pioneered the use of medical records to derive a retrospective measure 
(Inouye et al. 2005). Developed in the US healthcare system, it has been useful in leveraging 
information from dementia cohorts. That study was much larger, and used slightly different 
methods. Firstly, a one-stage approach was used for abstraction and diagnosis (with variation in 
agreement assessed by kappa). Secondly, the CAM was used as a reference standard and in the 
Cork Delirium Prevalence Study, CAM applied by trained geriatricians had a sensitivity of 0.83 
and specificity of 0.71 for DSM-IV delirium. As with our findings, diagnostic test accuracy was 
lower in the group with dementia. The overall accuracy of the US chart technique reported 
sensitivity 0.74 and specificity 0.83. Our findings are comparable, though the outcome from the 
consensus panel offered ‘possible’ (when sensitivity is more important, and ‘probable’ (when 
specificity is more important) diagnostic categories. 
Overall, the technique can said to perform well, and allowing an intermediate category (‘possible 
delirium’) depending on if it is more relevant to identify true positives (sensitivity) or true 
negatives (specificity). As might be expected, the diagnostic test accuracy is lower in patients with 
existing dementia and the optimum method for delineating delirium with or without dementia 
remains uncertain. 
7.5.2 Implications 
The general implications of the present results are that routine clinical data can be used to 
systematically gather information on delirium. There is the potential to use a consensus approach 
to establish evidence of incident delirium during hospitalisation, though this is time consuming. 
Linking this to information from prospective studies with cognitive outcomes has research 
utility, thereby leveraging information from existing cohorts with linkage to medical records. In 
addition, a standardised consensus technique might also have a place in clinical governance and 
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audit. Future work should establish whether the delirium status could be ascertained with fewer 
people. The outcomes from apparent false negative delirium diagnoses could also be of interest. 
More generally, this technique could be useful in existing and on-going studies where the 
relationship between delirium and trajectories of cognitive decline is of interest. 
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8 General discussion 
This thesis has explored the relationship between delirium and cognitive decline. Chapter 1 
discussed the clinical dimensions of delirium, and outlined the wider context to delirium 
research. Chapter 2 framed the specific questions for this thesis in terms of epidemiological 
principles. Chapter 3 detailed the cohorts used to address these questions. This concluding 
chapter will summarise the findings, discuss the strengths and limitations, and then describe how 
these results make a contribution to knowledge. The final section suggests future directions for 
research. 
Chapter outline 
 Main findings 
 Strengths and limitations 
 Context and wider impact of findings 
 Conclusions 
 
8.1 Main findings 
8.1.1 Algorithmic definition of delirium 
In the absence of a systematic description of delirium in CFAS and CC75C, it was necessary to 
attempt a definition from the existing standardised interviews. From the GMS data, including the 
informant data documented in the HAS, an algorithm was constructed based on the clinical 
principles of the DSM-IV criteria. It was possible to test the criterion validity of this definition 
against death and future dementia diagnosis in this sub-sample enriched for cognitive outcomes. 
This algorithmic definition of delirium was associated with increased mortality, even after 
adjusting for the usual delirium predisposing factors (dementia) and precipitating factors (illness 
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severity) (HR 1.28, 95% CI 1.03 to 1.60). The risk of incident dementia at two-year follow-up 
was also strongly associated with the algorithmic definition (OR 8.82, 95% CI 2.76 to 28.2). 
These estimates are very similar to those ascertained in the only population cohort to have 
measured delirium (Vantaa 85+). Taken together, these findings suggest that a valid study-
diagnosis of delirium can be operationalised from psychiatric interview schedules. 
8.1.2 The clinical impact of delirium in Vantaa 85+ 
Vantaa 85+ was the only population cohort to have specifically assessed a history of delirium at 
each interview. The definition was based on clinical interview of patient and informant, together 
with medical records to minimise recall bias (in either direction, that is, over- or under-recall). 
Clinical outcomes were explored in relation to this variable.  
Dichotomous outcomes investigated were: mortality (HR 1.6, 95% CI 1.2 to 2.1); odds of 
dementia at follow-up (OR 8.7, 96% CI 2.1 to 35); odds of worsening dementia severity score 
(OR 3.1, 95% CI 1.5 to 6.3); worse functional decline (OR 2.8, 95% CI 1.4 to 5.5, measured by a 
Likert global function score). In addition, trajectory of MMSE change was assessed in a random-
effects longitudinal model, showing that delirium adversely affected both the intercept (β = -
2.95, 95% CI -4.47 to -1.43 points) and slope (β -1.00, 95% CI -1.89 to -0.11 points per year). 
Some preliminary analyses of the interaction between delirium, dementia and neuropathology 
were possible in the Vantaa 85+ dataset. It investigated the observed associations between 
various pathology or genetic markers known to be related to dementia (neurofibrillary tau, 
amyloid, ApoE, infarcts, Lewy-bodies and neuronal loss in substantia nigra). The analysis found 
that when stratifying by history of delirium, associations with these markers remained effectively 
the same in the pure dementia group, but weaker when delirium was part of dementia. Though 
underpowered to definitively conclude there was an underlying interaction, the suggestion was 
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that when dementia follows delirium, the pathological substrates were not fully accounted for by 
these conventional dementia markers. 
8.1.3 Delirium modified the relationship between dementia and pathology 
A more detailed analysis of the relationship between delirium, trajectories of cognitive decline 
and dementia pathology was possible in the harmonised EClipSE database. Here, the outcome 
was rate of cognitive decline in the last years of life (intercept centred at 6 years before death) 
and the exposures were delirium (never/ever) and pathology burden (where ‘pathology’ was a 
composite measure of conventional dementia pathology, specifically: neurofibrillary tangles, 
neocortical amyloid, vascular lesions, Lewy bodies in substantia nigra). Interactions were tested 
between delirium and pathology on the model intercept and slope. 
The analysis found that delirium and classical dementia-related pathology were both negatively 
associated with rate of cognitive decline. An interaction between delirium and dementia 
pathology was evident such that individuals with fastest rate of decline had both these, with a 
multiplicative effect beyond that expected for each variable alone. This suggests that delirium 
accelerates cognitive decline in late life, over and above the decline contributed to by dementia. 
The pathophysiological substrate(s) of this interaction is unclear and not captured by the current 
paradigm for the pathological correlates of cognitive impairment in this population. 
8.1.4 A validated method for extracting information from clinical records 
There are many more longitudinal studies with cognitive outcomes than those which record 
delirium exposures. Therefore, there is a possibility of leveraging information from existing 
cohort studies with respect to a method for deriving a delirium diagnosis.  
The opportunity to develop this came from use of routine medical records of participants in a 
point-prevalence study of delirium in an acute adult inpatient population. Symptoms reported in 
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the healthcare record pertaining to each DSM-IV criterion for delirium extracted by multiple 
abstractors, resulting in a clinical vignette. This vignette was then submitted to a consensus panel 
expert in clinical delirium diagnosis and their decision tested against the diagnosis in the original 
study.  
This method yielded a sensitivity of 0.88 and specificity 0.75 for ‘possible delirium’, with lower 
sensitivity (0.58) and higher specificity (0.93) for ‘probable delirium’ (AUC 0.86, 95% CI 0.82 to 
0.89). In the subgroup of individuals aged ≥70 years, sensitivity for ‘possible delirium’ remained 
high (0.88). Sensitivity for ‘possible delirium’ was also 0.88 in the group with prior cognitive 
impairment, though specificity was much poorer (0.57). Collectively, these findings suggest that 
the method is a feasible approach for ascertaining delirium in cohort studies with linkage to 
hospital records (at least in this population and healthcare setting). 
 
8.2 Strengths and limitations 
8.2.1 Strengths 
This thesis focuses on a common exposure (delirium) and a common outcome (cognitive 
impairment). Therefore, its strengths lie in its attempt to address as series of important questions 
in the epidemiology of ageing:  What is the optimum way of studying delirium in whole 
populations? What are the clinical consequences of delirium? How does delirium relate to the 
pathological determinants of cognitive decline?  
Another major strength of these analyses derives from their basis as population samples. As a 
result, the findings have high external generalisability for the oldest-old, a population widely 
under-represented in the literature (Schoenmaker et al. 2004). 
 145 
 
8.2.2 Limitations 
8.2.2.1 Systematic reviews 
There are limitations that apply to the systematic reviews in Chapter 2. These may relate to the 
search strategy, data extraction and synthesis (both quantitative and narrative). Though the 
searches were performed in three databases (Medline, Embase, Science Citation Index), there is a 
possibility that some studies were not identified. To some extent, errors in study selection and 
data extraction were mitigated by having had a second reader. 
8.2.2.2 Prospective studies 
The data from cohort studies are limited by the sampling, response, measurement, attrition and 
analytical issues. These were mainly explored in Chapter 3. However, there are specific 
limitations that principally relate to the lack of direct correlation of the delirium variable with 
clinical assessment (except in Chapter 7). Delirium was ascertained by different methods and 
different sources (retrospective clinical interview; information from medical records, 
standardised psychiatric interview). Interestingly, there was great consistency across the cohort 
studies despite these differences, suggesting that the core features of delirium – acute cognitive 
change precipitated by acute illness – is a harbinger for adverse events regardless of the exact 
operational definition used. Nonetheless, there is uncertainty as to the degree and direction of 
any misclassification bias. Moreover, the associations presented here will be subject to residual 
confounding, especially given the limited number of other covariates accounted for. 
 
8.3 Context and wider impact of findings 
The purpose of this section is to show how the results from this thesis have made a contribution 
to our understanding of delirium, providing answers to the questions posed in the introductory 
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chapters. This thesis provides a narrative that can be summarised in three areas: descriptive 
epidemiology, analytic epidemiology, and biological underpinnings. 
 
8.3.1 Descriptive epidemiology 
8.3.1.1 Previous state of knowledge 
The vast majority of descriptive epidemiology studies in delirium had been undertaken in 
selected samples, mainly hospitalised cohorts (Siddiqi et al. 2006). As summarised in Section 2.2, 
three studies reported point-prevalence in whole populations and two described period-
prevalence. There was an understanding that point-prevalence at any time might have been low, 
though this may have been limited by survey response rates being lower during intercurrent 
illness / delirium. Therefore period prevalence might have been more informative, and one 
study, GERDA, showed the one-month period prevalence of 27% in 503 individuals aged ≥85. 
8.3.1.2 Specific contribution to knowledge 
Chapter 4 offers another report on the age-specific period prevalence of delirium in the general 
population. With 122 cases identified in a denominator of 2197 (representative of 13004), it is 
the largest analysis of its kind. Chapter 4 also describes the period prevalence of subsyndromal 
delirium, the first report in a population sample. 
In this subsample enriched for cognitive impairment, the estimates show that period prevalence 
of delirium increases with age. In confirming this, the study also proposes an efficient approach 
to investigating delirium in population-samples, that is, by using a stratified sample at higher-risk 
for cognitive dysfunction.  
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Complementary to the delirium algorithm, the validation of a delirium diagnosis through case 
notes review offers a new method to ascertain the descriptive epidemiology of delirium in 
hospital samples.  
8.3.2 Analytic epidemiology 
8.3.2.1 Previous state of knowledge 
The cognitive and functional sequelae of delirium had never been tested in whole populations. In 
addition, the outcome data from hospital cohorts were usually limited by the inability to account 
for both precipitating and predisposing factors (Siddiqi et al. 2006; Witlox et al. 2010). Two 
prospective studies demonstrated worsened cognition after hospitalisation (from any cause) 
(Ehlenbach et al. 2010; Wilson et al. 2012a) and after severe sepsis (Iwashyna et al. 2010). 
However, none could examine delirium. 
One study had described the cognitive outcomes after incident delirium (retrospectively 
determined). This was in a community-based cohort of 402 persons already diagnosed with 
dementia (Fong et al. 2009). This reported that delirium was associated with worsening in 
dementia severity, confirmed in a subset (n=263) with longer follow-up (median 3.2 years) 
(Gross et al. 2012). 
In unselected populations, Vantaa 85+ had published preliminary data on cross-sectional 
associations between delirium and dementia (Rahkonen et al. 2001). 
8.3.2.2 Specific contribution to knowledge 
Constructing an algorithmic diagnosis using data from a standardised psychiatric interview was 
novel. In testing its construct validity, it added to the findings from Vantaa 85+ (described 
below) that showed that delirium, and its symptom clusters, were separately and independently 
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associated with mortality and dementia risk. This was also the first analysis in an unselected 
population to account for both illness severity as well as baseline dementia. 
Vantaa 85+ extended these findings. The analyses showing an association with greater dementia 
severity scores corroborated the conclusions from the Fong study, but in a larger and unselected 
sample. The random-effects models of the longitudinal trajectories had also not previously been 
attempted. Altogether, the Vantaa 85+ study could be regarded as the largest and most 
comprehensive assessment of cognitive outcomes after delirium, and the first in an unselected 
population. 
8.3.3 Biological underpinnings  
8.3.3.1 Previous state of knowledge 
Substantial work has been done in clinical and animal models of delirium, and the putative 
pathophysiology of delirium was described in Section 1.4. However, none have been able to take 
a whole-population perspective, and none had related findings to clinical neuropathology. 
8.3.3.2 Specific contribution to knowledge 
The neuropathology analyses in Vantaa 85+ alone suggested a possible interaction between 
delirium, dementia and neuropathology. EClipSE was powered to test these interactions more 
conclusively. The EClipSE study adds data from two further population cohort studies and 
therefore reports the largest analysis to date of the relationship between delirium and trajectories 
of cognitive decline. As such, it is also the first study sufficiently powered to show that this 
decline is beyond that expected for conventional dementia-related neuropathology. Delirium, 
and/or its precipitants, appear to act through unmeasured neuropathological processes, and 
should be considered as an independent and additive mechanism for cognitive impairment in late 
life. As such, these findings challenge the current paradigm for the biopathological basis of 
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dementia, arguing for a broader understanding of the pathophysiology of cognitive impairment 
in late life. 
 
8.4 Conclusions 
This thesis has sought to understand the impact of delirium on cognitive outcomes in population 
samples, adding to the emerging evidence that delirium can be a critical event in cognitive 
decline. This work has shown that after an episode of delirium, there are implications for 
dementia prognosis. Prospectively linking delirium with permanent decrements in cognitive 
function challenges the construct of dementia because it suggests that dementia pathophysiology 
may be affected by processes outside the brain, e.g. peripheral infection.  This appears to act 
over and above mechanisms already known to be pathological in dementia, such as tau 
phosphorylation or amyloid cleavage, opening up novel areas of research. 
This final section examines how the conclusions of this thesis, in the context of previous work, 
might contribute to an understanding of the nature of the association between delirium and 
dementia. Firstly, the methodological difficulties of investigating the inter-relationship itself are 
outlined. Understanding these challenges allows for a more nuanced understanding of the 
research possibilities. Secondly, the strength of the wider evidence is summarised, along with a 
description of the clinical and research implications. Finally, future directions for the field are 
considered. 
8.4.1 Methodological challenges for studying delirium and dementia 
Three particular difficulties apply to research in delirium with respect to dementia: (1) the 
phenomenological constructs around delirium superimposed on dementia; (2) identifying 
apparently new cognitive deficits after an episode of delirium may be confounded by 
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undiagnosed dementia; (3) predisposing and precipitating factors accounting for cognitive 
decline and these factors must be adequately adjusted for when examining the independent effect 
of delirium on cognitive outcomes.  
8.4.1.1 Phenomenology of delirium and dementia 
The prevailing view is often that delirium and dementia are phenomenologically distinct. As 
dementia is the major risk factor for delirium, delirium superimposed on dementia is very 
common. However, there is likely to be widespread under-diagnosis of superimposed delirium, 
under an assumption that observed cognitive deficits are due to dementia. Delirium symptoms 
can persist for months or even years, and therefore potentially related conditions of ‘persistent 
delirium’ and ‘reversible dementia’ blur the boundaries between these syndromes of cognitive 
dysfunction (Inouye 2006; Cole et al. 2009) (Section 2.1.2.2.). More detailed characterisation of 
the neuropsychology when delirium and dementia co-exist is required, both for clinical 
diagnostic purposes as well as for research standardisation. 
8.4.1.2 Temporal sequence and undiagnosed dementia 
In hospital series, when cognitive deficits are described after an episode of delirium (or delirium 
itself it persistent), it is difficult to be certain to what degree these deficits are new. That is, to 
what extent can residual impairments be attributed to delirium, or were such impairments 
actually pre-existing, yet unrecognised, dementia? Some studies following hospitalised patients 
have sought to derive retrospective measures of pre-delirium cognition (e.g. IQCODE), though 
this is probably imperfect (Rockwood et al. 1999; Gruber-Baldini et al. 2003; Wacker et al. 2006; 
Furlaneto et al. 2007; Kat et al. 2008). This inferential limitation is a principal justification for the 
epidemiological work in prospective studies and the general work of this thesis.  
8.4.1.3 Adjusting for precipitating and predisposing factors 
Theoretically, any apparent association between delirium and dementia should adjusted for 
predisposing and precipitating factors in order to assess the independent effect of delirium. How 
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these constructs are measured and operationalised is not straightforward (Section 2.1.2.4.). Few 
have been validated in relevant populations and others need revision in light of secular trends 
(e.g. Charlson co-morbidity score, originally described in 1986). In addition, given that causal 
pathways in delirium pathophysiology are yet to be fully elaborated, careful choice of covariates 
is essential to avoid the possibility of over-adjustment. In this respect, there may be merit in 
considering the marginal structural models that have a role in causal inference, though to date, 
these have not been used in delirium research (Robins et al. 2000; Moore et al. 2012). At the very 
least, it should be acknowledged that attention to the measurement of both predisposing and 
precipitating factors should be an integral component of delirium studies. Broader agreement on 
how to measure and standardise these variables in clinical epidemiological studies would greatly 
facilitate progress in the field. 
8.4.2 Evidence for delirium leading to dementia  
8.4.2.1 Epidemiological evidence 
As outlined in Section 2.3, prospective studies more reliably establish the temporal sequence 
between baseline cognitive function, incident delirium and subsequent cognitive impairment. 
This approach has shown that cognition can decline after hospitalisation (from any cause) 
(Ehlenbach et al. 2010; Wilson et al. 2012a), and after severe sepsis (Iwashyna et al. 2010). 
However, as above, none of these cohort studies specifically considered delirium. On the other 
hand, it is possible that systemic inflammation may lead to accelerated rates of cognitive decline 
in dementia, even in the absence of delirium (Holmes et al. 2009). Ascertaining delirium in the 
context of an epidemiological survey is challenging, and efforts to date have relied on 
retrospective measures. Nonetheless, incident delirium has consistently shown to adversely affect 
cognitive decline (Section 2.3, Chapters 5 and 6). 
Together, these epidemiological cohorts show that delirium may be a determinant of cognitive 
trajectories. Moreover, the pathological substrates may be different to conventional dementia 
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pathology. The possible mechanisms underlying this relationship are discussed below (Section 
8.4.2.3. Experimental evidence). Though further research is necessary, at the very least it could 
be argued that the pathological paradigm for dementia must include some concept of how acute 
changes in mental status can signal more permanent underlying neuronal damage. 
8.4.2.2 Clinical populations 
Though studies in clinical populations have less external generalisability, prospective studies in 
this group have the advantage over community studies in that there are usually better 
opportunities to characterise the delirium episode. Two studies identified by systematic review 
(Section 2.3.) suggested that long-term cognition could be adversely affected by peri-operative 
delirium in elective surgery (Bickel et al. 2008; Saczynski et al. 2012). 
In critically unwell patients, finding persistent cognitive impairments in previously young healthy 
persons after an ICU admission has led to a new paradigm as far as brain care during critical 
illness. Diffusion tensor imaging and cortical volumetric analyses found that longer duration of 
delirium was associated with more white matter disruption and smaller brain volume respectively 
and, both these correlated with worse cognitive scores 12 months later (Gunther et al. 2012; 
Morandi et al. 2012b) (Section 1.4.2.2.). These findings have been confirmed in a much more 
comprehensive multi-centre study of 821 ICU admissions with a median age of 61 years, 
assessing the independent effects of delirium duration and sedative exposure, adjusting  for a 
wide range of confounders (Pandharipande et al. 2013). At follow-up, global cognitive scores 
were found to be between 1 and 2 standard deviations below what might be expected for the 
general population, i.e. a significant proportion of participants had scores in the range of 
individuals with mild cognitive impairment or frank dementia. Longer duration of delirium was 
associated with worse cognitive scores at both 3 and 12 month follow-up. Taken together, these 
findings in ICU populations indicate that duration of delirium exposure is progressively 
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associated with long-term cognitive impairment, independent of burden of illness severity and 
pre-morbid co-morbidities. 
8.4.2.3 Experimental models 
8.4.2.3.1 Animal models 
Though delirium is clinical complex and heterogeneous, experimental models provide an 
opportunity to explore specific pathophysiological pathways in delirium and dementia (Section 
1.4.1.)(Cunningham et al. 2013). As highlighted above, any clinically relevant experimental 
approach to delirium must capture both predisposing and precipitating dimensions. Murine 
models for this have specifically been developed using various methods of mimicking 
predisposing dementia (prior pathology) with a superimposed inflammatory challenge to simulate 
bacterial or viral infection (e.g. lipopolysaccharide and poly I:C respectively) (Field et al. 2010; 
Murray et al. 2012b). In these models, prior pathology has been induced by either 
neurodegeneration associated with prion infection (Cunningham et al. 2005; Murray et al. 
2012b), or through selective and partial lesioning of the cholinergic projections of the basal 
forebrain (Field et al. 2012). In these mice, acute peripheral inflammation leads to acute deficits 
cognition and motor function, and these behavioural effects are consistent regardless of the 
underlying prior pathology.  
Where neurodegeneration has led to microglial priming, it has been shown that these microglia 
elaborate a more aggressive inflammatory cytokine response during peripheral inflammation 
(Cunningham et al. 2005). This cytokine response may be responsible for the acute and transient 
cognitive deficits observed during T-maze testing, but in themselves lead to further 
neurodegeneration (Cunningham et al. 2009). However, microglial priming was not essential for 
the same deficits reproduced in cholinergically deficient mice, which could be blocked by 
donepezil (Field et al. 2012). Therefore, the interplay between acetylcholine deficiency and 
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microglial priming requires better definition. Nonetheless, these models have begun to explore 
pathophysiological pathways that may identify future targets for intervention. In the progressive 
neurodegeneration model, microglia express cyclo-oxygenase (COX) 1 and synthesise 
prostaglandins. Inhibition of this using COX-1 selective inhibition or indeed ibuprofen is 
protective against systemic LPS or IL-1 induced cognitive deficits (Griffin 2013). There is not yet 
direct evidence that the delirium per se and the concurrent neuronal death actually occur by the 
same mechanisms. However, it has been shown in other murine models that lipopolysaccharide 
in itself can result in generation of nitric oxide, inducing neuronal apoptosis and persistent 
cognitive deficits (Semmler et al. 2005; Weberpals et al. 2009). 
8.4.2.3.2 Clinical models 
Investigations into biomarkers for delirium are still in their infancy, though some have focused 
on putative pathophysiological links between delirium and dementia in clinical populations (Hall 
et al. 2011; Khan et al. 2011). Insofar as the biological mediators of delirium may result in 
permanent neuronal damage, four systems have come to attention: specific Alzheimer’s 
pathology, S100B, cortisol, and inflammatory cytokines. 
In a cohort of individuals with hip fracture, postoperative delirium was strongly associated with 
premorbid cognitive decline, though this was not associated with  CSF Aβ1-42, tau, and 
phosphorylated-tau levels (Witlox et al. 2011),  This was underpowered to detect mediating 
pathways between premorbid cognitive impairment, biomarkers of Alzheimer’s pathology and 
subsequent delirium. Nonetheless, consistent with the Vantaa study of epidemiological 
pathology, postoperative delirium might be taken to arise through pathophysiological pathways 
distinct from Alzheimer’s disease. 
S100B, a marker of astrocyte damage, has been shown to be elevated in delirium, both in plasma 
and in CSF (Van Munster et al. 2010b; Hall et al. 2013). 
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The hypothalamus-pituitary-adrenal (HPA) axis may be dysregulated in delirium and dementia. 
Chronic hypercortisolaemia is directly cytotoxic (e.g. cognitive impairment in Cushing’s disease) 
and aberrant stress responses may be a core feature of delirium (Seckl et al. 1995; MacLullich et 
al. 2008). Moreover, neurodegeneration in the limbic system may lead to inappropriately 
sustained cortisol after a stress response, and delirium itself is associated with elevated CSF 
cortisol (Pearson et al. 2010; van Munster et al. 2010a; Bisschop et al. 2011; Colkesen et al. 2012). 
Though these studies are small and require cautious interpretation, this accumulating evidence 
lends support for the impact of delirium itself contributing to and/or being a mediator of 
permanent cognitive impairment. Future human studies with careful baseline characterisation of 
cognitive function, control for confounding factors, and long-term follow-up, including 
neuropsychological testing and neuroimaging, will be helpful to address this important area. 
8.4.2.4 Implications of viewing delirium and dementia as being inter-related  
8.4.2.4.1 Clinical 
The prompt diagnosis and management of delirium is manifestly clinically important. However, 
additional urgency should arise from the recognition that ‘brain care’ for delirium could 
contribute to the secondary prevention of dementia and chronic cognitive impairment. Moves in 
England and Wales to link hospital remuneration to delirium and dementia screening in 
inpatients aged ≥75 (Commissioning for Quality and Innovation payment framework) will lead 
to better detection. Persons with delirium diagnosed in hospital should be routinely seen at 
outpatient follow-up, and this should be integrated with appropriately resourced memory 
services. 
Delirium prevention has been most successful with multicomponent interventions in both 
medical and surgical series (Inouye et al. 1999; Marcantonio et al. 2001). In particular care, 
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should focus on an enabling environment such that cognitive, but also functional preservation 
should be prioritised.  
8.4.2.4.2 Research 
Delirium may serve as an important model system for research, offering a unique approach to 
advance our understanding of cognitive disorders and dementias more generally. The frequency 
and acuity of delirium and its associated serious adverse outcomes make it a promising area for 
investigation. The development of delirium may help to identify persons who are vulnerable to 
cognitive decline through genetic predisposition or through the presence of unrecognised 
dementia. Indeed, if the magnitude of illness precipitants could be quantified, then this could 
offer a measurement of remaining cognitive reserve.  
Investigation of delirium also provides a window to observe the link between brain 
pathophysiology and behavioural manifestations, which may hold broader implications for other 
neurologic and psychiatric disorders. Moreover, advancing the understanding of the pathogenesis 
of delirium will be critical to identify preventable factors which can lead directly to neuronal 
injury, and thus, permanent cognitive sequelae. Finally, though most dementia intervention trials 
have chosen to recruit persons with mild cognitive impairment, the group of individuals post-
delirium, cognitively-recovered might be a better a population in whom to detect treatment 
differences. Indeed, targeting delirium for new therapeutic approaches may offer the sought-after 
opportunity for early intervention, preservation of cognitive reserve capacity and prevention of 
permanent cognitive damage, which may potentially delay or halt the progression to dementia.  
8.4.3 Future recommendations for epidemiological study designs 
This section ties together the overall findings from this thesis to suggest directions for future 
work in delirium epidemiology. A program of work such as this would have the following aims:  
(1) To characterise more precisely the temporal relationship between delirium and trajectories of 
cognitive decline. 
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(2) To understand which clinical aspects of delirium (e.g. duration, severity or aetiology) most 
strongly determine cognitive outcomes. 
(3) To use the infrastructure from epidemiological cohorts as a platform for investigating 
biological underpinnings, e.g. delirium biomarkers. 
(4) The scope of this research should be broad (in whole populations), perhaps adopting a life-
course perspective. 
8.4.3.1 Population 
The conclusions from both systematic reviews (Sections 2.2 and 2.3) indicate that there are very 
few population-based studies assessing delirium prevalence. However, it is probable that point-
prevalence of delirium in the community is low. Nonetheless, the value of these studies is that 
they describe an approach to characterising a base population, with the possibility of enriching it 
with groups likely to eventually yield more incident delirium cases (older, persons with pre-
existing cognitive impairment). Therefore, though the point-prevalence at any given moment 
may be low, in persons aged ≥85 years, the one-month period-prevalence may be as high as 
25%. More intensive follow-up of higher risk subsamples – randomly selected to maintain 
external generalisability – has been successfully employed in CFAS and CC75C for dementia 
ascertainment and delirium could be usefully considered in conjunction. 
Though issues of consent and capacity were not detailed in this thesis, these must be addressed 
in the recruitment of representative populations. The ethical framework for approaching this has 
been reviewed elsewhere, and this highlights the need to protect vulnerable participants while 
also asserting the equal moral status for persons with delirium to have their condition researched 
in a valid way (Holt et al. 2008; Sweet et al. 2013). Other studies have also demonstrated that 
methods used to assess capacity, including individuals with fluctuating capacity, had an effect on 
the research conclusions, depending on whether persons were included or excluded according to 
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capacity status (Adamis et al. 2010). In some circumstances, the use of proxy consent, especially 
for low-risk studies, may be a practical option. 
8.4.3.2 Case-ascertainment 
From systematic review in Section 2.3, the next steps would be to establish a system whereby 
acute changes in mental status can be identified (e.g. via GPs). As in the OXVASC study 
(Section 2.1.1.1), this requires excellent links between hospital and community services. Use of 
GPs to notify study personnel of acute changes is likely to need dedicated resources to be 
effective.  A brief screening instrument would be the first step for case-ascertainment. It is not 
known if delirium can be optimally diagnosed, investigated and treated in the community, and 
the study should have access to clinical personnel able to determine the need for hospitalisation.  
Once in secondary care, longitudinal delirium assessments must try to account for temporal 
fluctuations. Information on delirium severity and duration in relation to long-term outcomes 
would be an important and new finding in the general population. The assessment of candidate 
biomarkers could be incorporated both at this stage, and earlier – as an assessment of delirium 
vulnerability. The optimum examination schedule will be based on resources and patient 
tolerability. They may range from several (shorter) assessments several times daily, or in other 
settings e.g. long-term care, twice-weekly assessments may be sufficient (Cole et al. 2012). In 
addition, the frequency of assessments minimises the risk of misclassification bias.  
8.4.3.3 Attrition and missing data 
Procedures for determining outcomes need to be reliable, using data from multiple, overlapping 
sources. Missing data are to some degree unavoidable and analyses must account for these with 
appropriate estimations of standard error. The random-effects models used in the cohort studies 
identified in the systematic review are generally flexible in this regard. However, missing data 
may well arise when competing outcomes are at play, for example when dementia or death might 
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follow delirium. Here, data on post-delirium cognition is ‘missing’ because of intervening death 
between resolution of the delirium and next follow-up in the cohort study. Techniques such as 
multi-state, or shared parameter models might be considered. 
8.4.3.4 Residual confounding 
Within the assessments for delirium and serial cognition function, other clinical factors need to 
be accounted for. Measurement of predisposing factors – e.g. age, sex, education, functional 
frailty, depression – needs to be embedded in the assessment schedule and standardised with the 
same degree of precision as the delirium and cognitive variables. Illness severity may be more 
complex to capture, but basic physiological parameters (such as those that comprise early 
warning score systems) have the advantage of being brief, reproducible, non-invasive and 
repeatable. Repeatability is an important dimension as these measures of physiological 
disturbance can then be tracked alongside fluctuations in delirium state. 
8.4.3.5 Final comments 
Acknowledging delirium as a determinant of chronic cognitive impairment obliges us to broaden 
our understanding of dementia. In recognising that otherwise slowly evolving neurodegenerative 
processes may be accelerated by delirium and/or its precipitants, future work needs to consider 
the long-term impact of acute illness on the vulnerable brain. 
Many questions of direct clinical relevance to the understanding and management of delirium 
could be addressed by a convincingly designed observational study. Starting with a cognitively 
characterised, unselected base population, tracking individuals longitudinally in and out of 
hospital settings, is essential. Case-ascertainment would benefit from a more standardised 
application, perhaps including a battery of objective tests alongside conventional subjective 
assessments, in consensus conferences and/or algorithmic operationalisation. Fluctuating 
symptoms are a core feature of delirium, and this will not be reliably captured without specific 
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attention to how this is to contribute to case-ascertainment. Despite these challenges, efforts will 
be rewarded by generating methodologically rigorous clinical data applicable to the broad 
generality of patients with delirium. 
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10 Appendix 
10.1 Search strategies for systematic review 1 
Search strategy for identification studies of descriptive epidemiology of delirium in community 
populations 
MEDLINE (Ovid SP) search strategy 
1. exp Delirium/ep [Epidemiology] 
2. delirium.mp or “acute confusion”.mp or “metabolic encephalopathy”.mp 
3. 1 and 2 
4. community or population 
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10.2 Search strategies for systematic review 2 
Search strategy for identification of cohort studies of dementia which include delirium 
MEDLINE (Ovid SP) search strategy 
1. exp Cohort Studies/ 
2. cohort.ti,ab. 
3. longitudinal.ti,ab. 
4. follow-up.ti,ab. 
5. "*year risk".ti,ab. 
6. (prospective adj2 (study or analysis or evaluation)).ti,ab. 
7. epidemiologic studies/ 
8. "observational study".ti,ab. 
9. "preclinical detection".ti,ab. OR predict*.ti. 
10. Disease Progression/ 
11. or/1-10 
12. (dement* OR “cognit* impair*”).ti. 
13. (alzheimer* or AD).ti. 
14. exp Dementia/di [Diagnosis] 
15. exp Dementia/ep [Epidemiology] 
16. *Cognition Disorders/di [diagnosis] 
17. ((endpoint* or outcome*) adj6 (dement* or alzheimer* or AD)).ab. 
18. (conversion adj4 (dement* or alzheimer*)).ti,ab. 
19. (convert* adj4 (dement* or alzheimer* or AD)).ti,ab. 
20. (predict* adj6 (dement* or alzheimer* or AD)).ti,ab. 
21. (progress* adj4 ("to dement*" or "to alzheimer*" or "to AD")).ti,ab. 
22. or/12-21 
23. "Predictive Value of Tests"/ 
24. (dement* or alzheimer* or AD).ti,ab. 
25. 23 and 24 
26. Neuropsychological Tests/ 
27. (dement* or alzheimer* or AD or “cognit* impair”).ti,ab. 
28. 26 and 27 
29. or/22,25,28 
30. 11 and 29 
31. (animals not (humans and animals)).sh. 
34. 32 not 33 
35. exp Delirium/ 
36. delirium.mp or “acute confusion”.mp or “metabolic encephalopathy”.mp 
37. 35 and 36 
38. 37 and 34 
 
 
 181 
 
10.3 Delirium questions 
10.3.1 CC75C 
Test Source Question 
CAMDEX Examination 20 to 1 
 Examination Serial 7s 
 Informant Drowsiness / clouding 
 Informant Impaired ability to focus, sustain and shift attention 
 Informant Has there been a sudden worsening in mental confusion in recent weeks 
or months, which has continued to the present time? 
 Informant Are there episodes lasting days or weeks when his/her thinking seems 
quite clear and then becomes muddled? 
 Informant Are there brief episodes during 24 hours when he/she seems much 
worse and then times when quite clear? 
 Informant Is the confusion worse towards dusk or the evening? 
 Informant How long have these changes been present (months)? 
 Judgement Primary psychiatric diagnosis of present condition 
 Judgement Recent acute physical illness (i.e. weeks or rarely months duration) 
   
RInI Informant Did his/her thinking seem muddled? 
 Informant Were there episodes lasting days or weeks when his/her thinking 
seemed quite clear and then became muddled? 
 Informant Were there brief episodes during the 24 hours when he/she seemed 
much worse and then times when quite clear? 
 Informant Was the confusion worse towards dusk/evening? 
 Informant Did he/she suffer confusion or delirium during his/her final illness 
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10.3.2 CFAS 
Test Source Question 
Prevalence 
screen 
Judgement Errors made in clouded consciousness, i.e. subject was falling asleep, 
under the influence of alcohol, drugs or delirium due to acute physical 
illness. The individual will be very distractible, unfocussed and may drift 
in and out of consciousness. Often worse in the evening and afternoon 
   
Incidence 
(re-)screen 
Judgement Errors made in clouded consciousness, i.e. subject was falling asleep, 
under the influence of alcohol, drugs or delirium due to acute physical 
illness. The individual will be very distractible, unfocussed and may drift 
in and out of consciousness. Often worse in the evening and afternoon 
 Examination Serial 7s 
   
Assessment Examination 20 to 1 
 Examination Serial 7s 
 Judgement Impaired ability to focus sustain and shift attention 
 Judgement Errors made in clouded consciousness 
   
Combined Judgement Errors in clouded consciousness 
 Examination 20 to 1 
 Examination Serial 7s 
 Judgement Repeatedly falls asleep 
 Judgement Sleepy, but not asleep 
 Judgement Attention impairment 
   
HAS 
 
Informant Has there been sudden worsening in mental confusion in recent weeks 
or months, which has continued to the present time? 
 Informant Are there episodes lasting days or weeks when his/her thinking seems 
quite clear and then becomes muddled? 
 Informant Has s/he been troubled by voices or visions not experienced by others? 
 Informant Are there long periods during the day when s/he is lucid and not 
confused (that is, knows where s/he is and knows what s/he is doing 
and saying)? 
 Informant Does s/he get confused at night, wander about or talk nonsense? 
 Informant Or at any other time? What about during the day time? 
 Informant How long has this difficulty been present (months)? 
 Judgement Could a physical illness (not drugs or alcohol intoxication) be sufficient 
explanation for the subject's mental or psychiatric symptoms (e.g. 
delirious due to acute infection)? 
 Informant Disturbance of consciousness, that is either being sleepy, or awake but 
unaware of their surroundings 
 Informant Or drowsy now? 
 Informant Is s/he physically ill at present? 
 Judgement Rate if actively physically ill. 
  
 
 
 
 
(continued) 
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RInI 
 
Informant Had there been an abrupt change towards mental confusion in the 
period before the final illness? 
 Informant Were there periods lasting days or weeks when his/her thinking still 
seemed quite clear? 
 Informant Were there brief episodes during the 24 hours when s/he seemed much 
worse and then times when quite clear? 
 Informant Did s/he become completely normal when the confusion cleared? 
 Informant Was the confusion worse towards dusk or evening? 
 Informant Were there marked fluctuations in his/her level of attention or 
alertness? 
 Informant How long had the confusion been present (months)? 
 Informant Do you think there was anything specific that caused these changes? 
 
10.4 Neuropathology methods 
10.4.1 Vantaa 85+ 
Paraffin-embedded tissue samples were assessed for neuropathology. All specimens were 
performed by one pathologist using exactly the same dissection and examination protocol, 
blinded to all clinical data. The protocols for assessing Alzheimer-type (Polvikoski et al. 2006), 
vascular (Rastas et al. 2007; Ahtiluoto et al. 2010), and Lewy body (Oinas et al. 2009) pathologies 
have been described previously. After fixation (phosphate-buffered 4% formaldehyde for at least 
two weeks), samples were obtained from the middle frontal, superior temporal and middle 
temporal gyri, and inferior parietal lobule, according to the standard Consortium to Establish a 
Registry for Alzheimer’s Disease (CERAD) protocol (Mirra et al. 1991). 
10.4.1.1 Alzheimer pathology 
10µm sections were stained with a modified Bielschowsky method for neuritic pathology (Mirra 
et al. 1991). For scoring, the maximum density of the neuritic plaques was evaluated in the 
cortical sections. Tissue blocks were embedded in polyethylene glycol 1,000 and then cut (80µm) 
for free-floating staining with the Gallyas silver method for neurofibrillary pathology (Kondoh et 
al. 1993). Apolipoprotein E (ApoE) genotyping was performed using a combination of 
polymerase chain reaction and solid-phase minisequencing technique (Syvanen et al. 1993). Braak 
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stage is a semi-quantitative measure of neurofibrillary tangle load (Braak et al. 1991), and was 
performed without knowledge of clinical diagnosis, neuritic plaque score or ApoE genotype.  
10.4.1.2 Vascular pathology 
Cavitary lesions or solid cerebral infarcts visible to the naked eye were identified by examination 
of the intact brain and from 1-cm-thick coronal slices of the cerebral hemispheres, from 5-mm-
thick transverse slices of the brain stem and sagittal slices of the cerebellum. These lesions were 
histologically ascertained to be infarcts (≥10mm diameter), lacunes (<10mm) or haemorrhages.  
10.4.1.3 Lewy body pathology 
For the assessment of Lewy body pathology, brain samples were obtained following 
recommendations of the First DLB Consortium International Workshop (McKeith et al. 1996) 
and assessed for changes in α-synuclein pathology (McKeith et al. 2005). Sections of the 
substantia nigra were stained with the haematoxylin and eosin (H&E) method and with 
antibodies against α-synuclein. If any Lewy bodies were detected in the screened areas, the 
immunohistochemistry for α-synuclein was performed on cortical samples. The type of α-
synuclein pathology (none, brainstem-predominant, limbic, diffuse neocortical) was determined 
for every participant (Oinas et al. 2009). A semiquantitative grading of the cell loss/atrophy in 
the ventrolateral tier of SN pars compacta was determined from none (0) to severe (3), as 
reported earlier (Oinas et al. 2009). 
10.4.2 Cambridge City over-75s Cohort 
After death, the brains were removed as soon as feasible in the local mortuary. The brains were 
cut in the sagittal plane. One hemisphere was dissected coronally into approximately one cm 
slices, macroscopically examined, and snap frozen at −80◦C. All assessments were performed 
blind to clinical status by neuropathologists at Addenbrooke’s Hospital, Cambridge, UK. 
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10.4.2.1 Alzheimer pathology 
The CERAD protocol was followed. Typical Alzheimer’s lesions were considered by taking the 
CERAD ratings for neuritic plaques, diffuse plaques, and neurofibrillary tangles in the following 
areas: entorhinal, hippocampal, frontal, temporal, parietal, and occipital. Ratings for tau reactive 
tangles were estimated according to Braak stage and ratings for neuritic amyloid-β-reactive 
plaques were estimated according to the age dependent CERAD protocol for all areas.  
Tau and amyloid-β protein were assessed on immunohistochemical preparations using antibodies 
obtained from the Cambridge Brain Bank Laboratory. Anti-tau antibody (mAb 11.57) was used 
to immunostain neurofibrillary tangles, neuritic plaques, and dystrophic neurites. Plaques were 
assessed using anti-amyloid-β antibody (DAKO (M872) Clone 6F/3D). Diffuse amyloid-β-
reactive plaques were distinguished from neuritic plaques by the presence or absence of 
dystrophic neurites. All sections were counterstained with Ehrlich’s haematoxylin with 3,3’-
diaminobenzidine as the chromagen. 
10.4.2.2 Vascular pathology 
Microinfarcts, irrespective of age of infarct, were assessed by their presence or absence in the 
following areas: entorhinal, hippocampal, frontal, temporal, parietal, occipital, deep grey, and 
other neocortical and subcortical areas. White matter pallor was assessed as present or absent in 
the occipital, parietal, frontal, temporal cortices, and as pallor in the deep white matter or internal 
capsule in slides containing the basal ganglia. 
Macroscopic vascular burden was assessed by the number, size, and location of visible 
macrovascular lesions in any area. The age of the infarct or whether they were present in grey or 
white matter was not noted. The arterial distribution for the largest infarct involved was 
recorded. Number of lacunes was recorded in categories of 0, 1–4, 5–9, or 10 or more in each of 
the following locations: basal ganglia, thalamus, cerebral white matter, brainstem, and other. For 
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diagnostic purposes, blocks for paraffin embedding were taken from: the hippocampus (at the 
level of the lateral geniculate body), entorhinal cortex (at the level of the mammillary body), 
frontal, temporal, parietal, and occipital lobes, the basal ganglia, thalamus, pons, medulla, 
cerebellum, and from two levels of the midbrain. The tissue blocks included subcortical white 
matter, deep cerebral white matter, and the internal capsule. 
Ten micrometre thick sections were stained with haematoxylin and eosin to qualitatively assess 
white matter pallor, perivascular gliosis, presence of microinfarcts, and microvascular changes in 
each area sampled. Separate scores were recorded in white and grey matter for V-R space 
expansion, perivascular gliosis, and microinfarcts. Small-vessel disease was defined as presence of 
white matter pallor, perivascular gliosis or ‘other’ microscopic vascular disease. 
10.4.2.3 Lewy body pathology 
Lewy bodies were assessed by their presence or absence in entorhinal, hippocampal, frontal, or 
temporal areas and, in addition, in the substantia nigra, nucleus basalis, dorsal raphe nucleus, 
locus coeruleus, and dorsal vagal nucleus. Sections were either immunolabelled with anti-
ubiquitin antibody (pAb BR 251 DAKO Z0458, early cases) or anti-α-synuclein antibody 
(Biomol International SA3400, later cases), or stained with haematoxylin and eosin to visualise 
Lewy bodies.  
10.4.3 MRC Cognitive Function and Ageing Study 
At necropsy, frozen samples of brain tissue were removed for storage. The remainder of the 
brain was fixed for standardised assessment on paraffin-embedded tissues, following the 
CERAD protocol with minor modifications (see the MRC CFAS website: www.cfas.ac.uk). 
Neuropathological examination was carried out without knowledge of clinical or interview data, 
with semiquantitative rating of specific lesions and a prediction of clinicopathological preliminary 
diagnosis, according to likely importance. To ensure consistency between the centres, inter-rater 
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reliability was addressed at the start of the study, including circulation of macroscopic brain 
photographs and microscopic slides. 
10.4.3.1 Alzheimer pathology 
Amyloid protein pathology and neurofibrillary tangles (NFTs) were assessed in the hippocampus 
(CA1), entorhinal cortex and in the frontal (Brodman Area 8/9), temporal (BA21), occipital 
(BA17/18) and parietal (BA7) lobes. Severity of pathology was scored as none, mild, moderate, 
or severe. Plaque pathology was assessed with Congo red, silver stains (including Bielschowsky, 
Palmgren and Gallyas), or immunohistochemistry. NFTs were assessed with 
immunohistochemistry (mAb AT8 or mAb 11/57). All slides were counterstained with Ehrlich’s 
haematoxylin and visualised with 3,3’-diaminobenzidine. For this analysis, burden of classical AD 
features was taken from the CERAD ratings in the entorhinal and hippocampal regions 
combined and in the neocortex. Each variable was defined as the maximum score in each region. 
10.4.3.2 Vascular pathology 
Vascular pathologies were assessed for each area examined using haematoxylin-eosin slides. 
Cerebrovascular pathology measures included the presence or absence of haemorrhages, infarcts 
(parenchymal ischemic lesions >10 mm), lacunes (parenchymal ischemic lesions <10 mm) and 
small vessel disease (diffuse pallor of myelin staining in white matter associated with hyaline 
degeneration of subcortical arteries and arterioles, micro-infarcts or a combination of these 
features).  
10.4.3.3 Lewy body pathology 
Lewy bodies (LB) were identified using hematoxylin-eosin and ubiquitin immunohistochemistry 
in the cortices, locus coeruleus, substantia nigra, nucleus basalis of Meynert, raphe nuclei, and 
dorsal efferent nucleus of vagus nerve.  
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10.5 Pilot study – notes abstraction 
10.5.1 Methods 
30 participants in CC75C with at least five study visits were selected from 34 eligible participants. 
All components of the case records (medical, nursing, physiotherapy, etc.) were comprehensively 
reviewed. Any reference to cognitive or higher neurological symptoms were recorded, along with 
the time, date and clinical experience of the commentator. In this way, it was possible to build a 
summary of clinical reports of cognition during the admission. Information on medications, co-
morbidities, and physiological parameters (heart rate, blood pressure, oxygen saturation, urea / 
creatinine, CRP) were also recorded. All assessments of case notes were performed blind to 
study data. A typical extract is reproduced below: 
 
 
10.5.1.1 Exposure 
These symptoms were mapped to items in DSM-IV. For the purposes of the pilot project, DSM-
IV criteria were applied by a single assessor (DD), however it is envisaged that this process will 
eventually be subject to assessment at a consensus conference. Delirium was recorded as total 
18/06. 13:00  NS  "appears increasingly confused during morning" 
18/06. 21:40  Med "confused at times" 
19/06. a.m.  NS  "Disorientated to place" 
19/06. 20:00  Med "well, orientated" 
20/06. 07:00  NS  "appears orientated to ward" 
21/06. 03:00  NS  "one episode of confusion noted earlier in evening" 
21/06. 21:00  NS  "seems confused at times" 
24/06. 04:30  NS  "disorientated early evening, but settled well” 
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days spent in hospital with evidence of delirium. At each analysis of hospital records, delirium 
was coded as: 
 Probable delirium, where the total record suggested symptoms sufficient to satisfy the CAM 
algorithm of DSM-IV criteria 
 Possible delirium, where the total record suggested symptoms of altered cognition, but not 
sufficient to meet DSM-IV criteria 
This analysis only considered those with probable delirium. Probable and possible delirium were 
regarded as mutually exclusive.  
10.5.1.2 Outcomes 
Dementia diagnosis in CC75C is based on a consensus according to DSM-IV criteria, though 
this is not currently available in the whole cohort. For this pilot, the working definition for 
cognitive impairment / dementia was taken as MMSE 0—20 (n=13). There were insufficient 
participants to use a more specific cut-off: MMSE<18 (n=6). While this classification was not 
decided a priori, it was deemed acceptable for the purposes of a pilot study. 
10.5.1.3 Statistical Analyses 
Associations between delirium and dementia were modelled using logistic regression, adjusting 
for age, sex and education. Analyses were restricted to delirium events occurring prior to follow-
up in CC75C. Power calculations for the wider PhD project are based on estimates from this 
pilot study and those Vantaa 85+, assuming α=0.05 and β=0.8. To allow for misclassification 
bias, the upper 90% CI for controls were compared to lower 90% CI for cases (two tailed test), 
and sample size calculated by the Kelsey method (Kelsey et al. 1996). 
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After receiving specific training in the chart abstraction, this pilot study has been repeated by a 
medical student. The level of agreement between the data awaits full assessment. 
10.5.2 Results 
The mean age of participants at study entry and death was 78 years (SD 2.2) and 96 years (SD 
3.0) respectively. The total number of admissions reviewed over an average of 18 years follow-up 
was 143, with mean of 4.8 admissions per participant over the entire adult medical record. 
From age 65 years, 85 admissions showed no evidence of delirium, 31 admissions had evidence 
of probable delirium (duration ranging from 1 to 71 days) with a further 18 admissions with 
evidence of possible delirium.  
Because the cognitive outcomes are derived from the measures at the study interview, the 
participants are limited to those in whom hospitalisation was followed by at least one study visit 
(n=7). Those participants who never had delirium can also be included in the denominator 
(further n=11). The association between delirium and subsequent dementia was strong (age-
adjusted OR = 21 (95% CI 1.3 to 300)). 
The two estimates of delirium prevalence in controls (pilot 0.15; Vantaa 0.22) and cases (pilot 
0.8; Vantaa 0.7) yielded an estimated total sample size of 150, where cases and controls are 
matched 1:1. 
10.5.3 Discussion 
The estimated prevalence of delirium at any given hospital admission is 23% (31 probable cases 
in 134 admissions). This is in keeping with hospital point-prevalence studies of delirium (Siddiqi 
et al. 2006). The OR for history of delirium in those with dementia is consistent with the Vantaa 
study, though the confidence intervals are very wide due to the small sample size. However, 
 191 
 
power calculations suggest that there are sufficient participants available in the EClipSE studies 
to investigate the relationship in more detail.  
Abstraction of information from hospital records is feasible in terms of: (i) consent to access 
notes; (ii) retrieval (if deceased within last ten years); (iii) deriving information on altered mental 
status due to acute conditions. Clinical information can be assessed (by consensus) to determine 
if sufficient evidence for a retrospective diagnosis of delirium (based on CAM operationalisation 
of DSV-IV criteria) can be made. The derived exposure can be demonstrated in cases (dementia) 
and controls, in proportions consistent with delirium measures in Vantaa.  
 
 
 
 
